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Abstract 
Introduction: Obesity is a complex, multifactorial disease that is the greatest epidemic 
of the 21st century and presents a major risk factor for the development of the metabolic 
syndrome and co-morbidities, contributing to medical, social and economic burdens. 
Dysregulated expansion of the adipose tissue in obesity is associated with changes in with 
the changes in its blood flow leading to the onset of local tissue hypoxia and presence of 
hypertrophic and dysfunctional adipocytes. Adipocyte hypertrophy is associated with 
increased endoplasmic reticulum stress, mitochondrial dysfunction, necrosis, apoptosis 
and altered secretory profiles adipokine and cytokine causing activation and infiltration 
of immune cells into the adipose tissue, boosting inflammation and further underpinning 
adipocyte dysfunction and death. The imbalance between signals that initiate 
inflammation and signals that resolve inflammation, worsen inflammation towards 
chronic irreversibility. The presence of low-grade chronic inflammation is considered to 
be a key underlying mechanism that links excessive adiposity to the development of the 
metabolic syndrome and obesity associated co-morbidities. Annexin A1 (ANXA1) and 
its peptides pose anti-inflammatory, pro-resolving properties and have shown to have 
significant effects in resolving inflammation in several disease models, however, their 
effects in obesity associated inflammation is not well explored. 
Research Aim and studies: The primary aim of this PhD project was to investigate the 
role of ANXA1 in obesity and associated inflammation. This project consists of four 
research studies including: Study 1: an in vivo study to investigate the potential roles of 
ANXA1 in mature adipocytes using a model mimicking the inflammatory status observed 
during obesity; Study 2: an in vivo study to investigate the role of ANXA1 in the 
differentiation of preadipocytes into mature adipocytes; Study 3: an in vitro pilot study 
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to investigate the plasma ANXA1 levels in response to rapid weight loss induced by 
bariatric surgery; and Study 4: an in vitro study to investigate the plasma ANXA1 levels 
in lipodystrophy patients.  
Results: Study 1: Acute treatment with ANXA1 peptide, AC2-26 differentially regulated 
gene expression in  mature adipocytes to indicate ANXA1 plays a protective role in 
obesity and inflammation. Treatment with AC2-26 significantly upregulated the mRNA 
expressions of BAX, PER3, PPARA, ADIPOQ, IL6 and ACHE, and downregulated the 
mRNA expressions of CD36, DPP4, ACOX1, PPP3CC, LEP, NAMPT, RETN, CFD, 
TNF, IRS1, SLC2A4, IGFR1, JUN and VEGFA. Study 2: Mature adipocytes 
differentiated with ANXA1 receptor antagonist and/or agonist accumulated significantly 
less lipids, indicative of an immature adipocyte phenotype. This effect was only apparent 
during later stages of adipocyte differentiation and it was concluded that ANXA1 may 
regulate the rate of adipogenesis through differential regulation of MAPK intracellular 
pathways associated with different receptors. Study 3: Plasma ANXA1 indicate 
increasing trends with decreasing body mass index (BMI), however, a firm conclusion 
regarding its associations with plasma biomarkers is difficult to form due to low number 
of participants. Study 4: Plasma ANXA1 levels were significantly reduced in 
lipodystrophy patients of all genotypes in comparison to control and inversely correlated 
with BMI and plasma C-reactive protein levels.  
Conclusion: Locally, in the adipose tissue ANXA1 may be involved in regulating 
adipogenesis and reducing adipocyte hypertrophy to prevent adipocyte dysfunction, local 
inflammation and development of insulin resistance. Peripherally, ANXA1 may act in an 
endocrine manner to regulate inflammatory biomarkers to dampen inflammation, regulate 
insulin secretion and improve the metabolic profile to reduce the risk of developing 
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obesity associated co-morbidities. However, this effect may be overshadowed by the 
continued increase in systematic inflammation associated with rapid adipose tissue 
expansion.  
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Chapter 1: General Introduction 
Obesity is the greatest epidemic of the 21st century with a multifactorial aetiology. It is 
defined by the excess accumulation of fat and primarily results from sustaining a long-
term positive energy balance, where energy intake exceeds energy output. Energy is 
stored in the adipose tissue as triacylglyceride (fat) for the purpose of providing energy 
during periods of energy deficit such as, fasting and starvation. In addition to its energy 
storing role, the adipose tissue synthesises and secretes several adipokines and bioactive 
molecules that regulate energy input and energy output to maintain energy homeostasis. 
However, long term positive energy balance disrupts the normal physiological function 
of the adipose tissue, disturbing energy homeostasis and increasing the risk of developing 
co-morbidities such as, type 2 diabetes mellitus. This chapter discusses the classification, 
risk factors and treatments for obesity (section 1.1), the maintenance and regulation of 
energy homeostasis (section 1.2), and the role of the adipose tissue as a regulator of 
energy storage and homeostasis (section 1.3) with references to obesity where applicable.  
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1.1 Obesity 
Obesity is a complex, multifactorial and a highly preventable disease affecting over a 
third of the world’s population (Stevens, Singh et al. 2012). The prevalence of obesity 
has increased at a rapid rate over the last 3 decades and if the trend continues at the same 
pace, it is estimated that 38% of the world’s population will be overweight and another 
20% will be obese by 2030. The prevalence of overweight and obesity show differential 
patterns due to gender, age, socioeconomic circumstances, lifestyle, race, geography and 
time. For example, the rates of obesity have risen from around 3% in men and just over 
6% in women since 1975. Obesity was considered a problem of high-income countries 
and reflected the socio-economic background of the individual, however, the rate of 
obesity in underdeveloped and developing countries is on the rise. Nearly half of the 
children who were overweight or obese in 2014 lived in Asia (World Health 
Organisation). The increase is likely to be complex and multi-factorial and may result 
from increased urbanisation, migration, modernisation and/or new eating habits that 
reflect the ‘western diet’, rich in animal produce, fat, salt and sugar as well as reduced 
physical exercise.   
Obesity is defined as the accumulation of excess fat that negatively impacts health and it 
is considered to be a greater threat than malnutrition, as death caused by obesity is 3 times 
greater than that caused by malnutrition (Neels 2013). Being overweight and/or obesity 
in the middle age is estimated to shorten life expectancy by 4-7 years (Peeters, Barendregt 
et al. 2003). Some studies suggest that excess body weight may protect against mortality  
and from certain chronic conditions, resulting in an ‘obesity paradox’, however, these 
studies have been conducted in older groups (>65), further adding to the complexity, 
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unclear roles and effect of excess adiposity in old age compared to young (Hu, F. B. 
2007).  
 
Obesity is also one of the most common and costly non-communicable diseases and is a 
major risk factor, and a contributor to the global burden of chronic diseases, listed in 
Table 1.1 (Goossens 2008). Being overweight or obese significantly increase the risk of 
developing devastating, but preventable diseases including, type 2 diabetes mellitus 
(T2DM), cancer, cardiovascular and hepatic diseases and related mental health problems. 
Economically, obesity is costing the NHS at least £5.1 billion and tens of billions to the 
UK society every year. By 2035, obesity related illnesses are estimated to cost an extra 
£2.5 billion a year (Obesity health alliance/NHS). Not only are obesity and the related co-
morbidities impacting the health services, but the economy in general due to reduced 
 CO-MORBIDITIES 
METABOLIC Type 2 diabetes mellitus, Insulin resistance, Hypertension, 
Hypertriglyceridemia, Low levels of high-density 
lipoprotein 
PSYCHOLOGICAL Depression, Anxiety, Social stigmatization, Reduced 
quality of life, Sick leave, Early retirement 
CARDIOVASCULAR Coronary artery disease, Stroke, Heart failure, Atrial 
fibrillation  
GYNAECOLOGICAL Infertility, Polycystic ovary syndrome, Obstetrical risks 
GASTROINTESTINAL Gastroesophageal reflux, Gallbladder disease, Liver 
steatosis, Non-alcoholic steatohepatitis 
RESPIRATORY  Sleep apnoea, Asthma, Pulmonary embolism 
BONE AND JOINTS Osteoarthritis, Gout, Back pain 
DERMATOLOGICAL Striae, Acanthosis nigricans, Hirsutism, Fungal infection 
CANCER Malignancies in the breast, endometrium, colon and 
rectum, oesophagus, pancreas, kidney, thyroid gland, 
gallbladder, hematopoietic system, malignant melanoma  
Table 1.1: Obesity associated co-morbidities. The excess accumulation of fat predisposes obese individuals 
to an array of metabolic, psychological, gastrointestinal and respiratory abnormalities. This Table 
represents the common co-morbidities associated with obesity.                        Adapted from (Bray 2004, Sin, 
Sutherland 2008, Sullivan, Karlsson et al. 1993, Haslam, James 2005) 
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productivity and employment, placing it as the 3rd  highest social burden in 2014 ( 
McKinsey Global Institute) (Tremmel, Gerdtham et al. 2017) (Figure 1.1). It is estimated 
that reducing the prevalence of obesity by as little as 1% per year from the predicted 
trends between 2015 and 2035 could save £300 million in direct health and social care 




Classifications BMI (kg/m2) 






Underweight <18.50 <18.50 Low (But risk of 
other clinical 
problems increase 
Normal Range 18.50-24.99 18.50-22.99 Average 
  23.00-24.99  
Overweight >25.00 >25.00  
Pre-obese 25.00-29.99 25.00-27.49 Increased 
  27.50-29.99  
Obese Class I 30.00-34.99 30.00-32.49 Moderate 
  32.50-34.99  
Obese Class II 35.00-39.99 35.00-37.49 Severe 
  37.50-39.99  
Obese Class III >40.00 >40 Very severe  
Table 1.2: BMI classifications and the risk of developing obesity associated co-morbidities. The principle 
cut off points are generally used to identify a normal weight and height in Caucasians and the additional cut-
off points are provided for individuals of Asian ethnicity as research shows the risk associated with excess 
body weight vary between different ethnicities.     (Nuttall 2015) 
                                Adapted from WHO, 1995, 2000 and 2014 
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 1.1.1 Classifications of Obesity 
Clinically, obesity is classified using the body mass index (BMI) categories; body weight 
in kilograms divided by height in meters squared (Nuttall 2015). BMI was developed by 
Adolphe Quetelet in the 1800s and is globally used to determine the level of obesity of 
an individual. The higher the BMI, the higher the risk of developing obesity associated 
co-morbidities (Nuttall 2015) (Table 1.2). Though BMI is widely used to classify 
individuals as obese, it does not distinguish between lean and fat body mass, therefore 
may produce false negative results (Nuttall 2015). In addition, accumulation of fat in 
certain sites around the body increases the risk of developing certain diseases. Though 
BMI positively correlates with the risk of developing co-morbidities, it does not indicate 
the distribution of fat around the body, thereby overlooking the risk of different fat depots 
(Nuttall 2015). Waist to Hip Ratio, Skin Fold Thickness, Bioelectrical Impedance, Dual 
Energy X-Ray Absorptiometry and Air Displacement Plethysmograph are used to 
overcome the limitations of BMI, however, these bear their own limitations, such as, staff 
training, cost and availability of the equipment.  
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1.1.2 Risk factors for Obesity 
Energy imbalance between energy consumed and the energy used, creates an energy 
surplus and a state of positive energy balance. The chronic state of positive energy balance 
contributes to excess body weight thus, results in the onset of obesity. Energy imbalance 
is partially a result of social and economic changes including, economic growth, 
availability of abundant, inexpensive and nutrient-poor food, industrialization, 
mechanized transportation and urbanization (Hruby, Hu 2015). However, hereditary 
factors (genetics, family history, racial/ethnic differences), socioeconomic and 
sociocultural environments have shown to affect the risk of developing obesity (Hruby, 
Hu 2015). Nonetheless, personal behaviours in response to these conditions continues to 
play a dominant role in the onset of obesity and all the risk factors apart from genetics are 
modifiable.  
1.2.1 Genetics of Obesity 
Although genetics may not play an immense role in the development of the obesity crisis, 
some genetic markers that increase susceptibility to obesity when exposed to certain 
behaviours or environments have been identified. Individuals respond differentially to 
overeating, some may gain up to 3 times more weight than others when purposefully 
overfed (Bouchard, Tremblay et al. 1990). Genetic susceptibility may be due to low 
resting metabolic rate, decreased rate of lipid oxidation, impaired appetite regulation and 
altered pattern of hormone release and/or sensitivity (Astrup, Gotzsche et al. 1999). In 
addition, mutations in certain proteins significantly contribute to the development of 
excessive adiposity (Table 1.3). These mutations cause rare, monogenic forms of obesity. 
These genes are commonly involved in the hypothalamic regulation of feeding behaviour 
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and individuals with defects in these genes typically have an increased drive to eat and an 
early-onset of obesity (Farooqi, S., O'Rahilly 2006).  
 
1.1.2.2 Environmental ‘Pathogens’: Viruses and Microbiome  
In addition to individual behaviours towards certain types of foods, physical inactivity, 
wealth and environmental pathogens as risk factors for obesity have received increasing 
attention. Research studies indicate that obesity may be attributable to infection, or that 
obesity itself may be a contagion (Hruby, Hu 2015). Several viruses such as, Adenovirus-
GENE ENCODE MUTATIONS BMI 
(kg/m2) 
LEPR Leptin Receptor G→A (Exon 16) 52.5-71.5  
POMC Pro-opiomelanocortin G7013T and C7133∆ (Exon 3) 
C3804A (Exon 2) 
n/a 
LEP Leptin G398∆ (codon 133) 
C→T (codon 105) (Exon 3) 
36.6-45.8  
32.5-55.8  
MC4R Melanocortin 4 Receptor ∆CTCT nt 631-634 (codon 
211) 















Table 1.3 Mutations in some well-known genes that induce obesity. Mutations in genes encoding for 
proteins involved in regulating energy intake and energy metabolism have been identified to induce the early 
onset of obesity. Leptin mediates its satiety signals by binding to and activating the leptin receptor (encoded 
by LEPR). Mutations in the LEP or LEPR cause significant hyperphagia and obesity with a BMI range of 
52.5-71.5 kg/m2. Similarly, Pro-opiomelanocortin stimulates neurones to secrete peptides mediating satiety 
and mutations in the POMC genes dysregulate its ability to induce satiety resulting in obesity with a range 
of 32.5-55.8kg/m2. The Melanocortin 4 receptor (MC4R) plays a central role in energy homeostasis. 
Deficiency of MC4R is the most common form of monogenic obesity identified. Mutations in the MC4R gene 
cause hyperphagia, severe hyperinsulinemia and severe obesity with a BMI range of 27.7-64.5kg/m2.           
                          Adapted from (Perusse, Chagnon et al. 2001) 
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36 have been associated with a possible cause of obesity in children and adults with links 
to other metabolic traits (McAllister, Dhurandhar et al. 2009, Parra-Rojas, Del Moral-
Hernandez et al. 2013, Atkinson, Dhurandhar et al. 2005, Almgren, Atkinson et al. 2012). 
Similarly, the human microbiome, ‘bacteria within the gut’ has received a lot of attention 
in the last decade in relation to obesity, energy metabolism and, carbohydrate and lipid 
digestion (Clarke, S. F., Murphy et al. 2012). The relationship between humans and the 
gut microbiome is mutualistic; the microorganisms are involved in many physiological 
functions (Figure 1.1) and dysregulation of the gut microbiome has been correlated with 
a broad range of inflammatory and autoimmune diseases (Shen, Wong 2016). The 
composition of the microbiome changes over time with changes in the diet and overall 
health. The phyla of bacteria differ in lean vs obese populations and the proportions 
change as the obese individuals lose weight, suggesting their contribution to the disease 
(Ley, Turnbaugh et al. 2006).  
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Figure 1.1: Physiological functions of the gut microbiome.  The human gut microbiome in involved in 
regulating many physiological functions that are beneficial to the host. However, changes in the number and 
the diversity of the gut microbiome present positively correlates with a broad range of inflammatory and 
autoimmune diseases. The gut microbiome is hypothesised as a risk factor for obesity as the phyla of bacteria 
present within the gut of obese individuals differs compared to lean.     
                            (Laukens, Brinkman et al. 2016) 
Some materials have been removed from this thesis due to Third Party Copyright. Pages where material has been 
removed are clearly marked in the electronic version. The unabridged version of the thesis can be viewed at the 
Lanchester Library, Coventry University.
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1.1.3 Treatments for Obesity 
One of the contributing factors in the increasing prevalence of obesity is the difficulty in 
treating it. As obesity is a result of positive energy balance, the only way to treat it is 
through negative energy balance, which is often difficult to adhere to. Theoretically, 
negative energy balance can be achieved by reducing food intake, reducing nutrient 
uptake and increasing energy expenditure. However, weight loss induced by caloric 
restriction results in both increased drive to eat and a reduced energy expenditure, 
restricting weight loss and these adaptive responses have been reported in both lean and 
obese individuals (Leibel, Rosenbaum et al. 1995).   
1.1.3.1 Lifestyle changes 
The treatment or management of obesity requires comprehensive lifestyles changes 
through diet, physical exercise and behaviour modifications. The two main categories of 
conventional diets are balanced, low calorie diets (or reduced portion size) and diets with 
different macronutrient compositions such as low-fat diets, low carbohydrate diets and 
Mid-level diets. The commonly used diet plan by dietitians and weight-management 
professionals is the low calorie and reduced portion size diet, though this may be only 
useful in the short-term as they are not associated with reliable, sustained weight loss. 
Increased physical activity in addition to dietary changes is associated with significant 
weight reduction and longer maintenance of weight loss (Jakicic, Marcus et al. 2008).   
1.1.3.2 Pharmacological interventions  
Several anti-obesity medications that act by suppressing appetite, accelerating satiety and 
blocking absorption of nutrients to induce weight loss are available and intended for 
patients with a BMI of 30 kg/m2 or more or 27 kg/m2 or more with co-morbidities. Table 
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1.4 shows a list of anti-obesity drugs and their mechanism of action that are approved for 
short-term use by the European Medicines Agency and are currently in use in the UK. 
Medications are intended to be used in addition to caloric restriction, increased physical 
exercise and behavioural modifications and not just on their own. They are to be 
discontinued if the patient has not lost at least 5% of baseline body weight in 12 weeks as 








MECHANISM OF ACTION 
ORLISTAT Adults and 
Children ages 12 
and older 
• Target Organ: Gut 
• Reduces the amount of food 
absorbed by the gut by blocking 
the action of pancreatic lipase  
LORCASERIN Adults • Target Organ: Brain 
• Acts on the serotonin receptors 
to induce sense of satiety 
PHENTERMINE-
TOPIRMATE 
Adults • Target Organ: Brain 
• Phentermine reduces appetite 




Adults  • Target Organ: Brain 
• Induce sense of satiety and 
reduce sense of hunger by 
increasing the activity of pro-
opiomelanocortin neurones 
LIRAGLUTIDE Adults • Target organ: Brain 
• Glucagon like peptide 1 
analogue and regulates appetite 
and calorie intake 
Table 1.4: A list of European Medicines Agency approved Anti-obesity drugs.  Anti-Obesity drugs or 
medication aim to induce weight loss and reduce the onset of obesity associated co-morbidities such as Type 
2 diabetes mellitus and Cardiovascular Disease. Majority of the anti-obesity drugs target the brain and 
induce the secretion of anorexigenic peptides to stimulate the sense of satiety thereby, decreasing energy 
intake and resulting in weight loss.                              
              Adapted from (Rankin, Wittert 2015) 
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Off-label medications for managing obesity include; T2DM medications; Metformin, 
Anti-depressants, Ephedrine and Caffeine, Cannabinoid-receptor antagonists and 
Catechin. Ghrelin antagonists, α-melanocyte-stimulating hormone (α-MSH) analogues, 
Enterostatin, Neuropeptide YY (NPY) antagonists and β3-adrenergic agonists are in the 
early phases of investigation and may prove to be useful in managing obesity.  
1.1.3.3 Surgical options 
Surgical therapy or bariatric surgery is the only available therapeutic strategy that is 
associated with clinically significant and relatively sustained weight loss in morbidly 
obese individuals with co-morbidities. It is an effective and durable treatment in 
comparison to non-surgical interventions such as, lifestyle modifications, 
pharmacological therapies and cognitive behavioural therapies. The ideal candidate for 
bariatric surgery should have BMI greater than 40 kg/m2 or more than 35 kg/m2 if at least 
one major comorbidity is present. The standard bariatric procedures include, Roux-en-Y 
gastric bypass, Adjustable gastric banding, Sleeve gastrectomy, Horizontal gastroplasty, 
Vertical banded gastroplasty, Duodenal-switch procedures, Biliopancreatic bypass and 
Biliopancreatic diversion (Figure 1.2) (Demaria, Jamal 2005). Research suggests that 1 
year after surgery individuals lose approximately 30% of their body weight and this may 
be accompanied with reduced insulin resistance, cardiovascular disease and mortality 
(Maciejewski, Arterburn et al. 2016). Bariatric surgery causes changes in the adipose 
tissue biology that impact systemic glucose utilisation thereby, affecting insulin 
sensitivity independent of weight loss (Moreno-Castellanos, Guzman-Ruiz et al. 2016). 
Metabolic changes observed after bariatric surgery are independent of weight loss are 
thought to result from altered hormonal patterns; i.e. upregulation of gastrointestinal 
insulinotropic polypeptide, glucagon-like peptide 1 (GLP-1) and peptide tyrosine tyrosine 
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(PYY) that cause inhibition of appetite, mediate satiety and stimulate insulin production 




Figure 1.2: Bariatric surgery procedures. Bariatric surgery is considered as a last resort for the treatment 
of obesity and is performed on individuals with a BMI greater than 40kg/m2 or 35kg/m2 if they have 1 or 
more co-morbidity such as Type 2 diabetes mellitus. The 3 common forms of bariatric surgeries include, 
Gastric Banding, Roux-en-Y gastric Bypass, and Sleeve Gastrectomy. Reducing the size of the stomach 
subsequently reduces food intake resulting in weight loss and improvement of obesity associated co-
morbidities.                          (Demaria, Jamal 2005) 
Some materials have been removed from this thesis due to Third Party Copyright. Pages where material has been 
removed are clearly marked in the electronic version. The unabridged version of the thesis can be viewed at the 
Lanchester Library, Coventry University.
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1.2 Energy homeostasis  
The ‘thrifty gene’ hypothesis suggest that the ability to effectively store fat in times of 
nutrient abundance is a positive trait selected over many years of human evolution to deal 
with periodic famine (Neel 1999).  Recent studies have reported the role of certain genes 
in predisposing individuals to gain weight and lead to an obesogenic phenotype (as 
discussed in section 1.2.1) however, they do not account for the rapid surge in the 
prevalence of obesity. But rather the rapid changes in the environment such as, 
availability and composition of food and reduced requirement for physical exertion 
disturbs the energy balance leading to obesity (Spiegelman, Flier 2001). Body weight, 
composition and energy stored as triglycerides in the adipose tissue are determined by the 
interactions between factors such as, genetics, the environment and psychological factors 
(Spiegelman, Flier 2001). These ultimately act by changing and unbalancing the long 
term homeostatically regulated energy equation between energy intake and expenditure 
(Figure 1.3). Although energy intake can be easily accounted for and measured as calories 
in food and drinks consumed, energy expended is difficult to assess as it accounts for 
Figure 1.3: Energy balance. Energy stored within food and drink is converted to heat energy, biological 
energy or stored (in the form of triacylglyceride) within the body for later use. Energy balance is the 
relationship between energy intake (calories in the form of food and drink) and energy output (calories used 
for biological processes). Thus, if energy intake exceeds energy output, the excess energy is stored, resulting 
in weight gain. Alternatively, if energy output exceeds energy intake, stored energy is used as a source, 
resulting in weight loss.   
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physical activity, basal metabolism and adaptive thermogenesis (Joosen, Westerterp 
2006).  
In a healthy individual, energy storage will only occur if energy intake (effective 
absorption) exceeds energy expenditure. Thus, in theory reducing energy intake and 
increasing physical exercise would result in weight loss. However, homeostatic control 
of energy balance is achieved by more than just behavioural and physical changes and for 
that reason the energy balance equation is considered too simplistic as it does not account 
of biological adaptations (Hopkins, Blundell 2016). For example, some individuals 
experience a compensatory reduction in basal metabolic rate (BMR) and increased fasting 
hunger following diet and exercise induced weight loss, deeming ineffective long-term 
and making it harder to sustain lost weight (Hopkins, King et al. 2010, Rosenbaum, 
Murphy et al. 2002, Hopkins, Gibbons et al. 2014). Furthermore, weight changes during 
periods of overfeeding are higher than those seen during underfeeding, indicative of 
‘tighter’ regulation of body weight during energy deficit than surfeit, suggesting the 
strength of putative feedback signals from neuronal, metabolic and endocrine systems 
vary under differing physiological conditions (Muller, Enderle et al. 2015). Dysregulation 
of these mechanisms is considered to be a contributing factor to the development of 
obesity.  
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1.2.1 Regulation of energy expenditure  
The thermodynamic law states that energy can neither be created or destroyed, rather it is 
converted from one form to another. The biological energy is expressed using the unit 
Calorie (kcal), therefore, when a calorie of food is consumed, one of three effects occur 
within the body; energy stored as body fat, converted to chemical energy in the form of 
adenosine triphosphate (ATP) to drive biological and chemical processes or dissipated as 
heat (Murphy, Bloom 2006, Field 1989). Energy released during oxidation of ATP is used 
to carry out 4 types of processes; 1) ~55-60% in obligatory thermogenesis (also known 
BMR) including, cellular metabolism, functioning of organs and maintenance of the 
body’s vital functions, 2) ~10-15% in postprandial thermogenesis (thermal effect of 
food), 3) ~20-30% in thermogenesis resulting from physical activity and 4) adaptive 
thermogenesis (Moehlecke, Canani et al. 2016). Though obese individuals have a higher 
rate of obligatory thermogenesis or BMR than their lean counterparts due to increased 
body cell mass (both fat and fat-free), some studies suggest lower BMR could be a 
predictor of weight gain in populations prone to obesity (Ravussin, Lillioja et al. 1988). 
Under physiologically normal conditions, oxygen consumption is increased after the 
ingestion of food to oxidise ATP to generate energy required for digestion, absorption 
and storage of ingested macronutrients. This process is regulated by the sympathetic 
nervous system (SNS) and studies in mice report an association between obesity and 
decreased SNS activity and suggest a contribution of thermal effect of food (TEF) in 
weight gain in obese individuals (de Jonge, Bray 1997). Though TEF is reduced in obese 
compared to lean, it is not observed in every obese individual (Tappy 1996). In fact, the 
response is suggested to be dependent on the type of foods consumed, i.e. TEF is reduced 
after glucose feeding but not after fructose or amino acid administration in obese 
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individuals (Simonson, Tappy et al. 1988, Tappy, Jequier 1993). Furthermore, TEF is 
reduced in nonobese patients with T2DM determined by reduced glucose uptake. 
Therefore, insulin resistance is suggested to be more likely a consequence rather than 
cause of obesity.  
Physical activity can be subdivided into three distinct categories; sedentary behaviour 
(spontaneous muscle contractions, maintaining posture and involuntary movements), 
nonexercised activity thermogenesis and planned/structured activity (exercise) 
(Schwartz, M. W., Seeley et al. 2017). An obese individual expends the same amount of 
energy as a lean individual to carry out non-weight bearing tasks; however, they may 
expend more when carrying out weight bearing tasks to account for their greater body 
weight (Segal, Presta et al. 1984). Physical activity is a variable component of daily 
energy expenditure and significantly varies between individuals. Increased physical 
activity alone is largely ineffective as a weight loss intervention in obese individuals. This 
is possibly due to better compensation for increased energy expenditure by increasing 
energy intake thus, resisting weight loss compared to energy intake by increasing energy 
expenditure to protect against weight gain (Schwartz, M. W., Seeley et al. 2017). Thus, 
reduced physical activity may not be a significant contributor to weight gain and 
development of obesity.  
Finally, adaptive thermogenesis is dependent on output from the SNS to the peripheral 
tissues (brown adipose tissue (BAT) and skeletal muscles) upon exposure to cold and 
food intake (Ricquier 2006, Schwartz, M. W., Seeley et al. 2017). Upon stimuli, the SNS 
raises thyroid hormone, triiodothyronine (T3) which plays an important role in both 
thermogenesis and BMR (Silva 2003). BAT regulates energy expenditure through 
adaptive thermogenesis by a process (discussed in section 1.3.1.3) that results in heat 
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production to maintain normal body temperature and its activity is inversely correlated 
with BMI, age and body fat percentage (Virtanen, Lidell et al. 2009).  
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1.2.2 Regulation of energy intake 
Physiologically, energy intake and energy storage are regulated by controlling appetite 
(hunger, satiation and satiety), but appetite control alone does not contribute to energy 
homeostasis. Though internal signals (metabolic, neuronal and endocrine) (Table 1.5) 
stimulate the feeling of hunger, non-physiological factors that affect foods consumed such 
as, hedonic (palatability, taste, texture), social (cultural, religion), psychological (the 
choice of low fat or high fat, energy dense) and environmental (variety and variability) is 
dependent on the individual and play an important role in creating a positive energy 
balance and weight gain in the long term (Hopkins, Blundell 2016). However, some 
factors regulating appetite are considered as risk factors because they can induce over-
consumption of foods in vulnerable individuals. The central and peripheral nervous 
system (CNS and PNS), the gastrointestinal tract and the adipose tissue work together to 
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Table 1.5: Summary of key peptides and neurotransmitters involved in regulating energy intake and 
output. The central nervous system , the gastrointestinal tract and the adipose tissue work together to 
regulate energy intake to achieve energy homeostasis. The adipokines and peptides secreted by the 
gastrointestinal tract and the adipose tissue directly and indirectly activate and inhibit orexigenic and 
anorexigenic neurones within the central nervous system (hypothalamus and brainstem). The neurones 
secrete neuropeptides that regulate the sense of satiety and hunger respectively. Furthermore, irisin, 
noradrenaline and thyroid hormones increase energy output via stimulating non-shivering thermogenesis.             
                             Adapted from (Hopkins, Blundell 2016) 
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1.2.2.1 Central Nervous System 
The processing unit of the CNS, the hypothalamus and the brainstem receive a variety of 
signals from the afferent pathway (the gut and endocrine organs) and together with the 
efferent pathway regulate appetite and satiety. The CNS regulates energy intake and body 
weight through three mechanisms; 1) psychological and behavioural (feeding and 
physical activity), 2) effects on autonomic nervous system (regulates physical activity 
and metabolism) and 3) effects on neuroendocrine system, including secretion of 
hormones (Spiegelman, Flier 2001).  The correct synchronisation of these levels reflects 
Figure 1.4: Hypothalamic and brainstem regions. The hypothalamus and brainstem receive and process 
neuronal, endocrine and metabolic signals and facilitate behavioural, autonomic and endocrine responses. 
 Hypothalamus- PVN=Paraventricular nucleus, DMN=Dorsomedial hypothalamic nucleus, LHA=Lateral 
hypothalamus, VMN=Ventromedial nucleus, ARC=Arcuate nucleus and ME=Median eminence. Brainstem- 
NTS=nucleus of the solitary tract, AP=Area postrema and DMV=Dorsal motor vagal nucleus 
    (Suzuki, Simpson et al. 2010) 
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the physiological impact of appetite on energy regulation, whereas, desynchronization of 
these processes disrupts appetite and result in eating disorders. 
1.2.2.1.1 Role of the Hypothalamus 
The hypothalamus is a critical region of the brain that is involved in regulating many 
physiological functions including thermogenesis, feeding and reproduction (Elmquist, 
Elias et al. 1999). The hypothalamus receives and processes neuronal, endocrine and 
metabolic signals and mediates behavioural, autonomic and endocrine responses 
(Spiegelman, Flier 2001).  
The role of the hypothalamus in feeding is based on early studies of lesioning experiments 
in the hypothalamus; lesions in the ventromedial hypothalamus or the satiety centre cause 
obesity whilst lesions in the lateral hypothalamus (LH) or the hunger centre cause 
leanness  and since many area of the hypothalamus have been identified to regulate satiety 
and hunger by interacting with the brainstem and higher cortical centres (Figure 1.4) 
(Elmquist, Elias et al. 1999, Suzuki, Simpson et al. 2010). In addition, some authors 
suggest a direct interaction between peripheral signals and the CNS may occur due to 
incomplete blood-brain barrier (BBB) (Suzuki, Simpson et al. 2010, Gross 1992).  
There are two populations of neurones with opposing effects that work in concordance 
on food intake within the arcuate nucleus (ARC) (Figure 1.5). One population of neurones 
express NPY and agouti related peptide (AgRP) that stimulate food intake, whereas the 
other population express pro-opiomelanocortin (POMC) and cocaine-and amphetamine-
regulated transcription (CART) that inhibit feeding (Suzuki, Simpson et al. 2010). The 
POMC neurones synthesise the α-MSH, which binds to melanocortin-4 receptors 
(MC4R) within the paraventricular nucleus (PVN) to supress food intake (Schwartz, 
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Woods et al. 2000). Knockouts and mutations of MC4R are associated with hyperphagia 
and obesity, and in fact, mutations of MC4R account of approximately 6% of serve early 
on-set of obesity (Huszar, Lynch et al. 1997, Tao 2005). Common variants near the MC4R 
gene have shown to influence fat mass, weight and increase the risk of obesity (Loos, 
Lindgren et al. 2008).  
 
Figure 1.5:  Appetite regulation by the central nervous system. Appetite is regulated by communication 
between the hypothalamus, brainstem and cortical areas. Peripheral signals convey information directly and 
indirectly via the vagus nerve or influence the appetite controlling pathways such as NPY/AgRP and 
POMC/CART neurones with the ARC, respectively.  
CNS=Central nervous system, ARC=arcuate nucleus, NPY=Neuropeptide Y, AgRP=Agouti related peptide, 
POMC/CART=Pro-opiomelanocortin and cocaine- and amphetamine-regulated transcript, 
PVN=Paraventricular nucleus, LHA=Lateral hypothalamic area, DMN=Dorsomedial nucleus, 
VMN=Ventromedial hypothalamic nucleus, ME=Median eminence, DVC=Dorsal vagal complex, 
DVN=The dorsal motor nucleus of vagus, NTS=The nucleus of the solitary tract, AP=Area postrema, GI 
tract=Gastrointestinal tract, TRH=Thyrotropin-releasing hormone, CRH=Corticotrophin-releasing 
hormone, MCH=Melanin-concentrating hormone, BDNF=Brain-derived neurotrophic factor, GLP-
1=Glucagon-like peptide-1, CCK=Cholecystokinin, PP=Pancreatic polypeptide, PYY=Peptide YY, 
OXM=Oxyntomodulin and BBB=Blood-brain barrier.                                  (Suzuki, Simpson et al. 2010) 
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The NPY/AgRP neurones extend in various areas within the hypothalamus including the 
PVN, dorsomedial nucleus (DMN) and LH. NPY mediates its orexigenic effect by 
stimulating the hypothalamic NPY receptor 1 and 5 and inhibiting POMC neurones in the 
ARC (Roseberry, Liu et al. 2004). Similarly, AgRP acts as a selective MC4R antagonist 
to stimulate hunger. Furthermore, the PVN also contains anorectic thyrotropin-releasing 
hormone and corticotrophin-releasing hormone that influence feeding and destruction of 
the PVN causes hyperphagia and obesity (Leibowitz, Hammer et al. 1981).  
1.2.2.1.2 Role of the Brainstem 
The brainstem plays an important role in regulating feeding behaviour as it receives, 
interprets and relays peripheral signals to the hypothalamus. It is involved in regulating 
ingestive behaviours including, swallowing, chewing, suckling and licking (Bailey 2008). 
The dorsal vagal complex, a region in the brainstem consists of the dorsal motor nucleus 
of vagus (primarily serves parasympathetic functions in the gastrointestinal tract), area 
postrema (controls feeding and metabolism) and the nucleus of the tractus solitarius 
(Suzuki, Simpson et al. 2010). The vagal afferent neurones within the brainstem express 
a variety of receptors including cholecystokinin (CCK) receptors, leptin receptor (Ob-R), 
NPY receptor, glucagon like peptide receptors, growth hormone secretagogue receptor 1 
and orexin receptor 1 and insulin receptors that regulate the feeling of satiety (Suzuki, 
Simpson et al. 2010).  
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1.2.2.2 Gastrointestinal tract 
The gastrointestinal tract (or the digestive tract) is responsible for regulating intake of 
food, digestion, absorption of nutrients and expelling waste. Communication between the 
gastrointestinal tract and the central nervous system allows the modulation of the 
gastrointestinal tract functions to increase the efficiency of digestion and influence 
appetite (Spreckley, Murphy 2015). It is the largest endocrine organ found in the body as 
it produces more than 30 hormones and over 100 active biopeptides that are involved in 
regulating functions that affect appetite such as, gastric emptying, digestion and 
absorption (Moehlecke, Canani et al. 2016) (Table 1.6). Dysregulated signalling of the 
gut hormones and peptides cause eating disorders. The most commonly known gut 
hormones and peptides and their implications in obesity are discussed below.  
1.2.2.2.1 Peptide tyrosine tyrosine   
PYY is a 37.5 kDa hormone encoded by the PYY gene and is secreted from the L-cells of 
the small intestine in response to nutrient ingestion and directly and indirectly regulates 
energy intake and homeostasis (Figure 1.6). The basal circulating levels of PYY rapidly 
increase following food intake and are proportionate to calorie intake (Adrian, Ferri et al. 
1985). Circulating PYY undergoes proteolytic cleavage by dipeptidyl-peptidase IV 
(DPPIV) to produce PYY 3-36, the most common form found in the circulation (Keire, 
Bowers et al. 2002). PYY3-36 binds to NPY receptor 2 present in the hypothalamus and 
inhibits the activity of NPY/AgRP and stimulates the POMC/CART neurones in the 
hypothalamus to induce satiety (Batterham, Cowley et al. 2002). Previous studies report 
obese individuals have reduced basal circulating levels of PYY and the rise in PYY 
following a meal is blunted (Batterham, Cowley et al. 2002, Alvarez Bartolome, Borque 
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et al. 2002, Ashby, Bloom 2007). Peripheral administration of PYY3-36 in mice reduces 
food intake and body weight and infusion in both lean and obese individuals reduce 
appetite (Batterham, Cowley et al. 2002, Batterham, Cohen et al. 2003).  
In addition to regulating energy intake, PYY may be involved in regulating glucose 
homeostasis via modulating the function of pancreatic β cells. Full length PYY inhibits 
glucose stimulated insulin secretion from murine islets and PYY-/- mice develop 
hyperinsulinemia and obesity (Spreckley, Murphy 2015, Boey, Lin et al. 2006). However, 
PYY3-36 does not appear to have additive effects in regulating glucose stimulated insulin 
secretion, as the combined intravenous infusion of PYY3-36 and GLP-1 to overweight 
individuals increased insulin secretion to the same level as GLP-1 alone (Tan, Salem et 
al. 2014).  
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1.2.2.2.2 Proglucagon derived peptides 
Proglucagon is an 18-kDa hormone encoded by the GCG gene and undergoes tissue 
specific posttranslational processing to generate peptides including, glucagon, GLP-1, 
glucagon like peptide 2 (GLP-2), oxyntomodulin (OXM) and glucagon peptides (Figure 
1.7) that are involved in glucose and energy homeostasis. The basal circulating levels of  
Figure 1.6: Summary of the target areas of PYY and GLP-1. PYY and GLP-1 are secreted by the intestinal 
L-cells and are secreted into the bloodstream following nutrient ingestion. PYY and GLP-1 directly and 
indirectly regulate energy intake and energy homeostasis by binding to and activating the energy regulating 
centres in the hypothalamus, regulate insulin secretion from the pancreas and communicate with the 
hypothalamus via the vagus afferent nerve.     
PYY= Peptide tyrosine tyrosine  and GLP-1= Glucagon line like peptide 1,Y1= PYY receptor 1 and Y2= 
PYY receptor 2                             (Spreckley, Murphy 2015) 
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GLP-1 increase after a meal or anticipation of a meal and decrease in the fasted state 
(Vahl, Drazen et al. 2010). GLP-1 reduces food intake, supresses glucagon secretion and 
delays gastric emptying by binding to GLP-1 receptor (GLP-1R) found in the brain, 
gastrointestinal tract and pancreas (Figure 1.6) (Holst 2007, Yamato, Ikegami et al. 1997). 
GLP-1 effects food intake via several mechanisms directly (central GLP-1) and indirectly 
(peripheral). Peripheral GLP-1 activates POMPC/MSH neurones to induce satiety as 
Figure 1.7: Summary of proglucagon posttranslational processing. The Proglucagon gene is expressed in 
several tissues including, the pancreas, the gastrointestinal tract and the pancreas and transcription of the 
gene is activated by fasting and hypoglycaemia. Proglucagon undergoes tissue specific posttranslational 
processing to generate different peptides. In the pancreas, proglucagon is cleaved by the PC-2 to produce 
GRPP, glucagon and major proglucagon fragment. In the gastrointestinal tract and the brain, proglucagon 
is cleaved by PC-1/3 to produce glicentin, (further processed to produce GRPP and oxyntomodulin), GLP-
1 and GLP-2.                                                            
PC-= Prohormone convertase GRPP= Glicentin-related Pancreatic Peptide, GLP-= Glucagon Like Peptide 
(Holst 2007) 
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supported by peripheral administration of liraglutide, a long-acting GLP-1 analogue 
which acts on POMC neurones to induce weight loss (Secher, Jelsing et al. 2014). Obese 
individuals have a blunted postprandial GLP-1 response compared to lean, however, 
studies show intravenous infusion of GLP-1 results in dose-dependent reduction in food 
intake in both obese and lean subjects (Verdich, Flint et al. 2001, Holst 2007).  Though 
GLP-2 delays gastric emptying to retain the sense of satiety, it has not shown any 
significant effects on food intake in both rodent and human studies (Nagell, Wettergren 
et al. 2004). Circulating OXM levels increase after food intake and are in proportion to 
calorie intake and may mediate their effects through binding to GLP-1R (Baggio, Huang 
et al. 2004). Exogenous administration has shown to decrease food intake and increase 
energy expenditure in humans (Cohen, Ellis et al. 2003). Similarly, administration of 
glucagon reduces food intake, meal size and body weight gain in rats (Chan, Mackey et 
al. 1984, Geary, Le Sauter et al. 1993).  
Peripherally, GLP-1 has several effects, the most notable being the incretin effect which 
is estimated to account for 50-70% of the insulin response to glucose taken orally opposed 
to intravenous infusion (Vilsboll, Holst 2004). GLP-1 binds to GLP-1R present in the 
pancreatic β cells and stimulates the rapid secretion of insulin in a glucose dependent 
manner (activates adenylate cyclase and increases cyclic Adenosine Monophosphate 
(cAMP) augments glucose dependent insulin secretion) (Meek, Lewis et al. 2016) . 
DPPIV cleaves and inactivates GLP-1 and DPPIV inhibitors have shown positive results 
when given in combination with other glucose lowering drugs such as Metformin. 
Combination of DPPIV inhibitors and metformin treatment show improved glycaemic 
control and reduction in body weight in obese T2DM individuals (Velija-Asimi, 
Izetbegovic et al. 2013). 
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1.2.2.2.3 Insulin 
Insulin is a 5.81 kDa peptide hormone encoded by the INS gene and primarily function is 
to regulate glucose and lipid metabolism by stimulating glucose uptake in peripheral 
tissues, stimulating lipogenesis and inhibiting lipolysis. It secreted by in a glucose 
stimulated manner (some amino acids and fatty acids can also induce its secretion) by 
inhibiting the ATP-sensitive potassium channels leading to depolarisation o the plasma 
membrane, opening of the voltage-dependent calcium channels and mediating calcium 
influx, eventually leading to exocytosis of insulin-containing granules (Fu, Gilbert et al. 
2013). Originally insulin activity was believed to be limited to peripheral tissues as it is 
too large to cross the BBB and neurones do not need insulin to take up and metabolise 
glucose as an energy source (Seaquist, Damberg et al. 2001). However, it is now known 
to enter the brain by receptor-mediated transport (bind to and activate insulin receptors) 
and trigger a diverse range of events including energy intake, SYS activity and peripheral 
insulin action (Plum, Schubert et al. 2005). Plasma insulin levels reflect adiposity, as they 
are increased in obese individuals and are directly proportional to the amount of white 
adipose tissue (WAT), therefore insulin is considered to be an important signal in 
indicating the degree of adiposity to insulin sensitive tissue (Woods, Lutz et al. 2006). 
High concentration of insulin receptors are expressed in the ARC nucleus of the 
hypothalamus where it is thought to mediate most of its catabolic actions (reduce food 
intake and reduce body fat) by supressing the expression and secretion of orexigenic 
peptides and increase the expression and secretion of anorexigenic peptides, as described 
in Figure 1.7 (Breton 2013). Furthermore, activation of the insulin receptors in the 
hypothalamus stimulate the vagal efferent signals to the liver to supress glucose 
production (Obici, Zhang et al. 2002). Mice lacking insulin receptors specifically in 
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neurones and mice with decreased insulin signalling in the hypothalamus have increased 
food intake and an obese phenotype, whereas, central administration of insulin decreases 
food intake resulting in weight loss in a dose dependent manner (Obici, Zhang et al. 
2002).  
Peripheral insulin resistance leads to elevated plasma fatty acid levels, decreased glucose 
uptake, increased lipolysis and elevated hepatic glucose production (Al-Goblan, Al-Alfi 
et al. 2014). Increased secretion of non-esterified free fatty acids (NEFA), hormones, 
cytokines, adipokines and glycerol in obesity are associated with the development of 
insulin resistance and T2DM (Al-Goblan, Al-Alfi et al. 2014). Pancreatic β cells of the 
islet of Langerhans overcompensate to overcome insulin resistance to maintain a normal 
glucose tolerance in obese individuals, therefore, most obese individuals do not develop 
hyperglycaemia, despite being insulin resistant (Roder, Porte et al. 1998). However, 
impairment of pancreatic β cell function and decrease in insulin sensitivity lead to the 
development of T2DM (Boden 1996).  
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1.2.2.3 Adipose tissue 
The adipose tissue serves two main functions; 1) storing energy and 2) regulating 
physiological functions including energy regulation, metabolism and inflammation 
(Trayhurn, Beattie 2001). It achieves the latter by secreting a range of adipose tissue 
specific hormones (adipokines) and cytokines into the surrounding environment and the 
systemic circulation where they act in an autocrine, paracrine and endocrine manner and 
regulate local and systemic metabolism and energy homeostasis.  
Leptin is a 16 kDa adipokine encoded by the LEP gene and is a well-known adipokine 
involved in regulating energy intake as it acts a ‘starvation signal’ and rapidly declines 
during fasting, it triggers a rise in glucocorticoids and reduces the levels of hormones 
associated with thermogenesis including thyroxine (T4), sex and growth hormone (GH) 
(Ahima, Kelly et al. 1999). Mice lacking functional leptin (ob/ob mice) show 
hyperphagia, obesity and insulin resistance (Friedman, Halaas 1998). Daily leptin 
injections rapidly decrease food intake, reduce body mass and percentage body fat, 
increase energy expenditure and restore euglycemia in ob/ob mice (Campfield, Smith et 
al. 1995). Leptin mediates it’s effects by binding to and activating the Ob-R in the brain 
and peripheral tissues. The Ob-Ra isoform is thought to play an important role in 
transporting leptin across the BBB (Bjorbaek, Elmquist et al. 1998). Once across, it binds 
to Ob-Rb isoform expressed in the hypothalamus, activates the janus kinase-signal 
transducer and activator of transcription pathway and decreases orexigenic and increases 
anorexigenic peptide synthesis thereby, decreasing appetite (Figure 1.8) (Breton 2013). 
However, leptin levels increase in models of human and rodent obesity but without the 
anorexic effect and have little to no impact on regulating energy homeostasis as expected, 
hence ‘leptin resistance’ is believed to occur (Bakker, Van Dielen et al. 2004). Preclinical 
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and clinical experiments show obese humans and rodents indeed display leptin resistance 
which may be a contributing factor in reducing lipid oxidation in insulin-sensitive organs 
and leading to lipid accumulation and insulin resistance (van den Hoek, Teusink et al. 
2008, Zhang, Xie et al. 2010).  Aside from mutations in the Ob-R, the underlying 
mechanisms leading to leptin resistance are under investigation (Montez, Soukas et al. 
2005). Suppressor of cytokine signalling 3 (SOCS3); a negative regulator of cytokines, is 
proposed to be involved in negatively regulating leptin-induced intracellular signalling 
cascade in the brain (Mori, Hanada et al. 2004) and neuronal deletion and whole body 
knockout of protein tyrosine phosphatase 1B; a negative regulator of insulin, increased 
leptin and insulin sensitivity, prevented weight gain in diet induced animal models of 
obesity (Bence, Delibegovic et al. 2006, Zabolotny, Bence-Hanulec et al. 2002). 
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Figure 1.8: Leptin and insulin intracellular signalling pathways in the Arcuate Nucleus of the 
hypothalamus. Leptin binds to the Ob-Rb in the arcuate nucleus and induces the JAK2-STAT3 mediated 
intracellular signalling cascade. STAT3 dimers translocate to the nucleus and transactivate target genes. 
Insulin binds to the InSR in the arcuate nucleus and induces receptor tyrosine autophosphorylation and 
activation of the PI3K-PKB (Akt) mediated intracellular signalling cascade to regulate cellular processes. 
Leptin and insulin reduced the expression and release of orexigenic peptides such as NPY and AgRP and 
activate anorexigenic peptide such as a-MSH.  Binding of NPY to YR1 receptors in the lateral hypothalamic 
area increases the expression and release of orexigenic peptides such as, orexins and MCH, whereas, 
binding of α-MSH binds to the MC4R receptors in the paraventricular nucleus decreases food intake and 
increases energy expenditure.  
Ob-Rb=Leptin receptor b, JAK2=Janus kinase 2, STAT3=Signal transducer and activator of transcription 
3, InSR=Insulin receptor, PI3K=Phosphoinositide 3 kinase, PKB/Akt=Protein kinase B, NPY=neuropeptide 
Y, AgRP=agouti-related peptide, α-MSH=α-melanocyte stimulating hormone, YR1=NPY receptor1, 
MCH=Melanin-concentrating hormone, MC4R=Melanocortin 4 receptors, CRH=Corticotropin-releasing 
hormone, TRH=Thyrotropin-releasing hormone, SOCS3=Suppressor of cytokine signalling 3 and 
IRS=Insulin receptor substrate.                    (Breton 2013)
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1.3 The adipose tissue as a regulator of energy storage and homeostasis 
The adipose tissue is a complex, essential and a highly active organ that serves as the 
primary energy storage hub for mammals (Table 1.6). It is a specialised connective tissue 
that is designed to synthesise and store energy in the form of triacylglyceride 
(triglycerides) within small droplets. It forms in utero in the peripartum period and 
throughout life (in adult humans the adipose tissue cells are continually generated at a 
substantial rate) (Berry, Stenesen et al. 2013).  It is thought to have evolved as a storage 
organ during times of plenty to regulate energy metabolism and provide fuel during 
periods of starvation. However, discoveries of adipokines in the early 1990’s recognised 
the tissue as an endocrine organ participating in many physiological functions including 
metabolism, inflammation and energy regulation (Trayhurn, Beattie 2001). The two 
common forms of adipose tissue are WAT and BAT, and both have distinct biological 
functions. The functional differences and balance between WAT and BAT help to 
maintain energy homeostasis within the body.  
ENERGY FORM STORAGE KCAL 
TRIACYLGLYCERIDE ADIPOSE TISSUE 100,000 
PROTEIN MUSCLE 25,000 
GLYCOGEN LIVER 600 
GLUCOSE OR LIPID BODY FLUIDS 40 
Table 1.6: Energy stores in a 70kg adult male. A typical 70kg man has fuel reserves of 100,000 kcal (420,000 
kJ) in triacylglyceride, 24,000 kcal (100,000 kJ) in protein, 600 kcal (2500 kJ0 in glycogen and 40 kcal (170 
kJ) in glucose. Triacylglyceride constitute about 11kg of the 70kg body weight and allow survival for several 
weeks. 
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WAT is far more prevalent than BAT and is thought to be more biologically relevant, 
especially in adults. In human adults, the WAT is one of the largest tissues and is found 
in many depots within the body and categorised as major depots, subcutaneous WAT 
(scWAT) and visceral WAT (vWAT). scWAT is located in the hypodermis layer of the 
skin where it acts as a barrier against infections, insulates to prevent heat loss and 
cushions for protection against mechanical stress (Kwok, Lam et al. 2016). In contrast, 
vWAT is found around vital organs within the peritoneum and rib cage where it provides 
protection to internal organs, as shown in Figure 1.9. WAT accounts for about 10-15% of 
the total body weigh increasing up to 50% in obese individuals (Obregon 2014). Although 
the primary function of the WAT is to serve as an energy store, it is now believed to be 
one of the largest endocrine organs of the body involved in regulating many aspects of 
Figure 1.9: Location of white adipose tissue depots. White adipose tissue is found in two main depots; 
scWAT and vWAT. scWAT is found beneath the skin (abdominal and gluteal-femoral) where it acts as an 
insulator and protects against mechanical stress. vWAT surrounds vital organs (epicardial and mesenteric) 
to provide protection.  
scWAT= Subcutaneous white adipose tissue and vSAT= visceral white adipose tissue.       (Obregon 2014) 
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the systemic metabolism by secreting adipokines, lipids and cytokines (Berry, Stenesen 
et al. 2013) . These molecules are involved in a range of biological activities including 
regulation of appetite, glucose homeostasis, insulin sensitivity, ageing and fertility. The 
role of WAT in regulating these activities is prevalent in metabolic diseases such as 
hyperglycaemia, hyperlipidaemia, hypertension and T2DM that occur as a consequence 
of too many (obesity) or too few (lipodystrophy) white adipocytes (Berry, Stenesen et al. 
2013). 
 
It is augmented that BAT gave mammals the evolutionary advantage to survive and be 
active during periods of nocturnal or hibernal cold, to survive the cold stress of birth and 
survive on diets low in essential macronutrients especially protein (Cannon, Nedergaard 
Figure 1.10: Location of brown adipose depots in human infant and adult. Brown adipose tissue (BAT) 
regulates body temperature and is more prevalent in infants than in adults due to the small volume to area 
ratio. In infants it is found within one big depot (interscapular) whereas, in adults it is found in different 
areas such as the neck, supraclavicular, periaortic, and perirenal.         (van den Berg, van Dam et al. 2017) 
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2004). Until recently, BAT was only considered physiologically relevant in new-borns 
and infants. The amount and distribution of the BAT varies between new-born, infants 
and adults as well as between different mammalian species. The distribution of 
physiologically active BAT is found in all areas of the body in new-born mammals 
(Figure 1.10) (van den Berg, van Dam et al. 2017). This gradually disappears and 
becomes confined with age. In human adults, BAT is distributed throughout the cervical 
(neck), supraclavicular (shoulder), axillary (underarm), paravertebral (spine), mediastinal 
(central) and upper abdominal regions serving as a warming mechanism for vital organs 
(Saely, Geiger et al. 2012), as shown in Figure 1.9. Furthermore, it provides protection 
for the heart, kidney and other organs (Obregon 2014).  
The WAT is a heterogeneous tissue composed to ~50% of energy storage cells (mature 
adipocytes) that synthesise and store triacylglyceride, and synthesise and adipokines, 
growth factors, cytokines and hormones to regulate energy homeostasis. The other ~50% 
are the stromal vascular fraction cells (SVF) which include, microvascular and immune 
cells, preadipocytes, mesenchymal stem cells and endothelial progenitor cells which are 
involved in secreting several inflammatory mediators including, cytokines and signalling 
proteins that promote angiogenesis, preadipocyte differentiation into mature adipocytes 
and activation of the immune system (Iyer, Fairlie et al. 2010). Thus, a healthy amount of 
adipose tissue is crucial for health and pathophysiological changes in the production and 
secretion of adipose tissue specific proteins can results in alterations in adiposity leading 
to diseases such as, obesity and cachexia (wasting syndrome).  
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1.3.1 Preadipocytes and mature adipocytes  
 
Adipocytes, otherwise known as fat cells, play a crucial role in regulating several aspects 
of ‘normal’ physiology. White adipocytes (of the WAT) are the principle site for energy 
storage and accumulate excess energy in the form of intracellular triacylglyceride packed 
into a large unilocular lipid droplet (Figure 1.11). The lipid droplet as it makes up about 
90% of the cells volume and determines the size of the adipocyte (however, a typical 
white adipocyte is about 0.1mm in diameter). White adipocytes synthesise and secrete 
adipokines, hormones and cytokines that influence several physiological functions, 
therefore, are also considered as endocrine cells (Ouchi, Kihara et al. 2001). In contrast, 
brown adipocytes (of the BAT) use intracellular triacylglyceride as an energy source, 
convert chemical energy (ATP) into heat to aid internal thermoregulation and regulate 
Figure 1.11: Transmission electron microscopy of white and brown adipocytes. The morphological 
differences of the white and brown adipocytes are indicated above. Nucleus (N), Mitochondria (M), Lipid 
droplet (L), pinocytotic vesicles (V) and external basal membrane (BM). White adipocyte bar=0.7mm and 
Brown adipocyte bar=0.6mm.                       (Cinti 2015) 
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glucose and lipid homeostasis. They are characterised by the abundant presence of 
mitochondria, multilocular lipid droplets and specific expression of uncoupling protein 1 
(UCP1) (Figure 1.11) (Rosen, Spiegelman 2014). Brown adipocytes have a large quantity 
of mitochondria which are also larger in size (>0.5µM) than white adipocytes, as shown 
in Figure 1.11 (Arbuthnott 1989). The cristae of mitochondria are tightly packed together 
creating a large surface of inner membrane in comparison to the outer membrane allowing 
increased presence of uncoupling component such as UCP1 to maximise heat production 
(Arbuthnott 1989). 
1.3.1.1 Development of adipocytes and their precursors 
The earliest studies of adipocyte development reported opposing views of their 
embryonic origin. Flemming; a notable anatomist argued adipocytes originated from 
loose connective tissue and that nearly all of the fibroblast-like cells had the capability to 
store triacylglyceride and become lipid-laden cells (Hepler, Vishvanath et al. 2017). Other 
notable anatomists; Toldt and Wasserman believed the adipose tissue also followed a 
developmental pattern in which adipocytes emerge from specific precursor cells (similar 
to other tissues and organs) and reported that they emerge in conjunction with dense 
network of blood vessels (Hepler, Vishvanath et al. 2017). Recent reports have 
highlighted and demonstrated the importance and dependence of adipocytes on 
angiogenesis for tissue development (Han, Lee et al. 2011).  
Adipocyte development occurs during the entire lifespan of an organism through a 
process called adipogenesis. It is a two-step process in which an undifferentiated 
mesenchymal stem cells (MSC) differentiates into a preadipocyte, which then undergoes 
a second differential process to become a mature lipid-filled adipocyte. Studying 
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differentiation of MSC to preadipocyte is difficult both in vivo and in vitro as they are 
difficult to distinguish from fibroblasts and are found in different developmental stages 
within the adipose tissue (Ali, Hochfeld et al. 2013). However, preadipocyte 
differentiation into mature adipocytes is the most intensively studied developmental 
process for two reasons; the increasing prevalence of obesity and the availability of good 
cell culture models of adipocyte differentiation.   
1.3.1.2 Origin of adipocyte precursors  
White adipocytes are widely distributed and are found throughout the body, organised 
into distinct tissues or depots. These depots are reflective of their general anatomical 
localisation and develop at different foetal stages (Hepler, Vishvanath et al. 2017). 
scWAT depots emerge perinatally, whilst most intra-abdominal depots (vWAT) take 
form after birth (Wang, Tao et al. 2013). Though the precise developmental origin of 
WAT during foetal development is unclear, lineage tracing studies in mice indicate 
scWAT and vWAT depots emerge from distinct mesenchymal lineages (Hepler, 
Vishvanath et al. 2017). Interestingly, adipocytes in vWAT depots, but not in scWAT 
depots descend from cells expressing the mesothelial cell marker Wilms tumour 1 (WT1), 
suggesting the lateral plate mesoderm as the foetal origin of vWAT (Figure 1.12) (Chau, 
Bandiera et al. 2014). Furthermore, individual depots may contain adipocytes that emerge 
through distinct lineages, such as neuroectoderm as neuroepithelia have the capacity to 
differentiate into mature adipocytes that have different functions and express differing 
molecular programs (Takashima, Era et al. 2007). Although developmental origins of 
white adipocytes and factors influencing this process remain inconclusive, they originate 
from an MSC population and develop from a myogenic factor 5 negative progenitor into 
committed white preadipocytes (Figure 1.11) (Obregon 2014). These cells are thought to 
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reside in mural cell compartment of the SVF of the adipose tissue (Tang, Zeve et al. 2008). 
Furthermore, genetic labelling of Zinc finger protein -423 (Zfp-423); a transcription 
factor enriched in adipocyte precursors demonstrated a perivascular origin, whilst 
vascular endothelial-cadherin promoter driven lineage tracing experiments concluded 
both pericytes and murine endothelial cells can differentiate into preadipocytes (Gupta, 
Arany et al. 2010, Gupta, Mepani et al. 2012, Tran, Gealekman et al. 2012). The resultant 
cells cannot be morphologically distinguished from MSCs in appearance, but they lose 
their ability to differentiate into other cell types. Several transcription factors have been 
identified as regulators of preadipocyte determination; these include, Zfp-423, 
Transcription factor 7I1 and Early B cell factor 1 as positive regulators and Zfp-521 and 
Wingless-type MMTV integration site family (WNT)-1 inducible signalling pathway 
protein 2 as negative regulators (Ma, Lee et al. 2015). This commitment involves gradual 
reduction of developmental options and ultimately renders the cells to becoming only a 
single cell type, in this case, a lipid bearing endocrine cell.  
BAT is the first to be formed during embryonic development and the thermogenic 
capacity is fully functional by birth (Hepler, Vishvanath et al. 2017). Like white 
adipocytes, the origin of brown adipocytes is thought to differ depending on the depot. 
Brown adipocytes in the dorsal depot are thought to originate from the paraxial 
mesoderm, whereas, cells marked by homeobox gene engrailed 1 expression give rise to 
brown adipocytes in anterior depots (Atit, Sgaier et al. 2006). Brown adipocytes also 
share common lineage with skeletal muscle cells rather than white adipocytes as they 
originate from myogenic factor 5 positive and paired box 9 positive cells; these 
transcription factors define the myogenic precursors and regulate skeletal myogenesis 
(Seale, Bjork et al. 2008, Lepper, Fan 2010). The emergence of brown adipocyte-like 
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cells (beige/brite) in WAT upon cold exposure suggests brown adipocytes also emerge 
from other cellular sources (Petrovic, Walden et al. 2010, Walden, Hansen et al. 2012). 
These adipocytes express high levels of UCP1 but are molecularly and possibly 
functionally distinct from classical brown adipocytes as they also exhibit properties of 
white adipocytes. Though the origin of these ‘beige/brite’ adipocyte is not fully 
understood, some researcher suggest that these may arise from direct transformation or 
trans-differentiation from white adipocytes, whilst some studies support the presence of 
distinct inducible beige/brite precursors within WAT (Barbatelli, Murano et al. 2010). 
The PRD1-BF-1-RIZ1 homologous domain containing protein-16 (PRDM16) is a key 
regulator of classical brown adipocyte development (Figure 1.12) (Seale, Kajimura et al. 
2007). Its expression is enough to induce brown adipocyte phenotype and functions 
including, biogenesis and respiratory uncoupling. Loss of PRDM16 causes near total loss 
of brown adipocyte characteristics.  PRDM16 is highly expressed in scWAT and its 
transgenic expression in all adipose tissue results in transformation of scWAT to brown 
adipocyte-like phenotype (Seale, Conroe et al. 2011). 
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Figure 1.12: Development of adipocytes. Adipocytes originate from the mesodermal germ layer. The 
mesenchymal stem cells differentiate into adipocyte precursors (adipoblasts/ Myf5- progenitor) and give rise 
to white adipocytes or muscle precursors (myogeneic lineage/ Myf5+ progenitor) and give rise to brown 
adipocytes.  
Myf=Myogenic factor 5, BMP7=Bone morphogenetic protein 7, FGF10=Fibroblast growth factor 10, 
Pref1=Preadipocyte factor 1, c/EBPα=CCAAT/enhancer-binding protein α, PRDM16=PR domain 
containing 16, PPARγ=Peroxisome proliferator-activated receptor γ, Myo D=Myoblast determination 
protein 1, HoxC9=Homeobox protein C9, Tcf21=Transcription factor 21, UCP1=Uncoupling protein 1, 
CD137=Clustering domain 137, CIDEA=Cell death inducing DFFA like effector A, dio2=Iodothyronine 
deiodinase 2,  PGC1=PPARγ coactivator 1α and Zic1=Zinc finger protein 1          
                                           (Obregon 2014) 
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1.3.1.3 Differentiation of preadipocytes into mature adipocytes 
Adipogenesis is a process described by chronological changes in the expression of 
specific genes and morphological changes that determine the exact adipocyte phenotype. 
The process of adipogenesis is separated into 3 phases; determination, growth arrest and 
terminal differentiation and depends on two factors; communication between individual 
cells and with the extracellular environment (Ali, Hochfeld et al. 2013). Though 
molecular details of adipogenesis are still unknown, it is clear that both white and brown 
adipocytes require key transcription factors that are necessary to promote this process. 
These include key transcriptional factors include, peroxisome proliferator-activated 
Figure 1.13: Differentiation of preadipocyte into a mature adipocyte.  The processes of adipocyte 
differentiation begin with clonal expansion of preadipocytes, followed by triacylglyceride (lipid) accumulation, 
a hallmark of mature adipocytes. The more triacylglyceride accumulate the more mature the adipocyte 
develops. Transcription factors that are positive and negative effectors regulate the process of differentiation 
and are induced at different stages.  
AP-1=Activator protein 1, KLF=Kruppel-like factors, C/EBP=CCAAT-enhancer-binding protein, 
PPARγ=Peroxisome proliferator-activated receptor γ, STAT5A=Signal Transducer and activator of 
transcription 5A, SREBP-1=Sterol regulatory element binding protein 1, GATA=GATA binding protein, 
PREF-1=Preadipocyte factor 1 and Wnt=Wingless/integrated  
                          (Sarjeant, Stephens 2012) 
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receptor γ (PPARγ), CCAAT/enhancer-binding proteins (C/EBPs), signal transducers and 
activators of transcription (STATs) and Kruppel-like factor (KLF) proteins. These 
transcriptional factors regulate the mRNA expression of proteins involved in adipocyte 
function such as synthesis and storage of triacylglyceride, endocrine factors and 
thermogenesis.    
Adipogenic stimuli such as, GH, cAMP, insulin, glucocorticoids, steroid hormones and 
thyroid hormones (T3 and T4) induce preadipocyte clonal expansion. The process of 
preadipocyte differentiation commences with the activation of activating protein 1 (AP-
1) family of transcription factors and continues with the activation of other transcription 
factor families, as shown in Figure 1.13. When activated, AP-1 proteins (including proto-
oncogenes; c-Fos, c-Jun, Fos-B, and Fos-related antigen 1 form homo or heterodimers 
and interactive with DNA to regulate the expression of genes involved in proliferation 
and differentiation in a variety of cell types (Sarjeant, Stephens 2012). Mice with 
disrupted Jun transcriptional activity display impaired WAT development and 
significantly reduced BAT (Moitra, Mason et al. 1998). Following AP-1 induction, a 
range of transcriptional factors are activated to regulate adipogenesis. Though, the exact 
sequence in which these transcriptional factors are activated in not clear, it is well 
documented that they regulate adipogenesis by modulating the activity of PPARγ (Shao, 
Wang et al. 2016).  
1.3.1.3.1 Kruppel-like Factor Family 
The KLF family of transcription factors act as inducers and/or inhibitors of adipogenesis. 
For example, KLF4 and KLF5 expression is induced during the early stages of adipocyte 
differentiation and small interfering RNA (siRNA) knockdowns in 3T3L-1 preadipocytes 
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show impaired lipid accumulation and adipogenesis (Oishi, Manabe et al. 2005, Soukas, 
Socci et al. 2001). KLF6 and KLF15 promote adipogenesis by repressing delta-like 
protein 1 and induce the expression of PPARγ, respectively (Li, Yea et al. 2005, Mori, 
Sakaue et al. 2005). KLF2 is highly expressed in preadipocytes and is significantly 
reduced during adipogenesis. Ectopic expression of KLF2 in 3T3-L1 preadipocytes 
disrupts lipid accumulation by repressing PPARγ2 gene expression and partially restores 
preadipocyte factor 1 (Pref-1) expression (Banerjee, Feinberg et al. 2003, Wu, Srinivasan 
et al. 2005). Ectopic expression of KLF17, significantly inhibits adipocyte development 
and expression of PPARγ and C/EBPα, thus inhibiting adipogenesis (Kawamura, Tanaka 
et al. 2006). 
1.3.1.3.2 CCAAT/enhancer-binding Proteins 
The C/EBP family of transcription factors act as inducers of adipogenesis. C/EBP 
transcription factors have highly conserved domains that serve as interaction points for 
homo or heterodimerisation with other family members to induce transcription (Vinson, 
Sigler et al. 1989). C/EBPβ and δ are induced during early stages of differentiation and 
work together to trans-activate C/EBPα (Cao, Umek et al. 1991). Inhibition of C/EBPβ 
and/or δ attenuate adipogenesis in preadipocyte cell lines and show defective tissue 
development in deficient mice (Yeh, Cao et al. 1995, Tanaka, Yoshida et al. 1997). 
Furthermore, lipid accumulation is significantly low in mice deficient in C/EBPα (Wang, 
N. D., Finegold et al. 1995, Flodby, Barlow et al. 1996).   Phosphorylation of C/EBPα 
inhibits proliferation and initiates final stages of differentiation (Wang, Shi et al. 2006). 
It is thought to mediate anti-mitotic actions by inhibiting the expression of proteins that 
induce growth (growth arrest and DNA damage 45 and p21) thereby, arresting growth 
and promoting differentiation (Mandrup, Lane 1997).  
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1.3.1.3.3 Sterol Regulatory Element Binding Proteins  
Sterol regulatory element binding proteins (SREBP) -1 is a helix-loop-helix regulatory 
molecule that was originally termed, the adipocyte determination and differentiation 
factor 1 because it acts as an inducer of adipogenesis (Tontonoz, Kim et al. 1993). 
SREBP-1 exists in three isoforms; SREBP-1a, SREBP-1c and SREBP-2. SREBP-1c is 
predominantly expressed in WAT and regulates the transcription of lipogenic proteins, 
whereas, SREBP-2 regulates the expression of genes involved in cholesterol biosynthesis 
(Shimomura, Shimano et al. 1997, Horton, Shimomura et al. 1998). In vitro studies 
suggest SREBP-1 is required for adipocyte differentiation however, in vivo studies 
conclude it is not critical for the development and/or the expansion of the adipose tissue 
(Yahagi, Shimano et al. 2002, Sarjeant, Stephens 2012). 
1.3.1.3.4 Signal Transducers and Activators of Transcription (STAT’s) 
STATs are widely distributed and regulate the expression of tissue specific genes (Darnell 
1997). They are primarily activated by hormones and cytokines, and binding of these 
ligands initiate an intracellular cascade that results in STAT tyrosine phosphorylation, 
dimerization and translocation into the nucleus. STATs 1,3, 5A, 5B and 6 are expressed 
in adipocytes and STATs 1, 5A and 5B are significantly induced during differentiation in 
3T3-L1 preadipocytes (Stephens, Morrison et al. 1996). Knockout of STAT5A and/or 5B 
result in abnormal adipose tissue in transgenic mice, possibly due to PPARγ 
downregulation (Kawai, Namba et al. 2007). The expression of STAT3 increases during 
the early proliferative phase of adipogenesis and its expression is tightly regulated by 
protein inhibitors of activated STAT 3 (Deng, Hua et al. 2006). However, the role of 
STAT3 in adipocyte development is not clear as ectopic expression of dominant-negative 
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STAT3 supresses adipocyte differentiation, whereas, mice lacking STAT3 have increased 
body weight and adipocyte size compared to control (Wang, Zhou et al. 2009, 
Cernkovich, Deng et al. 2008). 
1.3.1.3.5 Peroxisome Proliferator-activated Receptor γ 
PPAR’s are nuclear receptors that act as transcription factors and play important roles in 
regulating adipogenesis, inflammation, atherogenesis, glucose homeostasis and cancer 
(Obregon 2014). PPARγ exists in two isoforms; PPARγ1 and PPAR γ2. PPARγ1 is 
expressed in multiple tissues, whereas, PPARγ2 is highly expressed in adipocytes and 
affects adipogenesis due to its increased sensitivity to ligands (Tontonoz, Hu et al. 1994, 
Ren, Collingwood et al. 2002, Mueller, Weaver et al. 2003). PPARγ is considered a 
master regulator of adipogenesis as mice with adipose tissue specific loss of PPARγ 
display decreased fat pad size and insulin resistance in the adipose tissue and liver, 
whereas, PPARγ heterozygous mice show enhanced insulin sensitivity, suggesting the 
amount of protein present is highly important (He, Barak et al. 2003, Miles, Barak et al. 
2000). Furthermore, in humans, mutations in PPARγ are associated with the development 
of severe insulin resistance, T2DM, hypertension and lipodystrophy (Barroso, Gurnell et 
al. 1999, Doney, Fischer et al. 2004, Monajemi, Zhang et al. 2007). Though PPARγ is 
required for adipogenesis, there is evidence to suggest it is not required to maintain the 
mature adipocyte phenotype (Liao, Nguyen et al. 2007). Majority of the activators and 
suppressors of adipocyte development mediate their action through modulating the 
activity of PPARγ. For example; C/EBPβ, C/EBPδ and KLF5 induce PPARγ mRNA 
expression, whereas, GATA2, KLF2 and CCAAT-enhancer-binding protein homologous 
proteins attenuate it (Rosen, Eguchi et al. 2009).   Due to its crucial role, the expression 
and activity of PPARγ is highly regulated and can be modulated by several pathways 
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including; the ubiquitin-proteasome system, small ubiquitin like modifier; SUMOylation 
and phosphorylation by mitogen-activated protein kinases (MAPK). However, in brown 
adipocytes, PPARγ coactivator-1α (PGC-1α) is the master regulator of mitochondrial 
biogenesis and is crucial for differentiation, as it stimulates UCP1 synthesis (Gill, La 
Merrill 2017). Other nuclear receptor co-regulators that induce brown adipocyte 
differentiation include, steroid receptor coactivator-1, transcriptional 
mediators/intermediary factor 2 and twist-related protein 1 (Glass, Rosenfeld 2000).  
1.3.1.3.6 GATA Factors 
The GATA transcription factors bind to specific (A/T)GATA(A/G) DNA consensus 
sequences and regulate cellular differentiation and proliferation (Weiss, Orkin 1995). 
From a total of 6 factors, only GATA2 and GATA3 are expressed in preadipocytes 
present within the WAT and not BAT and are thought to supress adipogenesis as their 
expression is repressed during this process (Tong, Dalgin et al. 2000). GATA2 deficient 
embryonic stem cells exhibit enhanced differentiation potential whereas, ectopic 
expression partially reduces adipocyte development by binding to PPARγ promotor 
region and supressing its activity (Tong, Dalgin et al. 2000). In addition, GATA2 and 
GATA3 can also disrupt the activity of C/EBPα and C/EBPβ thus, dysregulating and 
attenuating adipogenesis (Tong, Tsai et al. 2005). 
1.3.1.3.7 Preadipocyte Secreted Factor -1 
Pref-1 is a transmembrane protein that belongs to a family of EGF-repeat-containing 
proteins and is activated by proteolytic cleavage to regulate cell fate specification (Smas, 
Chen et al. 1997). Pref-1 is abundantly expressed in preadipocytes and the levels diminish 
during adipocyte differentiation (Smas, Kachinskas et al. 1998). Like other inhibitory 
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factors, constitutive expression of Pref-1 reduces PPARγ and C/EBPα expression and 
inhibits differentiation of 3T3-L1 preadipocytes (Smas, Sul 1993). Mice lacking Pref-1 
showed growth retardation and accelerated adiposity, whereas, ectopic expression in the 
adipose tissue led to severe lipodystrophy, impaired glucose tolerance and 
hypertriglyceridemia in transgenic mice (Moon, Smas et al. 2002, Lee, Villena et al. 
2003). 
1.3.1.3.8 Wingless-type MMTV Integration Site Family 
The WNT family of secreted glycoproteins have multiple effects on cell-fate 
specification, proliferation and differentiation (Cadigan, Nusse 1997). Upon binding to 
the Frizzled receptor, WNT activates the canonical pathway that inhibits glycogen 
synthase kinase-3 and results in an increase of cytosolic β-catenin which translocate to 
the nucleus and bind to the T-cell factor/lymphoid-enhancing factor transcription factors 
to regulate the expression of WNT target genes (Cadigan, Nusse 1997). WNT signalling 
proteins inhibit adipogenesis by reducing the expression of PPARγ and C/EBPα in 
preadipocytes (Ross, Hemati et al. 2000). WNT10b and Wnt5a are repressed during 
adipogenesis. Ectopic expression of WNT10b in transgenic mice results in 50% reduction 
in WAT, severally reduced BAT and they have a leaner phenotype without lipodystrophy 
diabetes (Longo, Wright et al. 2004). 
1.3.2 Energy storage function of adipocytes  
The main function of adipocytes is to store energy and maintain energy homeostasis by 
responding to different energy states and hormonal cues. The balance between energy 
storage and release is the main determinant of triacylglyceride build up within the adipose 
tissue and subsequently the body. During times of positive energy balance 
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(postprandially) adipocytes take up excess energy and stores it in the form of 
triacylglyceride. This approach serves to prevent ectopic lipid accumulations and 
metabolic complications as observed in lipodystrophy patients (Kwok, Lam et al. 2016). 
In contrast, they release energy in the form of NEFA’s from lipid droplets during phases 
of fasting, nutrient deficit and starvation. These NEFA’s enter the Krebs cycle and are 
converted into ATP via oxidative phosphorylation in the mitochondria (Figure 1.14). 
However, NEFA’s can also be taken up and accumulate as triacylglyceride in non-adipose 
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1.3.2.1 Storage of dietary fat and de-novo lipogenesis 
The synthesis and storage of triacylglyceride is crucial and strictly regulated in multiple 
tissues including, the adipose tissue, liver, muscle, heart and pancreas. Most of the energy 
stored within adipocytes is derived from diet. The specific fatty acid (saturated, 
Figure 1.14: Summary of ATP synthesis. Fatty acids and glucose are metabolised through enzymatic 
reactions, glycolysis and TCA cycle to generate reduced NADH and FADH2. The electrons derived from 
NAHD and FADH2 are used to generate ATP in oxidative phosphorylation. 
ATP= Adenosine triphosphate TCA= Tricarboxylic acid cycle, FAO= Fatty acid oxidation, NADH= 
Nicotinamide adenine dinucleotide, FADH2= Flavin adenine dinucleotide, H
+= Hydrogen, CI-CV= 
Oxidative phosphorylation complexes        
        (Nsiah-Sefaa, McKenzie 2016) 
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monounsaturated and polyunsaturated) stored in adipocytes reflects dietary intake (Frayn, 
Arner et al. 2006). Dietary lipids such as, triacylglyceride and fats are emulsified by bile 
salts/bile acids in the small intestine and are broken down to fatty acids by triacylglyceride 
lipases. The fatty acids are taken up by enterocytes by binding to intestinal fatty acid 
binding protein. Here, the fatty acids are converted back to triacylglyceride and packed 
into lipoprotein particles called chylomicrons and are circulated to lipid storing sites that 
express lipoprotein lipase (LPL), such as the adipose tissue, skeletal muscle and the liver 
(Frayn, Arner et al. 2006). LPL is an enzyme bound on the endothelial lining of the 
capillaries that catalyses the hydrolysis of triacylglyceride into glycerol and fatty acids 
which can migrate though the endothelial cell wall into the tissue. In adipocytes, the 
migration is mediated through fatty acid transporters such as, fatty acid translocase/CD63 
or through the fatty acid transport protein family (Frayn, Arner et al. 2006). 
The first step of free fatty acid esterification derived from the diet is the synthesis of 
glycerol-3-phosphate (G3P).  The synthesis of G3P and its subsequent conversion to 
triacylglyceride was described more than 40 years ago by Kennedy and co-workers 
(Ahmadian, Duncan et al. 2007). G3P is a glycolysis intermediate and is synthesised by 
reducing dihydroxyacetone phosphate by glycerol-3-phosphate dehydrogenase 
(Saponaro, Gaggini et al. 2015). The synthesis is also possible from amino acids and citric 
acid cycle intermediates via glyceroneogenesis and by phosphorylating glycerol 
generated upon hydrolysing fats with glycerol kinase (Nye, Hanson et al. 2008). Fatty 
acids are converted to Acyl-CoA by Acyl-CoA synthetase and along with G3P are 
converted to lysophosphatidic acid (1-acylglycerol-3-phosphate) by the rate limiting 
enzyme, glycerol-3-phosphate acyltransferase (Lehner, Kuksis 1996, Dircks, Sul 1999). 
Lysophosphatidic acid is further esterified and converted to phosphatidic acid (1,2-
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diacylglycerol-3-phosphate) by 1-acylglycerol-3-phosphate acyltransferase. 
Lysophosphatidic acid is shunted into the synthesis of various phospholipids or 
triacylglyceride (Ahmadian, Duncan et al. 2007).   
 
The body is also capable of synthesising triacylglyceride using non-fat precursors through 
a process known as de novo lipogenesis (DNL). It primarily occurs in the liver (and some 
in the adipose tissue) following high carbohydrate or glucose load. The excess glucose 
remaining after glycogen storage is converted to triacylglyceride, as shown in Figure 
(1.15) (Hellerstein 1999). During glycolysis, glucose is converted to pyruvate, which is 
Figure 1.15: Systematic representation of lipolytic and lipogenic pathways.  
TAG= Triacylglyceride, PEP= Phenolpyruvate, PEPCK= Phosphoenolpyruvate carboxykinase, AA= 
Amino acid, GK= Glycerol kinase, GPAT= Glycerol-3-phosphate acyltransferase, PAP= Phosphatidate 
phosphatase 1, AGAPT=acylglycerolphosphate acyltransferase, DAGK=Diacylglycerol kinase, DGAT= 
Acyl-CoA:diacylglycerol acyltransferase, ATGL=Adipose tissue triglyceride lipase, HSL= Hormone 
sensitive lipase, MGL=Monoacylglycerol lipase, ACSL= Long-chain-fatty-acid CoA ligase, FAS= Fatty 
acid synthase, ACC= Acetyl CoA carboxylase, ACLγ=ATP citrate lyase γ, PL=Phospholipid, LPA= 
Lysophosphatidic acid, PA= Phosphatidic acid, DAG=Diacylglycerol, MAG=Monoacylglycerol, FFA= 
Free fatty acids                                  (Saponaro, Gaggini et al. 2015) 
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further converted to acetyl-CoA in the mitochondria. The synthesis of malonyl-CoA is 
catalysed by acetyl-CoA carboxylase (ACC); an ABC enzyme (as it requires ATP, Biotin 
and CO2 the reaction). The rate of fatty acid synthesis is controlled by a balance between 
monomeric acetyl-CoA (inactive) and polymeric acetyl-CoA (Clarke, Clarke 1982). 
Following the synthesis of malonyl-CoA, all the fatty acid synthesis of fatty acids is 
carried out by the multiple enzymatic activities of fatty acid synthase (FAS). These 
involve 4 primary enzymatic activities; β-ketoacyl-ACP synthase, β-ketoacyl-ACP 
reductase, 3-hydroxyacyl-ACP dehydratase and enoyl-CoA reductase. The primary fatty 
acid synthesised by FAS is palmitic acid (palmitate), which once released can undergo 
separate elongation and/or unsaturation to yield other fatty acid molecules.  The 
regulation of the enzymes involved in lipid metabolism mediates fatty acid synthesis or 
degradation.  
In the liver, the synthesised triacylglyceride are incorporated into very low-density 
lipoproteins particles, secreted into the circulation and the content is deposited into 
extrahepatic tissues such as, muscle and adipose tissue for storage or oxidation (Strable, 
Ntambi 2010). DNL derived triacylglyceride account for up to 20% of the stored content 
in adipocytes (Strawford, Antelo et al. 2004). Although, DNL is low in the adipose tissue 
of both lean and obese individuals, it is an important contributor to increased fat mass as 
low expression of lipogenic genes in the adipose tissue of morbidly obese individuals 
following bariatric surgery have been associated with better outcome and improved 
anthropometric variables (Garrido-Sanchez, Vendrell et al. 2012). Furthermore, increased 
rates of DNL are associated with high postprandial glucose and insulin concentrations, 
inflammation, oxidative stress and macrophage infiltration, thus may be involved in the 
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dysregulation of metabolic functions associated with obesity (Bechmann, Hannivoort et 
al. 2012).  
1.3.2.2 Lipolysis of stored triacylglyceride and fatty acid β-oxidation 
During the fasted state, energy depletion and/or exercise, the body uses the stored sources 
of energy to regulate its processes. Lipolysis is a process by which stored triacylglyceride 
are hydrolysed into glycerol and free fatty acids (FFA) in adipocytes and released into the 
circulation to be used by peripheral tissues, where they serve as substrates for β oxidation 
and ATP synthesis (Kolditz, Langin 2010). The adipose tissue acts as a FFA- buffering 
system as it is the only organ that can secrete FFA into the circulation (Kolditz, Langin 
2010). Essentially, lipolysis of triacylglyceride is a sequential process in which one 
triacylglyceride molecule is hydrolysed to release three molecules of FFA and one 
glycerol by a class of hydrolytic enzymes, the lipases. In mammalian lipolysis, three 
lipases are involved and one FFA is released with each lipase action (Figure 1.15). In the 
first step, a rate limiting enzyme; adipose triglyceride lipase converts triacylglyceride into 
diacylglycerol (DG) and a FFA molecule (Zimmermann, Strauss et al. 2004). DG is 
converted into monoacylglycerol (MG) and FFA molecule by hormone sensitive lipase 
(HSL) and monoacylglycerol lipase further cleaves MG into glycerol and a FFA molecule 
completing the process (Haemmerle, Zimmermann et al. 2002). FFA undergo β oxidation 
in the mitochondria to produce energy. In the liver, FFA are converted to ketone bodies, 
which are released into the circulation and taken up other tissues such as brain, muscle or 
heart. The ketone bodies are converted back to acetyl-CoA, which enters the Krebs cycle 
to produce ATP (Figure 1.15). Obesity is associated with increased levels of β oxidation 
and elevated circulating levels of FFA’s, which activate PPAR-α; a regulator of genes 
encoding enzymes required for this process resulting in a positive feedback loop (Yu, Rao 
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et al. 2003). Lipid intermediates DG, MG and FFA play essential roles in the systematic 
signalling pathways and at intracellular levels (Zechner, Zimmermann et al. 2012).  
1.3.2.3 Regulation and dysregulation of energy storage in obesity 
The balance between lipogenesis and lipolysis is critical and the regulation of these 
processes is influenced by diet, hormones and neuronal stimuli that either stimulate or 
inhibit the activity of enzymes involved in these processes. Dysregulation negatively 
impacts several physiological functions of the body.   
Lipogenesis is very responsive to nutritional changes in the diet. For example, 
polyunsaturated fatty acids decrease the rate of DNL, whereas, carbohydrates stimulate it 
in the liver and adipose tissue (Kersten 2001). Plasma glucose levels stimulate DNL 
through several mechanisms, 1) it acts as a substrate for DNL, 2) it induces the expression 
of key lipogenic genes and 3) it stimulates the release of insulin and inhibits the release 
of glucagon (Kersten 2001). Similarly, the activity of LPL is altered in a tissue specific 
manner, according to the metabolic demands of the individual tissues. Starvation and 
malnutrition decrease LPL activity in the WAT whereas, postprandially the activity is 
increased (Oller do Nascimento, Ribeiro et al. 2009). High levels of circulating FFA 
interact with and inhibit the activity of LPL on endothelial surface, thereby delaying 
triacylglyceride clearance from the blood.  
Plasma hormone levels are significantly altered during the fasted and fed states. For 
example, insulin and leptin are decreased and GH and glucagon are increased during the 
fasted state and vice versa during the fed state (Boden, Chen et al. 1996, Norrelund, Nair 
et al. 2001). Insulin increases the uptake of glucose in adipocytes, activates glycolytic and 
lipogenic enzymes and reduces the activation of HSL, thus promoting lipogenesis (Saleh, 
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Sniderman et al. 1999). Yet, lipid storage is still effective in insulin resistant obese 
individuals. Conversely, leptin stimulates fatty acid oxidation and release of glycerol 
from adipocytes, thereby inhibiting lipogenesis and promoting lipolysis (Harris 2014). 
Insulin and leptin are stimulated by FFA or dietary lipids, and they in turn regulate lipid 
homeostasis and tissue disposition of these FFA and lipids (Dimitriadis, Mitrou et al. 
2011, Reidy, Weber 2000).  
Furthermore, changes in the plasma catecholamines levels during the fed and fasted states 
regulate lipogenesis and lipolysis. They activate fasting induced lipolysis by binding to β 
adrenergic receptors on adipocytes and generate cAMP (Robidoux, Martin et al. 2004). 
cAMP activates protein kinase A (PKA) which regulates the expression of several 
proteins involved in lipolysis including HSL. Phosphorylation of HSL induces rapid 
activation and translocation from the cytosol to the surface of the lipid droplets to initiate 
the lipolytic pathway (Egan, Greenberg et al. 1992). Other hormones and agents 
regulating lipolysis through the cAMP-dependent pathways include; thyroid stimulating 
hormones, melanocortin’s, adrenocorticotrophic hormones, α-MSH, NPY, angiopoietin-
like protein 4, GH, glucocorticoids and tumour necrosis factor α (TNFα) (Nielsen, Jessen 
et al. 2014).  
Both scWAT and vWAT associated obesity share a common underlying feature, an 
increase in circulating FFA levels (Saleh, Sniderman et al. 1999). Excess circulating 
FFA’s are also taken up by other tissues such as liver, muscle, heart and pancreas where 
they accumulate as ectopic fat and promote lipotoxicity. FFA’s induce several changes 
within the cells by alternating expression of genes associated with energy metabolism, 
inflammation, oxidative stress and apoptosis (Saponaro, Gaggini et al. 2015). Thus, the 
consequences of increased circulating FFA are associated with metabolic changes which 
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promote obesity, insulin resistance and hyperlipidaemia (Szendroedi, Roden 2008). FFA 
induced lipotoxicity has universal and tissue specific effects, as shown in Figure 1.16. 
Increased circulating FFA’s are associated with increased markers of endothelial 
activation such as, vascular cell adhesion molecules and intracellular adhesion molecule 
and, increased markers of inflammation, suggesting an increased risk of atherosclerosis 
and cardiovascular disease (Siriwardhana, Kalupahana et al. 2013). Some studies found 
a strong link between metabolic syndrome and non-alcoholic fatty liver disease, liver 
damage and hepatocellular carcinoma, with adipose tissue insulin resistance being a key 
player (De Minicis, Agostinelli et al. 2014, Lomonaco, Ortiz-Lopez et al. 2012). 
Furthermore, ectopic accumulation within the pancreas is associated with β-cell 
dysfunction, impaired insulin secretion and development of T2DM (Gastaldelli 2011).  
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Figure 1.16: Ectopic lipid accumulation and effects of lipotoxicity.  Excess lipid accumulation in non-
adipose tissues promotes cell dysfunction, insulin resistance and inflammation contributing to organ 
dysfunction. 
CVD= Cardiovascular disease, eNOS= Endothelial nitric oxide synthase, VCAM= Vascular cell adhesion 
molecule, ICAM=Intracellular adhesion molecule, PAI-1=Plasminogen activator inhibitor-1, VLDL= Very-
low density lipoprotein, NO= nitric oxide, FFA= Free fatty acids, ATP= Adenosine triphosphate   
               (Saponaro, Gaggini et al. 2015) 
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1.3.3 Thermogenic function of brown adipocytes  
BAT is lobulated and has a rich nerve and blood supply and appears yellow in colour 
when full of lipid. However, as the lipids deplete, the colour changes from yellow-brown 
to red-brown (when fully depleted). The brown colour is due to high content of 
mitochondrial cytochromes that are required for thermogenesis.  BAT is the key site for 
heat production through non-shivering thermogenesis and diet induced thermogenesis 
(DIT). The heat produced by the BAT is essential for the survival of small mammals in 
cold environments, maintenance of deep body temperature, re-warming after hibernation 
and food intake-energy balance ratio (Cannon, Nedergaard 2004). Cold is a classic 
activator of BAT function by activating the SNS (Cannon, Nedergaard 2004). It induces 
non-shivering thermogenesis in the brown adipocytes and affects the developmental 
programs of other cell types found within the tissue to coordinate heat production. For 
example, it activates alternatively activated macrophages to produce catecholamine’s 
(such as dopamine, adrenaline and noradrenaline), sprout the growth of blood vessels in 
the tissue to facilitate oxygen delivery and heat exchange (Harms, Seale 2013). The 
mitochondria exhibit an electrochemical proton gradient across the inner membrane and 
the movement of protons from a high to low concentrations through ATP synthase, results 
in the generation of energy in the form of ATP in a process called oxidative 
phosphorylation (Arbuthnott 1989, Saely, Geiger et al. 2012). However, in brown 
adipocytes, the ATP synthase is suppressed to increase the proportion of the membrane 
potential towards heat production opposed to ATP synthesis. Brown adipocytes express 
a unique protein (thermogenin) that uncouples ATP synthesis by opening a passive proton 
channel (UCP1) in the inner mitochondrial membrane that allows the movement of 
protons down the mitochondrial gradient resulting in heat production (Saely, Geiger et al. 
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2012). The function of UCP1 is inhibited by purine nucleotides (guanosine diphosphate 
and adenosine diphosphate) at physiological concentrations, and the inhibition is 
overcome by FFA released from intracellular triacylglyceride stores following adrenergic 
activation in response to daily stimuli, such as food, cold and exercise (Harms, Seale 
2013). 
The awareness of DIT originated from experiments conducted by Rothwell and Stock in 
the 1970’s. Rats fed a cafeteria diet (junk foods high in sugar and fat) gained less weight 
than expected. These rats show increased hyperphagia, BAT mass, noradrenaline 
turnover, oxygen consumption, respiratory enzyme activity and UCP1 protein (Kozak 
2010). Thus, they hypothesised that the excess caloric intake was burnt off through BAT 
induced thermogenesis (Rothwell, Stock 1979). DIT is defined as ‘the increase in energy 
expenditure above basal fasting levels’ and it is one of the three components of daily 
energy expenditure, with others being basal metabolic rate and activity induced 
thermogenesis (Westerterp 2004). DIT is thought to be mediated by the SNS and 
stimulation of β adrenergic receptors on thermogenic tissues, similar to non-shivering 
thermogenesis (Bachman, Dhillon et al. 2002). It is assumed that the excessive caloric 
intake is sensed by the brain and activation of DIT is a way of regulating body weight 
homeostasis to prevent weight gain and onset of obesity.   
1.3.3.1 Regulation and dysregulation of thermogenesis in obesity 
In addition to discovery of BAT in adults, a negative correlation between BAT, BMI and 
body fat percentage has been reported. Higher abundance of BAT is associated with lower 
levels of blood glucose, improved systemic glucose homeostasis and insulin sensitivity, 
decreased inflammation and risk of cardiovascular disease. Previous studies have 
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reported the possibility of increasing BAT activity as a therapy, therefore, BAT has 
received substantial interest, as a target for the control of whole-body energy balance, 
adiposity and obesity (van den Berg, van Dam et al. 2017).  
Thermogenesis is regulated by both neuronal and endocrine factors. Adrenaline causes 
vasodilation and enhances glucose and oxygen consumption in skeletal muscle as well as 
enhancing thermogenesis in humans. Noradrenaline stimulates β-adrenergic receptors on 
adipocytes to induce lipolysis and release of FFA. In addition to lipolysis, PKA 
phosphorylates p38 mitogen activated protein (p38-MAPK), which phosphorylates and 
activates PGC-1α, a cold-induced interacting partner of PPARγ (Harms, Seale 2013). 
PGC-1α regulates the expression of thermogenic genes by interacting with PPARγ, 
PPARα and thyroid receptors (TR).   
Thyroid hormones increase metabolic rate and thermogenesis in thermogenic species and, 
therefore, are important modulators of energy homeostasis (Reddy, Tan et al. 2014). 
Individuals suffering from hypothyroidism or hyperthyroidism display predictable 
clinical manifestations of altered brown adipose tissue activity such as, decreased cold 
tolerance and weight gain and heat intolerance and weight loss respectively (Lopez, 
Varela et al. 2010). Activation of the isoforms by T3 results in different outcomes, binding 
to and activating TR-β induces UCP1 gene expression and binding to and activating TR-
α regulates facultative thermogenesis in BAT (Ribeiro, Carvalho et al. 2001). The full 
thermogenic response of BAT to adrenergic stimulation via T3 is achieved by the type 2 
deiodinase enzyme (D2)  (Reddy, Tan et al. 2014).  It increases the conversation of T4 to 
T3, thereby controlling the concentration of the hormones within the tissue (Obregon 
2014).  Therefore, D2 could also be considered as a marker of thermogenesis. 
Furthermore, D2 is involved in lipogenesis under adrenergic stimuli, but lipogenesis 
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doesn’t provide the FFA required, thereby impairing adaptive thermogenesis (under cold) 
(Obregon 2014).   
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1.3.4 Endocrine function of white adipocyte  
The concept of WAT as an endocrine organ originated in the late 1990’s with the 
discovery of a key adipokine, leptin and its wide range of biological functions (Barinaga 
1995). Mature white adipocytes synthesise and secrete a diverse range of adipokines and 
small bioactive molecules (over 600 identified to date) into the surrounding adipose tissue 
environment. Adipokines play important roles in the regulation of appetite and satiety 
control, fat distribution, insulin sensitivity and insulin secretion, energy expenditure, 
inflammation, blood pressure, homeostasis and endothelial function (Bluher 2012). In an 
autocrine and paracrine manner, adipokines contribute to the regulation of adipose tissue 
phenotype such as, adipogenesis, adipocyte function, metabolism and immune cell 
migration and infiltration into the tissue (Bluher 2012). Additionally, adipokines are 
secreted into the systemic circulation where they have significant effects on target organs 
including, the brain, liver, muscle, vasculature, heart and pancreatic β cells in an 
endocrine manner and regulate systemic metabolism, energy homeostasis and 
inflammation (Bluher 2012) (Figure 1.17). The synthesis and secretion pattern of the 
adipokines reflect adipose tissue function and are considered important factors for 
determining the risk of developing obesity associated metabolic and cardiovascular co-
morbidities (Van Gaal, Mertens et al. 2006, Bluher 2009, Bays 2009). The synthesis and 
secretory profile of adipokines are significantly changed towards a diabetogenic, pro-
inflammatory and atherogenic pattern during adipose tissue inflammation and 
dysfunction in obesity (discussed in more detail in Chapter 2).   
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1.3.4.1 Leptin  
Leptin has direct and indirect effects on adipocyte development, function (inhibits 
lipogenesis, increases triglyceride hydrolysis and fatty acid and glucose oxidation) and 
modifying adipocyte metabolism through regulating the release and function of 
metabolically active hormones (Harris 2014, Minokoshi, Kim et al. 2002). Insulin 
stimulates the synthesis and secretion of leptin, however, leptin is thought to inhibit 
insulin synthesis and secretion by affecting the pancreatic β cell mass (changes in 
proliferation, apoptosis and cell growth) (Marroqui, Gonzalez et al. 2012). Mice treated 
with leptin antagonist show increased fasting and glucose stimulated plasma insulin 
levels, decreased whole body insulin sensitivity, elevated hepatic glucose production and 
Figure 1.17: Adipokines secreted by the adipose tissue and their local and systemic effects. 
IL6= interleukin 6, MCP-1= monocyte chemotactic protein 1, Dlk-1= Delta-like homologue 1, TNFα= 
Tumour necrosis factor α, FABP4= Fatty acid binding protein 4 and RBP4= Retinol binding protein 4   
                                    (Bluher 2012) 
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impaired insulin-mediated suppression of hepatic glucose production (Levi, Gray et al. 
2011). Whereas, adenoviral induced expression of leptin receptors in the ARC nucleus in 
leptin deficient rats improves peripheral insulin sensitivity by supressing hepatic 
gluconeogenesis (with no effect on glucose uptake). However, the role of leptin in insulin 
resistance is unclear.  
Leptin levels are decreased in low insulin states such as experimentally induced diabetes 
and increase after insulin treatment, but are elevated in human models of insulin 
resistance and the increase is independent of body fat mass (MacDougald, Hwang et al. 
1995, Segal, Landt et al. 1996). However, leptin levels are reduced and significantly 
correlate with markers of insulin resistance in patients with lipodystrophy (Moon, 
Dalamaga et al. 2013). Prolonged leptin replacement therapy (4 months) improved 
metabolic state (hyperglycaemia (reduced glycosylated haemoglobin), hyperlipidaemia 
(decreased triglyceride levels by 60%), decreased liver volume by 28%), insulin 
sensitivity and led to reduction in or suspension of anti-diabetic medication in human 
lipodystrophy or leptin deficiency participants (Oral, Simha et al. 2002, Wolfsdorf, 
Sadeghi-Nejad et al. 2002). Similar results were observed in severely obese children with 
no functional leptin (Farooqi, Jebb et al. 1999). Though, overexpression of leptin gene 
reduces food intake and weight in rodents, very large doses of recombinant leptin 
administration is required to achieve similar effects in humans (Farooqi, Matarese et al. 
2002).  Therefore, it is suggested that leptin may act as a signal that contributes to the 
regulation of insulin sensitivity (Oral, Simha et al. 2002). Hyperphagia, decreased 
metabolic rate and changes in hormone levels are thought to act as compensatory 
responses to restore energy balance in leptin deficient phenotypes, further supporting the 
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importance of altered leptin signalling for the development of obesity and T2DM (Flier 
1998).  
1.3.4.2 Adiponectin  
Adiponectin (also known as adipocyte complement-related protein (ACRP30) is a ~30 
kDa adipocyte specific adipokine encoded by the AQIPOQ gene that plays fundamental 
roles in regulating energy homeostasis and inflammation. It was first discovered in 1995 
and has pleiotropic effects including, promoting insulin sensitivity, supressing cell death, 
enhancing cell survival and inhibiting inflammation (Wang, Z. V., Scherer 2016). It is 
exclusively synthesised and secreted by white adipocytes, positively correlates with 
adipocyte size and promotes adipogenesis, increases lipid content and insulin sensitivity 
in an autocrine manner (Waki, Tontonoz 2007, Fu, Luo et al. 2005). Furthermore, it 
mediates crosstalk between the adipose tissue and other metabolic organs such as, the 
liver, heart, endocrine β  pancreatic cells, kidney and muscle (Wang, Z. V., Scherer 2016). 
The circulating levels of adiponectin are high and account for ~0.01% of total plasma 
proteins (Ronti, Lupattelli et al. 2006). Circulating levels are present in 3 isoforms; a 
trimer, hexamer or high molecular weight (HMW). The HMW isoform is specifically 
increased in adipocytes and in plasma in response to PPARγ agonists (thiazolidinediones) 
and induces more potent glucose-lowering effects compared to other isoforms (Wang, Z. 
V., Scherer 2016).  
mRNA levels are dramatically supressed in fat pads of obese mice compared with controls 
(Wang, Z. V., Scherer 2016). Furthermore, adiponectin levels and its receptors are 
significantly reduced in human obesity, despite increased fat mass and negatively 
correlate with BMI and visceral adiposity, whilst the levels increase with weight loss (Hu, 
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Liang et al. 1996, Yang, Lee et al. 2001). Hypoadiponectinemia is associated with 
cardiovascular disease, hypertension and the metabolic syndrome (Waki, Tontonoz 
2007). Interestingly, hypoadiponectinemia is suggested to contribute to the pathogenesis 
of T2DM. Adiponectin levels are reduced in human T2DM patients and prospective 
longitudinal studies in rhesus monkeys revealed a drop-in adiponectin levels before the 
onset of T2DM (Hotta, Funahashi et al. 2001). Human genetic studies have identified 
several single nucleotide polymorphisms and rare missense mutations in the adiponectin 
gene and associated these with hypoadiponectinemia and T2DM (Waki, Tontonoz 2007).  
Adiponectin knockout mice show impaired insulin signalling, elevated TNFα expression, 
reduced fatty acid transport protein 1 expression in muscles, delayed free fatty acid 
clearance and severe hepatic but not peripheral insulin resistance (Kubota, Terauchi et al. 
2002, Maeda, Shimomura et al. 2002, Nawrocki, Rajala et al. 2006). Adiponectin receptor 
1 deficiency results in reduced adiponectin induced 5’AMP-activated protein kinase 
(AMPK) activation (a cellular energy sensor), increased glucose production and impaired 
insulin resistance, whereas, adiponectin receptor 2 deficiency decreases activity of 
PPARα signalling pathway and enhances insulin resistance (Waki, Tontonoz 2007). 
Adiponectin treatment ameliorates insulin resistance and lowers plasma triglycerides by 
acting in both skeletal muscle and liver in KKAy (T2DM model) and db/db HFD fed mice 
(Yamauchi, Kamon et al. 2001). This effect may be achieved by inhibiting enzymes 
involved in gluconeogenesis such as, phosphoenolpyruvate carboxykinase and glucose-
6-phosphatase in the liver as demonstrated by both in vitro and in vivo studies (Berg, 
Combs et al. 2001, Tomas, Tsao et al. 2002). In addition, globular adiponectin expression 
in transgenic mice crossed with ob/ob mice show improved insulin resistance (possibly 
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due to increased glucose uptake and fatty acid oxidation in muscle) with no changes in 
body weight (Yamauchi, Kamon et al. 2003).  
1.3.4.3 Resistin  
Resistin is a 12.5 kDa adipokine encoded by the RETN gene and is a member of the 
cysteine-rich family of Resistin like molecules that are associated with the activation of 
inflammatory processes. It is implicated to play a role in glucose metabolism, specifically 
neoglucogenesis, insulin resistance, and inflammation (Makki, Froguel et al. 2013).  
Circulating levels of resistin are significantly increased in obese humans and rodents and 
positively correlate with insulin resistance in T2DM patients (Makki, Froguel et al. 2013). 
The synthesis and secretion are stimulated by pro-inflammatory cytokines such as, IL6 
and TNFα and inhibited by PPARγ agonist; rosiglitazone, indicative of its pro-diabetic 
effects (Steppan, Bailey et al. 2001).  
Although the exact physiological role of resistin remains unknown, it is proposed as a 
link between obesity and T2DM (Al-Suhaimi, Shehzad 2013). ob/ob mice lacking resistin 
are extremely obese but have improved glucose tolerance and insulin sensitivity. 
Administration of a recombinant form of resistin worsens glucose tolerance in mice, 
whereas, injection of neutralizing antibodies improves insulin sensitivity in ob/ob mice 
(Steppan, Bailey et al. 2001). Furthermore, mice lacking resistin display improved blood 
glucose levels post-fasting due to low hepatic glucose production whereas, infusion of 
resistin rapidly induces hepatic insulin resistance, resulting in hepatic glucose production, 
possibly through activating SOCS3, an inhibitor of insulin signalling in adipocytes 
(Rajala, Obici et al. 2003, Steppan, Wang et al. 2005). In addition, in vitro studies in 3T3-
L1 preadipocytes indicate a more direct role for resistin in insulin resistance. It appears 
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to interfere with the normal insulin signalling pathway by decreasing insulin receptor and 
insulin receptor substrate (IRS) expression and phosphorylation as well as activation of 
AMPK (Palanivel, Maida et al. 2006, Fisher 2006).  
In humans, resistin expression is detected in various tissues including the adipose tissue, 
however, it is predominantly synthesised and secreted by resident macrophages and very 
little by adipocytes (Schwartz, Lazar 2011).  Resistin mRNA expression levels are higher 
in human obese individuals, possibly due to increased infiltration of macrophages in the 
adipose tissue, as resistin mRNA expression levels isolated from human adipocytes do 
not correlate with insulin resistance and obesity (Steppan, Bailey et al. 2001). Therefore, 
resistin may have an indirect effect on insulin resistance in humans through worsening 
pro-inflammatory status.  
1.3.4.4 Visfatin  
Visfatin (also called pre-B cell colony enhancing factor) is a ~55 kDa adipokine encoded 
by the NAMPT gene and is proposed to be is involved in inflammation and metabolism 
(Saddi-Rosa, Oliveira et al. 2010). It facilitates adipogenesis and promotes lipid 
accumulation through the activation of glucose transport and lipogenesis (Fukuhara, 
Matsuda et al. 2005). It is predominantly synthesised and secreted by the vWAT rather 
than scWAT. Interestingly, visfatin is thought to play important roles in insulin secretion, 
as heterozygous deficient mice show to have reduced glucose stimulated insulin secretion 
in the pancreas, contributing to glucose intolerance (Revollo, Korner et al. 2007). 
Furthermore, it interacts with the insulin receptor and exerts insulin-like hypoglycaemic 
effects, however, unlike insulin, circulating visfatin levels are down-regulated by 
overfeeding in healthy young men and appear to regulate lipid metabolism as opposed to 
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glucose metabolism (Jacques, Holzenberger et al. 2012, Sun, Bishop et al. 2007). Thus, 
the evidence regarding its physiological function in obesity and associated co-morbidities 
is not clear.  
1.3.4.5 Adipsin 
Adipsin (also called complement factor D) is a 28kDa adipokine encoded by the CFD 
gene and is a serine protease secreted by adipocytes and is crucial for the initiation of the 
complement activation via the alternative pathway. It catalyses the rate limiting step in 
the formation of the C5-C9 membrane attack complex and the generation of 
anaphylatoxins C3a and C5a (Ricklin, Hajishengallis et al. 2010). However, evidence 
regarding the function of adipsin in relation to energy homeostasis and metabolism is 
limited. Adipsin stimulates triglyceride storage in adipocytes by stimulating glucose 
transport, enhancing fatty acid esterification and inhibiting lipolysis, thus promoting 
adipogenesis (Van Harmelen, Reynisdottir et al. 1999). Adipsin levels are reduced in 
mouse models of obesity and are selectively decreased in T2DM patients with pancreatic 
β cell failure (Lo, Ljubicic et al. 2014, Cianflone, Xia et al. 2003). Mice lacking adipsin 
show deteriorated glucose homeostasis when subjected to metabolic stress of diet-induced 
obesity whereas, replacement of adipsin significantly improves glucose homeostasis 
which indicates an anti-diabetic effect (Lo, Ljubicic et al. 2014).  
The circulating levels of adipsin in human obesity are controversial. Some studies report 
higher levels of adipsin in obesity and a positive correlation with BMI, whereas others 
report no significant relationship between adipsin and BMI (Gursoy Calan, Calan et al. 
2016, Natarajan, Hagman et al. 2015, Napolitano, Lowell et al. 1994, Zhou, Ge et al. 
2018). The increase in adipsin levels in obesity is suggested to be a compensatory effect 
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of increased fat mass, however, the role of adipsin in obesity requires further investigation 
(Lo, Ljubicic et al. 2014).   
1.3.4.6 Tumour Necrosis Factor α 
TNFα is a 55 kDa cytokine encoded by the TNF gene and is involved in systemic 
inflammation and metabolism. It is synthesised as a 26 kDa transmembrane protein and 
the biologically active trimer (17 kDa) is formed after proteolytic cleavage of 
transmembrane precursor by the TNFα converting enzyme (Waki, Tontonoz 2007). It is 
a potent pro-inflammatory cytokine secreted by myeloid cells, mainly tissue resident 
macrophages and adipocytes via activation of MAPK and nuclear factor kappa β 
pathways and induces the release of other inflammatory cytokines such as, interleukin -
1β and interleukin 6 (IL6) (Makki, Froguel et al. 2013). Adipose tissue TNFα is not 
secreted into the systemic circulation, rather it is thought to act in an autocrine and 
paracrine manner and impact several mechanisms including adipocyte differentiation and 
metabolism (Makki, Froguel et al. 2013). TNFα inhibits adipocyte differentiation by 
supressing the expression of key adipogenic markers such as PPARγ, C/EBP, LPL and 
GLUT4 (insulin-regulated glucose transporter 4). Furthermore, it promotes lipolysis and 
the secretion of FFA, supresses genes involved in lipid uptake and storage and affects the 
expression of several adipocyte secreted factors in mature adipocytes (Feve, Bastard 
2009, Ruan, Miles et al. 2002, Hector, Schwarzloh et al. 2007).  
TNFα expression is increased in the adipose tissue of obese humans and animal models 
and is thought to auto-regulate its own biosynthesis contributing to maintained levels in 
obesity (Tzanavari, Giannogonas et al. 2010). Likewise, the plasma levels are also 
elevated in obesity and T2DM and positively correlate with BMI, percentage body fat 
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and markers of insulin resistance (Hotamisligil, Shargill et al. 1993, Ronti, Lupattelli et 
al. 2006). Neutralization of TNFα improves insulin resistance in obese rats thereby, 
indicating an important role of TNFα in obesity related insulin resistance, however, this 
effect is not apparent in T2DM patients, rather acute treatment with inhibitors reduced 
systemic inflammation without reducing insulin resistance in these patients (Hotamisligil, 
Shargill et al. 1993, Ofei, Hurel et al. 1996, Dominguez, Storgaard et al. 2005). However, 
improved fasting glucose levels have been reported in patients diagnosed with metabolic 
syndrome who were subjected to long-term inhibitor treatment (Stanley, Zanni et al. 
2011). Furthermore, obese mice lacking either TNFα or its receptor show protection 
against the development of insulin resistance (Uysal, Wiesbrock et al. 1997).  
TNFα is thought to induce insulin resistance by directly affecting the insulin signalling 
pathway or indirectly by affecting adipocyte function as discussed. It interferes with 
insulin signalling by stimulating the serine phosphorylation of insulin receptor substrate 
1 (IRS1), thereby reducing the tyrosine phosphorylation of IRS1 by insulin in muscle and 
adipose tissue promoting insulin resistance (Waki, Tontonoz 2007). Thus, increased 
TNFα levels in obesity contribute to the impaired glucose homeostasis in humans via 
direct and indirect actions.  
1.3.4.7 Interleukin 6 
IL6 is a 22-27 kDa multifaceted, pleiotropic cytokine encoded by the IL6 gene that plays 
a central role in the regulation of inflammation, haematopoiesis, immune responses and 
host defence mechanisms (Eder, Baffy et al. 2009). It is considered an adipokine as one-
third of the circulating IL6 in healthy individuals is estimated to originate from the white 
adipose tissue, (Wieckowska, Papouchado et al. 2008). However, only a small fraction is 
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synthesised and secreted by adipocytes, fibroblasts and endothelial cells whilst the 
majority is produced by macrophages (Makki, Froguel et al. 2013). Additionally, IL6 is 
synthesised and secreted by the skeletal muscle and the liver to a smaller degree 
(Wieckowska, Papouchado et al. 2008).  IL6 exerts anti-obesity effects by acting through 
the central nervous system. Central administration of IL6 increases energy expenditure 
and reduces adiposity in mice whereas, IL6-/- mice develop mature onset obesity and 
insulin resistance (Wallenius, Wallenius et al. 2002).  
The role of IL6 in obesity and related diseases is controversial. Plasma IL6 levels are 
elevated in obesity and T2DM, levels positively correlate with visceral adiposity, BMI, 
waist circumference, free fatty acid levels and are predictive of the development of T2DM 
(Pradhan, Manson et al. 2001, Vozarova, Weyer et al. 2001). It stimulates insulin 
secretion by enhancing the expression of GLP-1 in pancreatic cells, therefore, the increase 
in obesity may reflect a compensatory mechanism to increase insulin production 
(Ellingsgaard, Hauselmann et al. 2011). Although some studies report no correlation 
between elevated IL6 levels and markers of insulin resistance, one study has reported 
higher levels of IL6 in obese insulin-resistant compared to obese insulin-sensitive 
individuals (Vozarova, Weyer et al. 2001, Kern, Ranganathan et al. 2001). It is suggested 
that a sustained increase in IL6 may lead to insulin resistance, whereas, a temporary 
increase may aid normal glucose homeostasis (Makki, Froguel et al. 2013). During 
exercise, IL6 increases glucose uptake in the skeletal muscle, AMPK-mediated fatty acid 
oxidation and anti-inflammatory effects, whereas, in the adipose tissue and liver, it exerts 
pro-inflammatory effects, promotes insulin resistance by upregulating SOCS3, promotes 
dysregulation of fatty acid metabolism, alters adipokine profile and inhibits adipogenesis 
(Starkie, Ostrowski et al. 2003, Senn, Klover et al. 2003, Pricola, Kuhn et al. 2009). 
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Furthermore, IL6 synthesis and secretion is upregulated by TNFα and induces insulin 
resistance by inhibiting glucose uptake and impairing insulin signalling in cultured 
murine adipocytes (Rotter, Nagaev et al. 2003). Likewise, IL6 administration to healthy 
volunteers increased plasma glucose levels in a dose dependent manner, possibly due to 
insulin resistance (Tsigos, Papanicolaou et al. 1997). Thus, suggesting IL6 may play a 
crucial role in metabolic diseases and its activity may depend on tissue type and the 
metabolic status. 
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Chapter 2: Adipose tissue associated 
inflammation in Obesity 
Inflammation is a physiological process that ensures the removal of foreign pathogens 
and injured cells and mediates repair of damaged tissues. Local acute inflammation in the 
adipose tissue is considered to be important to maintain a healthy tissue environment and 
is a necessity for healthy tissue expansion (Kraakman, Murphy et al. 2014). However, 
increased lipid accumulation and dysregulated adipose tissue expansion in obesity alters 
the structure and the functions of the tissue leading to a pathological state (stress and 
hypoxia) contributing to metabolic derangements, enhanced atherosclerosis and 
endocrine activity (Mraz, Haluzik 2014). Obesity induced inflammation has profound 
effects on the metabolic pathways and is considered to be a central player in the 
development of obesity associated co-morbidities and the metabolic syndrome 
(Medzhitov 2008). The imbalance between the signals that initiate inflammation and 
signals that resolve inflammation may be a contributing factor in the development and 
maintenance of obesity associated co-morbidities (Lee 2013, Mathis 2013). This chapter 
discusses the cellular and molecular changes that occur during dysregulated adipose 
tissue expansion that contribute to the inflammatory status in obesity (Section 2.1) and 
role of the pro-resolving factor, Annexin A1 in inflammation and its expression levels in 
obesity (Section 2.2).  
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2.1 Adipose tissue inflammation 
2.1.1 Inflammation 
Inflammation is a host response to injury (i.e. bacterial, trauma) with the main purpose to 
restore tissue homeostasis and induce tissue recovery and repair (Vago, Nogueira et al. 
2012). It consists of a series of highly orchestrated cellular and molecular events that 
recognise and remove harmful stimuli, and begin repair (B. C. Lee, Lee 2014). Acute 
inflammation starts rapidly, becomes severe in a short time and lasts for a few days (innate 
immunity). Clinically, acute inflammation is characterised by five cardinal signs as 
observed by Celsus (ca 30bc-38ad) and Vichow (19th century): dolor (pain), calor (heat), 
tumor (swelling), rubor (redness) and function laesa (loss of function) and 
microscopically, it involves expansion of blood vessels (vasodilation), increase in blood 
flow, capillary permeability and migration of neutrophils (diapedesis) to the site of injury. 
These features continue as the inflammation becomes chronic, with the replacement of 
neutrophils with macrophages and lymphocytes (adaptive immunity) (Figure 2.1). 
Chronic inflammation is slow, lasts for several months to years depending on the extent 
of injury and the body’s ability to repair and overcome the damage. The key features of 
chronic inflammation include, infiltration of mononuclear immune cells, increase in 
secretion of pro-inflammatory cytokines, growth factors and enzymes that all contribute 
to the progression of tissue damage and secondary tissue repair including, tissue fibrosis 
(Lawrence, Gilroy 2007). Risk factors including, age, obesity, diet and smoking all 
promote and contribute to the development of a low-grade chronic inflammatory 
response. Low-grade chronic inflammation is considered to be an underlying cause of 
most chronic diseases such as, cardiovascular diseases, cancer, type 2 diabetes mellitus 
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(T2DM), Alzheimer’s disease and chronic kidney disease and presents a major threat to 
the health and longevity of individuals (Ferrucci, Fabbri 2018).    
 
  
Figure 2.1: Acute and chronic inflammation. Cell disruption through injury or infection induces acute 
inflammation that involves the activation of intracellular signalling pathways resulting in the synthesis and 
secretion of pro-inflammatory cytokines and lipid mediators that activate and recruit leukocytes. Activated 
leukocytes such as neutrophils infiltrate, degrade and remove damaged tissue. These features continue as the 
inflammation becomes chronic, with the replacement of neutrophils with macrophages and lymphocytes. 
   (Adapted from (Clifford, Howatson et al. 2015)
  
 Chapter 2: Adipose tissue associated inflammation in obesity 
81 | P a g e  
 
2.1.1 Overview of the inflammatory cascade 
 
The inflammatory cascade occurs in 4 phases (Figure 2.2). Phase I is initiated by cell or 
tissue injury leading to the activation of intracellular signalling pathways that mediate the 
synthesis and secretion of leukotrienes, prostaglandins and pro-inflammatory cytokines 
and chemokines (Figure 2.1). During phase II, these proteins activate patrolling 
neutrophils and tissue resident immune cells to synthesise and secrete chemokines that 
induce their activation, adhesion and migration. During Phase II and III, neutrophils 
recognise, phagocytose and destroy the pathogen or injured cells through a combination 
of cytotoxic mechanisms including, production of reactive oxygen species (ROS), 
degranulation and release of anti-microbial peptides, and become apoptotic. Monocytes 
differentiate into macrophages and in addition to other immune cells (discussed in Section 
2.1.2.1.2) aid in destroying the pathogen or injured cells and removal of the pro-
inflammatory stimuli. During the last phase, phase IV, pro-resolving cytokines, 
Figure 2.2: Phases of the inflammatory cascade. Phase 1: Activation of immune system cells and secretion 
of cytokines and chemokines. Phase 2: Extravasation and migration to the site of inflammation. Phase 3: 
Removal of damaging stimuli. Phase 4: Clearance of apoptotic cells and tissue repair.                  
LTB4=Leukotriene B4,   LL-37= Cathelicidin      (Tan, Weninger 2017) 
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chemokines and proteins are synthesised and secreted to prevent further immune cell 
infiltration. Phagocytosis of apoptotic neutrophils and tissue repair leads to resolution of 
inflammation and tissue homeostasis.     
2.1.2 Adipose tissue inflammation  
The onset of low-grade chronic inflammation positively correlates with adipose tissue 
dysfunction in obesity and is considered to play a central role in the development of 
obesity associated metabolic abnormalities (Medzhitov 2008). Dysregulated expansion 
of the adipose tissue in obesity is considered to induce the onset of sterile inflammation. 
The evidence of local inflammation in the adipose tissue has emerged from the research 
that reflects altered adipocyte secretome, altered adipose tissue plasticity and, increased 
presence and altered phenotype of immune cells within the tissue (Bluher 2016).  
Obesity-related adipocyte degradation causes the release of cell-free deoxyribonucleic 
acid (DNA) and damaged associated molecular patterns such as, high mobility group box 
1 that bind to pattern recognition receptors present on multiple cell types and activate 
intracellular stress responses (Lee, Y. H., Mottillo et al. 2014, Nishimoto, Fukuda et al. 
2016). However, the exact mechanisms underlaying the development of inflammation in 
the adipose tissue in obesity remains unclear. Adipocyte hypertrophy in obesity is 
hypothesised to most likely to initiate the events leading to the development of adipose 
tissue inflammation (Figure 2.3) (Bluher 2016). Increased adipocyte size and limited 
expandability of the adipose tissue induces cellular stress, reflected by the activation of 
intracellular pathways including, Jun-kinase and nuclear factor kappa β (NF-κβ) causing 
adipocytes and other adipose tissue cells to secrete pro-inflammatory adipokines, 
endothelial adhesion molecules and chemotactic mediators such as, interleukin -6 (IL6), 
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tumour necrosis factor α (TNFα) and macrophage colony proliferating factor 1 (MCP1) 
(Shoelson, Lee et al. 2006, Walden, Hansen et al. 2012). These mediators bind to and 
activate patrolling and resident immune cells and induce their migration from the 
circulation into the adipose tissue (Shoelson, Lee et al. 2006). Resident and infiltrating 
immune cells contribute to the synthesis and secretion of similar pro-inflammatory 
mediators and promote local and systemic inflammation. 
2.1.2.1 Immune cells 
Adipose tissue resident immune cells play important roles within the tissue as they 
contribute to maintaining tissue homeostasis in lean individuals (Mraz, Haluzik 2014). 
However, during dysregulation expansion of the adipose tissue leads to significant 
changes in the quantity and the function of the immune cells. The changes in the immune 
cells result in increased numbers and the function of pro-inflammatory cells such as, 
classically activate macrophages (M1), mast cells, neutrophils, T and B lymphocytes and 
decreased number and function of anti-inflammatory cells such as, eosinophils, 
alternatively activated macrophages (M2), T helper 2 cells (Th2), T regulatory cells 
(Treg) and invariant natural killer cells (Figure 2.4) (Cildir, Akincilar et al. 2013).  
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Figure 2.3: Adipocyte hypertrophy induces adipose tissue inflammation. Chronic positive energy 
imbalance causes impaired expansion of the adipose tissue. Increased adipocyte size and limited 
expandability of the adipose tissue induces hypoxia and cellular stress reflected by the activation of 
intracellular causing adipocytes and other adipose tissue cells to secrete pro-inflammatory mediators. These 
mediators act in an autocrine, paracrine and endocrine manner inducing the onset of low-grade chronic 
inflammation.      
FFA= Free fatty acids, M1= Classically activated macrophages and M2= Alternatively activated 
macrophages                                    (Choe, Huh et al. 2016) 
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2.1.2.1.1 Neutrophils and other granulocytes  
Neutrophils are the most abundant granulocyte constituting ~40-60% of the total 
circulating white blood cell population found in mammals (Wright, Moots et al. 2010). 
They are short lived, highly mobile and patrol the circulation in a resting state. 
Neutrophils form part of the innate immune response consisting of short and rapid series 
of defence mechanisms to protect the host from infections and internal insults. The 
defence mechanism used by neutrophils and other granulocytes include phagocytosis, 
degranulation and oxidation. Within their cytoplasm, neutrophils contain granules that 
are packed with toxic reagents including proteinase, elastases and collagenases (Wright, 
Moots et al. 2010). Following phagocytosis, these granules fuse with the pathogen and 
the stored reagents aid the destruction of the pathogen.  
Figure 2.4: Change in immune cell balance in obese adipose tissue. The adipose tissue of lean contains a 
mix of anti-inflammatory immune cells such as, eosinophils, M2 macrophages, Th2 and Treg cells that are 
involved in regulating energy homeostasis. In the adipose tissue of obese, the numbers of pro-inflammatory 
immune cells such as M1 macrophages, neutrophils, CD8 and Th1 cells are significantly increased. The 
imbalance between anti- and pro-inflammatory immune cells greatly contributes to adipose tissue 
dysfunction in obesity. 
iNKT cells= invariant natural killer T cells, Th cells= T helper cell, CD= Cluster of differentiation   
             (Choe, Huh et al. 2016) 
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Neutrophils undergo programmed cell death within tissues in a matter of hours following 
an inflammatory event and are removed from the circulation by reticulo-endoplasmic 
system to ensure their toxic intracellular content is not released. Pro-apoptotic signals 
such as, TNFα and Fas ligand shorten the lifespan and induce neutrophil cell death, 
thereby limiting their damaging effects (El Kebir, Jozsef et al. 2008). Suppression of 
neutrophil apoptosis is observed in inflammatory diseases such as, acute coronary artery 
disease (El Kebir, Jozsef et al. 2008).  Sustained neutrophil activation due to delayed 
apoptosis may induce chronic inflammation (Solito, Kamal et al. 2003).  
Neutrophils make up a small population of cells in the adipose tissue, but their infiltration 
acts as an initial and persistent step in the development of diet induced obesity (Khan, 
Alsahli et al. 2018). Although neutrophils represent only a small proportion of the total 
immune cells within the adipose tissue under normal conditions,  a 20 fold increase in 
neutrophils in response to a high fat diet (HFD) is observed, increasing the representation 
to ~2% of non-adipocyte cells (Elgazar-Carmon, Rudich et al. 2008, Nguyen, Favelyukis 
et al. 2007). The plasma concentrations of myeloperoxidase (a peroxidase enzyme 
expressed by neutrophils) and calprotectin (a cofactor derived from neutrophils) are 
increased in human obesity in comparison to human lean controls (Nijhuis, Rensen et al. 
2009). In addition, neutrophils secrete pro-inflammatory cytokines and chemokines that 
mediate the recruitment and migration of macrophages, dendritic cells and lymphocytes, 
initiating a second wave of inflammation (Mraz, Haluzik 2014). Sustained activation of 
neutrophils and increased secretion of pro-inflammatory cytokines and chemokines may 
contribute to the accumulation of macrophages and other leukocytes in the adipose tissue, 
instigating the development of chronic inflammation (Talukdar, Oh da et al. 2012, 
Elgazar-Carmon, Rudich et al. 2008).  
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Other granulocytes are also involved in contributing to the imbalanced cytokine profile 
observed in obesity. Mast cells secrete cytokines such as, TNFα and interleukin-1β that 
activate the vasculature and promote the recruitment of inflammatory cells notably M1 
macrophages (Mathis 2013). Mice deficient in mast cell population accumulate less 
macrophages in the visceral adipose tissue (Mathis 2013). Eosinophils secrete majority 
of the interluekin-4 (IL-4) that is important for the differentiation and survival of M2 
macrophages present within in adipose tissue, therefore, their inability to maintain the M2 
macrophage phenotype may further contribute to the development of inflammation (Wu, 
Molofsky et al. 2011).   
2.1.2.1.2 Macrophages 
Tissue resident macrophages are involved in both innate and adaptive immune systems, 
providing both rapid and prolonged nonspecific and specific responses (Xuan, Qu et al. 
2015). Macrophages have three key roles, antigen presentation (to activate other cells), 
phagocytosis and synthesis and secretion of cytokines (pro/anti-inflammatory) to 
modulate the immune response. Tissue resident macrophages contribute to tissue 
homeostasis via surveillance, maintenance and repair by modifying the extracellular 
matrix promoting wound healing and tissue repair (Lee, Lee 2014). Adipose tissue 
macrophages represent the largest subpopulation of the adipose tissue immune cells. In a 
lean state, the adipose tissue is populated with 5 % of macrophages, substantially 
increasing to ~60 % in obese mice (Berg, Scherer 2005). Majority of the cytokines and 
chemokines present are thought to derive from adipose tissue macrophages (Xu, Grijalva 
et al. 2013). Physiologically, adipose tissue resident macrophages are thought to function 
as scavenger cells to mediate the clearance of moribund adipocytes which increase 
dramatically with obesity (Greenberg, Obin 2006). The vast infiltration of macrophages 
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into the adipose tissue, with their altered function and anatomical location (Figure 2.5) 
are considered as the main contributors of obesity associated inflammation.  
2.1.2.1.2.1 Infiltration  
The infiltration of macrophages into the adipose tissue positively correlates with the body 
max index (BMI), adipocyte size and stromal vascular expression of pro-inflammatory 
mediators including, TNFα, inducible nitric oxide synthase (iNOS) and I-kappa-B-kinase 
β (Mraz, Haluzik 2014). Majority of the infiltrating macrophages are thought to come 
from sources outside body fat, mainly from the systemic circulation, with a small 
percentage differentiating from preadipocytes (Xu, Grijalva et al. 2013). The exact 
instigator of infiltration is unclear, however, a number of processes including, adipocyte 
hypertrophy and necrosis, lipid spill over, metabolic endotoxemia and ER stress could be 
potential stimuli of this event (Maury, Brichard 2010). Cytokines and chemokines bind 
to their corresponding receptor on macrophages to mediate their recruitment and 
infiltration to the site of inflammation.  The chemotactic pathways that are involved in 
adipose tissue macrophage recruitment include; monocyte-chemoattracting protein 1/ 
chemokines C-C motif receptor 2, chemokines CX3C motif ligand 1/chemokines CX3C 
motif receptor 1, and leukotriene B4/leukotriene B4 receptor (Osborn, Olefsky 2012). For 
example, MCP1, that is most likely secreted by hypertrophic adipocytes, binds to its 
receptor chemokines C-C motif receptor 2 on macrophages and stimulates their 
migration. Over-expression of MCP1 leads to adipose tissue macrophage infiltration, 
insulin resistance and liver steatosis without increasing body weight, whereas deletion of 
MCP1 results in reduced adipose tissue macrophage infiltration and improves insulin 
resistance (Weisberg, McCann et al. 2003, Kanda, Tateya et al. 2006). 
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2.1.2.1.2.2 Altered function 
Macrophages can be divided into two sub-populations based on their cytokine profile; 
classically activated M1 type and the alternatively activated M2 type. The M1 phenotype 
can be induced with pro-inflammatory cytokines including, granulocyte-macrophage 
colony-stimulating factor, interferon γ (IFN-γ) and bacterial lipopolysaccharides (LPS), 
whereas, the M2 type macrophages can be induced by anti-inflammatory cytokines 
including; IL-4, interleukin -13 (IL-13), interleukin -10 (IL-10) and macrophage colony-
stimulating factor. M1 macrophages are generally considered to be pro-inflammatory as 
carry out initiate pro-inflammatory activities, whereas, M2 macrophages are considered 
to be anti-inflammatory as they promote wound healing and angiogenesis (Chung, 
Markiewicz et al. 2014). The recruitment and migration of macrophages to the site of 
inflammation is carried out in a phase dependent manner with the M1 macrophages 
recruited first to mediate the clearance of pathogens and injured cells followed by M2 
macrophages to mediate tissue repair (Xuan, Qu et al. 2015). The M1 macrophages are 
thought to be recruited into the adipose tissue by inflammatory cytokines and adipokines 
secreted by hypertrophic adipocytes and other inflammatory cells (Amano, Cohen et al. 
2014). In contrast, the stromal vascular fraction of the adipose tissue is thought to 
accommodate resident M2 macrophages to maintain a homeostatic environment. It is 
hypothesized that the imbalance between M1 and M2 macrophages may lead to 
significant changes in tissue homeostasis in obese individuals, inducing the onset and 
maintenance of inflammation. 
In the adipose tissue, macrophage polarisation towards M1 or M2 depends on the extent 
of adiposity. In the lean, M2 macrophages dominate the adipose tissue, however, factors 
regulating M1 polarisation are increased in obesity, therefore, increasing M1 macrophage 
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accumulation in the adipose tissue. The accumulation of M1 macrophages is thought to 
be a primary feature of the chronic low-grade inflammation exhibited in obesity as M1 
macrophages mediate pro-inflammatory and inhibit the effects of M2 macrophages 
causing tissue dysfunction (Huang, Manickam et al. 2013, Lee, Lee 2014, Kraakman, 
Murphy et al. 2014).  
Monocytes and macrophages can evolve and attain different phenotypes and occupy 
mixed characteristics depending on the environment. Although some authors agree that 
phenotypic conversion of M1 to M2 does occur, others argue that the microenvironment 
of the injured/inflamed tissue is not sufficient enough to accommodate the change, 
therefore, the increase in M1 is solely due to the polarisation and infiltration of M1 
macrophages (Xuan, Qu et al. 2015). Nonetheless, flow cytometry analysis demonstrate 
that adipose tissue macrophages can bear both M1 and M2 characteristics simultaneously 
(Lee, Lee 2014). HFD causes an increase in M1 macrophages in mice adipose tissue after 
8 weeks has also been reported (Shaul, Bennett et al. 2010). However, after 12 weeks, the 
M1 macrophages exhibited an increase in the expression of M2 macrophages associated 
transcripts (Shaul, Bennett et al. 2010). The induction of M1 macrophages appears to be 
linked to an increase in circulating lymphocyte antigen 6 complex monocytes observed 
in diet induced obesity (Singer, Morris et al. 2013). These monocytes are preferentially 
recruited to active areas of inflammation such as, atherosclerotic plaques (Singer, Morris 
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2.1.2.1.2.3 Localisation 
The proliferation and accumulation of resident macrophages within the adipose tissue is 
found around dead adipocytes forming crown like structures (CLS) (Figure 2.5) (Amano, 
Cohen et al. 2014). The density of the CLS is increased in obese individuals indicating 
increased adipocyte necrosis leading to infiltration of macrophages (Amano, Cohen et al. 
2014). Live imaging and cell tracking techniques have shown that M2 macrophages 
originate within the CLS and secrete pro-inflammatory cytokines which may contribute 
to the clearance of moribund adipocytes (Kraakman, Murphy et al. 2014, Haase, Weyer 
et al. 2014). However, other authors suggest that M1 macrophages originate from the CLS 
rather than infiltrating from the systemic circulation (Nishimura, Manabe et al. 2009). 
The phenotypic change between the M1 and M2 macrophages could be a possible reason 
to explain these conflicting views.  
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2.1.2.1.3 Dendritic cells 
Dendritic cells synthesise and secrete cytokines, chemokines and present antigens to 
naive cells. The cytokines they produce are involved in the maturation and activation of 
adaptive immune cells (for example, they secrete interleukin -12, which induces the 
differentiation of naive T cells into Th1 type T cells) (Lee, Lee 2014). They present 
antigens to the effector lymphoid cells via histocompatibility complex II (MHCII), 
thereby mediating the transition from innate to adaptive immunity. Due to the ideology 
that adipose tissue associated inflammation is primarily an innate immune response, the 
involvement of dendritic cells in obesity has not been extensively studied. Although the 
adipose tissue has a small population of tissue resident dendritic cells, the expression of 
Figure 2.5: Presence of macrophages in crown like structures in inflamed adipose tissue. Histological 
analysis of inflamed adipose tissue indicates the presence of macrophages around moribund adipocytes 
forming crown like structures. 
              (Bigornia, Farb et al. 2012) 
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the surface antigen, cluster of differentiation 11c (CD11c) is also expressed by M1 type 
macrophages, making it difficult to distinguish the two populations (Mraz, Haluzik 2014). 
Nonetheless, HFD has shown to increase the adipose tissue dendritic cell population in 
mice and the expression of dendritic cell antigens CD11c and  cluster of differentiation 
38 are elevated in the subcutaneous depots of obese humans compared to lean controls 
(Bertola, Ciucci et al. 2012). The cytokines inducing the differentiation of  T helper 17 
cells (Th17) are increased and those inducing differentiation of Treg are decreased in 
obesity (Bertola, Ciucci et al. 2012). Thus, the imbalance between Th17 (pro-
inflammatory) and Treg (anti-inflammatory) may lead to M1 polarisation of adipose 
tissue macrophages.  
2.1.2.1.4 Lymphocytes 
Lymphocytes include T cells (for cell mediated, cytotoxic adaptive immunity), B cells 
(for humoral, antibody-driven adaptive immunity) and natural killer cells (for cell 
mediated, cytotoxic innate immunity) (Lee, Lee 2014). B and T cells recognise specific 
antigens with their cell surface receptors, therefore, are thought to play important roles in 
adaptive immunity. The infiltration of B and T cells into the adipose tissue positively 
correlates with adiposity (Mathis 2013). T cells express a limited number of T cell 
receptors (TCR) as they respond to specific antigens (Cho, Morris et al. 2014). Clonal 
expansion of T cells is exhibited in adipose tissue suggesting the presence of antigen 
specific responses (Subramanian, Ozcan et al. 2015). A small percentage of the T cell 
population express antigen binding ץδ chains in the TCR, therefore, are known as ץδ T 
cells (Lee, Lee 2014).   The ץδ T cells secrete both anti and pro-inflammatory cytokines 
thus, suggesting they have a dual role in inflammation (Lee, Lee 2014). However, most 
of the T cell population is composed of antigen binding αβ chains in the TCR, therefore, 
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are known as αβ T cell. The αβ T cell population is further divided into categories based 
on the cell surface expression of cluster of differentiation transmembrane glycoprotein’s 
and functional activities. The two major co-receptor molecules, cluster of differentiation 
4 (CD4) and cluster of differentiation 8 (CD8) define the two different T cell lineages 
with different functions. CD8+ T cells are activated by major histocompatibility complex 
I, which are expressed by all nucleated cells within the body and form effector cytotoxic 
T lymphocytes (Lee, Lee 2014). CD4+ T cells are activated by MHC II which are 
expressed by antigen presenting cells such as, macrophages, B cells and dendritic cells 
and form cytokine secreting and effector T helper cells (Lee, Lee 2014). CD4+ T cells 
are further subdivided into Th1, Th2, Th17 and Treg cells subsets based on their secretary 
cytokine profile.  
There are conflicting views on the role of B and T cells in obesity induced inflammation 
as some authors suggest B and T cells play a protective role, as a lack of B and T cells 
has been shown to increase insulin resistance in mice (Subramanian, Ozcan et al. 2015). 
However, others argue that B and T cells play a negative role given the observation that 
depletion of CD8+ T cells lead to improved glucose homeostasis and lack of B cells 
improves insulin sensitivity (Subramanian, Ozcan et al. 2015).  
2.1.2.1.4.1 T Cells 
Adipose tissue T cells influence the inflammatory set point of obesity; thereby 
contributing to obesity-induced inflammation. The expansion of the adipose tissue in 
obesity may cause the activation of T cells, which in turn contribute to the onset of 
inflammation (Cho, Morris et al. 2014). Adipocytes are characterised as antigen 
presenting cells as they are able to present antigens and co-stimulatory molecules to 
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activate adipose tissue resident T cells (Mathis 2013). Obesity leads to upregulation of 
MHCII expression on the surface of adipocytes (Cho, Morris et al. 2014). Obesity induced 
activation of T cells suggest that adipose tissue T cells are stimulated by signals within 
the adipose tissue environment (Cho, Morris et al. 2014). Thus, the activation of T cells 
may be a leading cause of M1 infiltration and accumulation, as the recruitment and 
accumulation of adipose tissue T cells within the adipose tissues is thought to occur before 
the infiltration of macrophages (Chung, Markiewicz et al. 2014). Macrophages play an 
important role in the activation and proliferation of adipose tissue T cells, as they residue 
closely with the adipocytes and sample the environment (Cho, Morris et al. 2014). M1 
macrophages mediate the development of Th1 CD4+ T cells (pro-inflammatory as they 
synthesise and secrete IFNγ, interleukin-2 and TNFα) and M2 macrophages mediate the 
development of Th2 CD4+ T cells (anti-inflammatory as they synthesise and secrete 
cytokines including, IL-4, interleukin-5, IL-10 and IL-13) (Muraille, Leo et al. 2014). 
Thus, the resident adipose tissue macrophage’s (M2) may participate in the initiation of 
T cell activation and proliferation, which later may be sustained by recruited macrophages 
(M1) within an obese inflammatory environment (Cho, Morris et al. 2014).   
In addition, obesity increases the number of CD8+ T cells in the adipose tissue and also 
induces the expression of IFNץ and granzyme B expression (Lee, Lee 2014). CD8+ T 
cells are considered as the key inducers of obesity associated inflammation even more so 
than macrophages. The number of CD8+ T cells exceed the number of macrophages in 
the adipose tissue of HFD fed mice (Nishimura, Manabe et al. 2009). CD8+ T cells are 
able to induce the activation and migration of macrophages in the adipose tissue of obese 
mice as concluded by co-culture experiments (Mathis 2013).  Neutralization of CD8+ T 
cells in HFD fed mice improves adipose tissue inflammation (Mathis 2013). Not only do 
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CD8+T cells contribute to inflammation induced by obesity, but the cell surface changes 
can provide a good indication of stress within adipose tissue. For example, the natural 
killer group 2D (NKG2D) receptor is a good indicator of inflammation and is upregulated 
in response to HFD in mice (Chung, Markiewicz et al. 2014). The NKG2D receptor binds 
to ligands that are only induced under stress such as infections, nutrient stress, ER stress, 
oxidative stress, hypoxia and chronic inflammation. 
2.1.2.1.4.2 B Cells 
The B cell population expresses clonally diverse cell surface immunoglobulin (Ig) 
receptors that recognise specific antigen epitopes (LeBien, Tedder 2008). Mice lacking B 
cells expressing IgG have the usual weight gain but have far less inflammation in visceral 
adipose tissue as well as improved metabolic indices such as, insulin resistance in 
comparison to the control group (Mathis 2013, Winer, Winer et al. 2011). B cell knockout 
using B cell specific deletion of inhibitor of DNA binding 3 in diet induced obese mice 
attenuates inflammation and insulin resistance in visceral adipose tissue and improves 
systemic glucose tolerance (Harmon, Srikakulapu et al. 2016). An increase in B1 type B 
(B1-B) cells in the visceral adipose tissue is observed with elevated IgM natural 
antibodies (Harmon, Srikakulapu et al. 2016). The B-1B cells reduce cytokine production 
in M1 macrophages and attenuate adipose tissue inflammation and glucose intolerance in 
diet-induced obese mice (Harmon, Srikakulapu et al. 2016).  
2.1.2.2 Adipocytes 
Adipocytes also express receptors that enable them to sense infectious pathogens and 
internal injury. Binding of ligands activate multiple intracellular stress pathways and 
inflammatory cascades that lead to the synthesis and secretion of cytokines, adipokines 
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and acute phase reactants that are involved in instigating inflammation (Berg, Scherer 
2005). These proteins act in an autocrine, paracrine and endocrine manner to modulate 
local and systemic metabolism and inflammation.  
The synthesis and secretion of adipokines varies amongst different adipose tissue depots 
and HFD promotes the development of a pro-inflammatory state in a similar manner 
within each depot (Samaras, Botelho et al. 2010, Fried, Bunkin et al. 1998). Although the 
functional importance of specific depots is not clearly understood, the diet induced 
adipokine changes are thought to influence the function of the associated tissue (Samaras 
et al. 2010, Fried et al. 1998). Most adipokines stimulating the inflammatory response are 
upregulated in obesity and therefore, the imbalance between pro and anti-
inflammatory/pro-resolving adipokines is considered to be a significant contributor 
towards the development of obesity associated metabolic diseases (Ouchi, Parker et al. 
2011).  
2.1.2.2.1 Leptin and inflammation 
Leptin plays important roles in controlling innate and adaptive immunity, and 
inflammation. The pro-inflammatory responses of leptin have been noted in several 
studies. The importance of leptin in inflammatory processes is demonstrated by using 
leptin deficient mice (ob/ob) or leptin receptor deficient mice (db/db). These mice have 
high levels of lymphocyte atrophy and significantly reduced thymus cortex  and normal 
thymic function. Intravenous injection of endotoxins, endotoxin-induced fever and pro-
inflammatory stimulus such as, TNFα and LPS induce a sudden rise in leptin levels in 
rats (Grunfield 1996) (Makki, Froguel et al. 2013). In the innate immune system, leptin 
induces the activation of neutrophils, ROS production and, proliferation and migration of 
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monocytes, development and maintenance of natural killer cells (development and 
maintenance) and the synthesis and secretion of IL6, TNFα and CC-chemokines (CCL3, 
CCL4 and CCL5) by macrophages via activating the janus activated kinase 2 – signal 
transducer and activator of transcription 3 pathway (Santos-Alvarez, Goberna et al. 1999, 
Loffreda, Yang et al. 1998, Zarkesh-Esfahani, Pockley et al. 2001). Furthermore, in the 
adaptive immune system it stimulates T cell proliferation, polarization of naïve CD4+ T-
cell proliferation towards Th1 phenotype, promotes Th1-type cytokine production, 
induces the expression of pro-inflammatory cytokines by macrophages and monocytes, 
and it directly acts on hepatocytes to promote C-reactive protein (CRP) expression 
(Loffreda, Yang et al. 1998).  
Leptin therapy increases the number of CD4+/CD8+ T cells, promotes Th1 differentiation 
and reduces thymic apoptosis in ob/ob and leptin-deficient children (Dardenne, Savino et 
al. 1983, Makki, Froguel et al. 2013). In addition, the functions of T cells, macrophages 
and dendritic cells are impaired in ob/ob mice and HFD-fed mice (Macia, Delacre et al. 
2006, Verwaerde, Delanoye et al. 2006).  
Furthermore, leptin has been proposed to be an independent risk factor for coronary heart 
disease, regardless of total adiposity as it may affect  the vascular structure as it has shown 
to exhibit angiogenic properties (Wallace, McMahon et al. 2001). It induces 
neovascularisation, contributes to arterial thrombosis by acting through the platelet leptin 
receptor and stimulates the production of ROS (Sierra-Honigmann, Nath et al. 1998, 
Bodary, Westrick et al. 2002, Xu, Chen et al. 2004). Therefore, it may not only regulate 
feeding behaviour and energy homeostasis in obesity, but rather it may be involved in 
inducing the development of associated metabolic diseases such as, T2DM by affecting 
vasculature health.    
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2.1.2.2.2 Adiponectin and inflammation 
In addition to its role in energy homeostasis, adiponectin has direct anti-inflammatory and 
anti-atherosclerosis effects. It stimulates the synthesis of anti-inflammatory cytokines 
such as IL-10, inhibits the synthesis and secretion of pro-inflammatory cytokines and 
binds to apoptotic cells to facilitate their uptake by macrophages (promotes M2 
phenotype) (Kumada, Kihara et al. 2004, Takemura, Ouchi et al. 2007). It inhibits TNFα 
induced activation of NF-κβ and expression of monocyte adhesion molecules in 
endothelial cells, thereby, inhibiting adherence and the formation of atherosclerotic 
lesions (Ouchi, Kihara et al. 2000, Ouchi, Kihara et al. 1999). Furthermore, it supresses 
the expression of class A macrophage scavenger receptor and lipid accumulation in 
human monocyte derived macrophages (Ouchi, Kihara et al. 2001). Although, transgenic 
overexpression of adiponectin leads to morbid obesity in mice. They have improved 
glucose metabolism, reduced number of macrophages in the adipose tissue and decreased 
expression of TNFα (Kim, van de Wall et al. 2007). Thus, adiponectin maintains an 
antagonistic action to TNFα; TNFα supresses the expression of adiponectin, and 
adiponectin supresses the expression of TNFα to achieve its anti-inflammatory, insulin 
sensitising effects (Makki, Froguel et al. 2013).  
2.1.3 Resolution of inflammation 
Resolution of inflammation results in tissue homeostasis owing to the return of tissue 
mononuclear cell numbers to basal level and clearance of damaged cells and pro-
inflammatory stimuli. Clearance of moribund cells by phagocytosis is essential as it 
protects the tissue at the site of inflammation. Phagocytosis mediates the clearance of 
contents released from disintegrated cells thus, further inhibiting the activation of immune 
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cells (Pupjalis, Goetsch et al. 2011). Resolution of inflammation is perceived to occur by 
the activation of endogenous events that result in the elimination of granulocytes by 
apoptosis and synthesis of pro-resolution molecules such as, specialised lipid mediators 
(lipoxis, resolvins, maresins and proectins), peptides/proteins (melanocortins, galectins 
and annexins) and cytokines (IL-10) (Vago, Nogueira et al. 2012). These pro-resolving 
mediators mediate the resolution of inflammation and repair by several mechanisms 
including, decreased endothelial activation, reduced leukocyte infiltration and activation 
of neutrophil apoptosis and clearance by macrophages (Sugimoto, Sousa et al. 2016). 
Persistent pro-inflammatory stimuli and/or dysregulated resolution results in chronic 
inflammation as exhibited in obesity (Figure 2.6) (Maskrey, Whitfield et al. 2011).  Thus, 
many anti-obesity therapies target the inflammatory status the in hope of resolving 
inflammation thereby, limiting the development of obesity associated metabolic co-
morbidities, rather than solely inducing weight loss. Unlike many of the pro-resolving 
mediators, Annexin A1 (ANXA1) is upregulated in the fat depots of diet induced obese 
mice models and is reduced in the plasma of obese individuals, therefore it is of 
significant interest in this project (Akasheh, Pini et al. 2013, Kosicka, Cunliffe et al. 
2013). Section 2.2 focuses on ANXA1, its mechanisms of action, functions and 
expression in obesity.  
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Figure 2.6: Failed resolution of inflammation develops into chronic inflammation leading to tissue 
damage. 
Th= T helper Cells, ILC2= Group 2 innate lymphoid cells               (Schett, Neurath 2018) 
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2.2 Annexin A1  
ANXA1 (also known as lipocortin I and calpactin II) is a member of the annexin 
superfamily. The shared homology across the family allows it to bind to phospholipids in 
the presence of Calcium (Ca2+) and mediate vesicle aggregation (Lizarbe, Barrasa et al. 
2013). It is present in the cytoplasm of cells and at the cytoplasmic surface of the plasma 
membrane, matrix vesicles, phospholipid liposomes, chromaffin granules and the 
cytoskeleton (F-actin) (Johnstone, Hubaishy et al. 1993).  ANXA1 has a similar structure 
to the other members of the annexin superfamily. It has a highly conserved C-terminal 
core and a variable N-terminal domain, which is thought to be involved in regulating Ca2+ 
binding. The N-terminal region of the protein is variable, both in length and the amino 
acid sequence and it is responsible for the diversity amongst annexins. In humans, the 
length of the N-terminal region ranges from a few to over 200 amino acids and based on 
this region, they have been classified into 3 groups; 1) Small: <20-21 amino acids (A3, 
A4, A5, A6, A8 and A13a), 2) Intermediate: <55 amino acids (A1, A2, A9 and A13b) 
and 3) Long: >100 amino acids (A7 and A11) (Lizarbe, Barrasa et al. 2013). Although 
the N-terminal region is smaller than the core, it is structurally and functionally involved 
in providing the members of the superfamily with unique properties. Post-translational 
modifications of the N-terminal region (acetylation, phosphorylation and proteolysis) lead 
to the modification of key regions within the protein’s core, thereby, deeming it as the 
main regulator of the protein both structurally and functionally. The N-terminal derived 
peptides of ANXA1, AC2-26, AC2-12 and AC9-25 have been reported to retain the 
effects of the full-length protein in various in vivo and in vitro studies (Gavins, Hickey 
2012).  
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The annexin proteins lack the hydrophobic signalling peptide that is required for secretion 
from cells, thus a number of mechanisms have been proposed, including, localisation on 
the outer plasma membrane, interaction with biological membranes that expose 
phosphatidylserine and the use of plasma membrane transporters (Figure 2.7) (Lizarbe, 
Barrasa et al. 2013). Annexins are secreted from the cells into the extracellular space 
where they bind to extracellular matrix components thereby, affecting cell functions and 
regulate different physiological processes. ANXA1 is thought to be secreted via the ATP-
binding-cassette transporters however, as it is stored in granules in neutrophils, it is 
rapidly mobilised and relocated to the outer leaflet of the plasma membrane and secreted 
(Perretti, D'Acquisto 2009). It acts in an autocrine, paracrine and endocrine manner and, 
exerts it’s roles by binding to the formyl peptide receptor (FPR) family. Full length 
ANXA1 binds to and activates formyl peptide receptor 2 (FPR2/ALX), whereas, AC2-26 
can bind and activate FPR2/ALX and formyl peptide receptor 1 (FPR1) (Dalli, Montero-
Melendez et al. 2012).   
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2.2.1 Formyl peptide receptors 
The FPR’s are a prototype of complex family of receptors that bind to several unrelated 
molecules (Solito, Kamal et al. 2003). FPR’s belong to the Gi protein coupled receptor 
(GPCR) family and are thought to have evolved to mediate trafficking of phagocytes to 
the sites of bacterial invasion and/or tissue damage.  The FPR family is similar to the toll 
like receptor family as it is capable of binding to peptides that have highly conversed N-
formyl methionine motifs (Dufton, Perretti 2010). N-formyl peptides originate from 
Figure 2.7: Annexin A1 secretory pathways. Annexin A1 is externalised through 5 different mechanism 
depending on the cell type. A) Myristoylation and phosphorylation of Serine 27 by protein kinase C, B) 
activation of ATP-binding cassette-A1 transporter, C) Fusion of annexin A1 containing granules, D) plasma 
membrane budding (inverted orientation of plasma membrane) and E) through exosome secretion. 
PKC= Protein kinase C, ABC-A1= ATP binding cassette A1 transporter, PM=Plasma membrane, MP= 
Membrane protein, MVE= Multivesicular endosome              (Boudhraa, Bouchon et al. 2016) 
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endogenous sources such as, the mitochondrial proteins of damaged host cells and/or 
exogenous sources, such as proteins from invading pathogens (Le, Murphy et al. 2002). 
This family of receptors is possibly the only known chemotactic GPCR’s that can bind 
both protein and lipid ligands (He, Ye 2017). These receptors bind to many different 
ligands, which are thought to mediate agonist and antagonist effects.  
Upon agonist binding, heterotrimeric Gi proteins coupled to FPR rapidly dissociate into 
α and βγ subunits, activating signalling molecules and pathways shared with most other 
leukocyte chemoattractant receptors (Le, Murphy et al. 2002) (Figure 2.8). Typically, 
phosphorylation of a G protein results in the activation of a phospholipase enzyme that 
mediates the cleavage of phospholipid phosphatidylinositol 4,5 bisphosphate (PIP2) into 
diacyl glycerol and inositol 1,4,5 triphosphate (IP3). IP3 diffuses through the cytoplasm 
to activate Ca2+ channels throughout the cell. Increased intracellular Ca2+ mediates 
various processes such as, cellular chemotaxis. Other intracellular signalling activated 
include tyrosine kinase mediated phosphorylation of phospholipase A and phospholipase 
D leading to the activation of actin-related protein 2/3 dependent pathways (thereby 
promoting cellular movements) and activation of members of the mitogen activated 
protein kinase (MAPK) family (Gavins, Hickey 2012).  
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2.2.2 Pro-resolving role of Annexin A1  
ANXA1 is involved in regulating several biological processes such as, cell growth 
regulation and differentiation, acute and chronic inflammation, ischemia/reperfusion 
injury, pain, fever, intracellular vesicle trafficking, arachidonic acid release, leukocyte 
migration, tissue growth and apoptosis (Gavins, Hickey 2012, Flower, Rothwell 1994) 
(well-studied functions are discussed in more detail below). ANXA1 protein is 
synthesised and secreted by many different cell types including, immune cells 
Figure 2.8: FPR intracellular signalling cascade. Binding of FPR ligands such as, fMLF results in 
activation of signal transduction cascade, cellular activation and PKC dependent desensitization of 
unrelated chemotactic receptors. The release of intracellular and sustained influx of extracellular calcium 
is required for neutrophil migration. 
 CKR= Chemokine receptor, DAG= Diacylglycerol, IP= Inositol phosphate, MAPK=Mitogen-activated 
protein kinase, PI3K= Phosphatidylinositol 3 kinase, PIP2= Phosphatidylinositol diphosphate, PIP3= 
Phosphatidylinositol triphosphate, PKC= Protein kinase C, PLA= Phospholipase A, PLC= Phospholipase 
C, PLD= Phospholipase D, RAC= Rac guanine triphosphatase family, SRC= Src- like tyrosine kinase and 
fMLF= Formyl-methionyl-leucyl phenylalanine                    
                        (Le, Murphy et al. 2002) 
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(monocytes, macrophages and neutrophils), epithelial cells and adipocytes where it 
mediates different functions depending on the cell type (Babbin, Jesaitis et al. 2007, 
Flower, Rothwell 1994, Kosicka, Cunliffe et al. 2013). Its highest cellular concentration 
is thought to be in neutrophils where it makes up between 2-4 % of total intracellular 
proteins (Brancaleone, Mitidieri et al. 2014). It is largely localised within the cytosol in 
gelatinous granules in resting neutrophils and is rapidly mobilized to the cell surface upon 
activation by an inflammatory stimuli (El Kebir, Jozsef et al. 2008). At low concentrations 
ANXA1 and its N-terminal peptides (AC2-26 and AC9-25) can elicit Ca2+ release through 
FPR’s without fully activating the MAPK pathway mediating neutrophil desensitization 
and inhibition of trans-endothelial migration induced by other chemoattractants (Ernst, 
Lange et al. 2004). Furthermore, it promotes macrophage phagocytosis and removal of 
apoptotic leukocytes (efferocytosis) without the production of inflammatory mediators, 
deescalating the inflammatory cascade (Maderna, Yona et al. 2005). However, in vitro 
studies conclude high concentrations of ANXA1 peptides can fully activate neutrophils 
and become potent pro-inflammatory stimulants (Ye, Boulay et al. 2009).  
Glucocorticoids exert their anti-inflammatory actions by regulating ANXA1 gene 
expression and secretion from existing intracellular pools by stimulating protein kinase C 
activity (Solito, Kamal et al. 2003). Glucocorticoids induce rapid serine phosphorylation 
on ANXA1, and its membrane translocation is via a glucocorticoid receptor-dependent 
mechanism that requires MAPK, phosphatidylinositol 3-kinase and Ca2+-dependent 
protein kinase C pathways (Solito, Kamal et al. 2003). ANXA1 is known to replicate 
many of the described anti-inflammatory effects of glucocorticoids such as, increasing 
the synthesis and secretion of anti-inflammatory mediators, inhibiting the synthesis of 
pro-inflammatory lipid mediators, reducing the survival of certain inflammatory cells 
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such as, eosinophils and T-cells and inhibiting the induction of adhesion molecules 
thereby, inhibiting leukocyte infiltration (Barnes 1998). Furthermore, ANXA1 inhibits 
the negative feedback effects of glucocorticoids on the release of corticotrophin, 
hypothalamic releasing hormones and pro-inflammatory mediators such as, 
cyclooxygenase- 2 (COX-2) and iNOS and induce apoptosis and, thereby dampen 
inflammation (Gavins, Hickey 2012). ANXA1-/- mice exhibit a complex phenotype 
including partial or complete resistance to the anti-inflammatory effects of 
glucocorticoids (Hannon, Croxtall et al. 2003). 
2.2.2.1 Innate immune system  
The role of annexins in inflammation is their best characterised biological function. 
ANXA1 is involved in several different processes of inflammation such as, inhibition of 
phospholipase A2 (PLA2), and iNOS activities.  It inhibits NF-κB activation, production 
of pro-inflammatory cytokines and promotes the synthesis and secretion of anti-
inflammatory cytokines (Ferlazzo, D'Agostino et al. 2003).  
2.2.2.1.1 Ceramide production and phospholipase A2 inhibition 
All annexin proteins act as intracellular sensors that detect changes in the environment 
and provide relevant responses. Annexins interact with the phospholipids at specific 
micro-domains that are characterised by their lipid composition and structure such as, 
phosphatidylserine, phosphatidic acid, phosphatidylinositol, PIP2, 
phosphatidylethanolamine, fatty acids (arachidonic acid), ceramides and lipid-derived 
metabolites providing lipid-mediated signalling (Lizarbe, Barrasa et al. 2013). ANXA1 
is thought to be involved in the Ca2+ dependent ceramide production and promoting it’s 
clustering in the membrane (Babiychuk, Monastyrskaya et al. 2008, Lizarbe, Barrasa et 
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al. 2013). Acid sphingomyelinase convert sphingomyelin to ceramide in the presence of 
elevated Ca2+ concentrations. Ceramides are thought to be key lipid mediators in cellular 
processes such as differentiation, proliferation, growth and apoptosis. The production is 
thought to be restricted to ANXA1 as they depend on its specific N-terminal domain 
(Babiychuk, Monastyrskaya et al. 2008).  
Activation of ANXA1 leads to the inhibition of phospholipase A2 phosphorylation which 
is responsible for the cleavage of phospholipids to produce arachidonic acid and 
lysophosphatidic which are further cleaved to produce eicosanoids, such as, leukotrienes 
and prostaglandins that contribute to inflammation (Gavins, Hickey 2012). Upregulation 
of phospholipase A2 and greater production of eicosanoids is observed in ANXA1-/- cells 
(Kwon, Lee et al. 2012). Interestingly, the inhibitory effects are induced by both full 
length ANXA1 protein and cleaved peptide in different areas of the cell. Full length 
ANXA1 interacts with phospholipase A2 in the cytosol whereas the peptide interacts at 
the membrane (Kwon, Lee et al. 2012). 
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Figure 2.9: Biosynthesis pathway of eicosanoids from arachidonic acid. An inflammatory stimulus results 
in the release of arachidonic acid from the plasma membrane and the activation of phospholipase A2. 
Arachidonic acid is transformed by several classes of enzyme such as, COX  and LOX to generate pro-
inflammatory mediators such as, prostaglandins, leukotrienes and lipoxins. Annexin A1 inhibits the 
activation of phospholipase A2 thus, inhibiting the production of these pro-inflammatory mediators thereby, 
contributing to resolving inflammation. 
COX= Cyclooxygenase, LOX= Lipoxygenase, HETEs= Hydroxy eicosatetraenoic acids   
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2.2.2.1.2 Inhibition of neutrophil adhesion and extravasation 
ANXA1 interferes with the adhesion of leukocytes (including neutrophils, monocytes and 
macrophages) to the endothelium cells thereby, inhibiting extravasation and trans 
endothelial migration (Figure 2.10) (Perretti, Flower et al. 1993). It does not affect the 
rolling and adhesion of neutrophils to the endothelium, which may suggest that the cell 
requires activation before ANXA1 can mediate its functions (Perretti, D'Acquisto 2009). 
Activation of leukocytes particularly neutrophils, lead to mobilisation of ANXA1 to the 
cell surface, where it interacts with the β integrins, inhibiting their interaction with the 
endothelial integrin counter-receptor thereby, dismantling attachment (Solito, Kamal et 
al. 2003). In addition, it mediates the shedding of L-selectin present on leukocytes 
resulting in detachment of adhered cells from the endothelium thus preventing their 
transmigration (Gavins, Hickey 2012).  
Figure 2.10: Effects of Annexin A1 on Neutrophil transmigration. 1) ANXA1 mediates L-selectin shedding 
2) interacts with β integrins and inhibits interaction of neutrophils with the endothelium. 3) However, cleaved 
ANXA1 induces the expression of  ICAM 1 promoting attachment and trans-endothelial migration.  
ANXA1= Annexin A1 and ICAM1= Intracellular adhesion molecule 1        (Gavins, Hickey 2012) 
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At the site of inflammation, activated neutrophils secrete ANXA1, which is cleavage by 
proteases and elastases from the c-terminus to produce a 33kDa pro-inflammatory peptide 
which acts to promote neutrophil transmigration by inducing the expression of clustering 
of intracellular adhesion molecule 1 on endothelial cell surface (Gavins, Hickey 2012). It 
is thought the cleavage is necessary for the secretion of ANXA1 as majority of the 
exogenous ANXA1 exhibited is in the truncated form. The cleavage is inhibited when the 
intracellular Ca2+ signalling is blocked (Kwon, Lee et al. 2012). The anti-inflammatory 
and pro-inflammatory actions mediated by endogenous and exogenous protein 
respectively, ensure enough activation is reached but not exceeded which could lead to 
chronic unresolved inflammation.  
2.2.2.1.3 Apoptosis  
The role of ANXA1 in apoptosis was first discovered using rat thymocytes. Exogenous 
application of ANXA1 exposed to hydrogen peroxide decreased necrosis of rat 
thymocytes, but mediated apoptosis through modulating the activity of cytosolic PLA2 
inhibiting the generation of anti-apoptotic prostaglandins such as, prostaglandin E2 
(PGE2) (Sakamoto, Repasky et al. 1996).  
Previous literature concludes that ANXA1 induces and accelerates the degree of 
apoptosis. In activated polymorphonuclear neutrophils ANXA1 produces selective 
changes in specific markers of cell activation i.e L-selectin shedding and changes in the 
Ca2+ levels, both are associated with apoptosis (Solito, Kamal et al. 2003). An increase in 
Ca2+ levels induces apoptosis in thymocytes and eosinophils, but leads to retarded 
apoptosis in neutrophil, which may suggest, apoptosis in neutrophils may not be 
dependent on intracellular Ca2+ concentrations (Solito, Kamal et al. 2003). It is thought 
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that an increase in cytosolic Ca2+ concentration may lead to the activation of protein 
phosphatase, calcineurin. Calcineurin dephosphorylates B-cell lymphoma (BCL)- 2 
associated death promoter, which hetero-dimerizes with BCL-extra-large and promotes 
apoptosis (Solito, Kamal et al. 2003). Low levels or over expression of ANXA1 does not 
modify the basal levels of BCL-associated X protein (BAX) and BCL-2, instead increases 
the susceptibility to apoptosis (Perretti, Solito 2004).  
Once neutrophils have extravasated and reached the site of inflammation, they up-
regulate ANXA1 synthesis. Higher levels of ANXA1 are associated with higher 
susceptibility to apoptosis (Solito, Kamal et al. 2003). Elevated levels of ANXA1 activate 
apoptotic pathways such as, BAX and Caspase 3 and inhibit survival pathways, such as 
of NF-κB (Vago, Nogueira et al. 2012). Apoptosis mediated by ANXA1 resembles that 
of TNFβ mediated rather than formyl-methionyl-leucyl phenylalanine, which induces cell 
death through the respiratory burst oxidation. Furthermore, the level of ANXA1 is in 
parallel with the activity of caspase 3 and inhibition of caspase 3 inhibits apoptosis and 
induces proteolysis of ANXA1 to generate the pro-migratory 33kD peptide (Perretti, 
Solito 2004). Hence, a decreased production of the pro-migratory peptide of ANXA1 may 
lead to decreased clearance of apoptotic/neurotic cells by macrophages sustaining 
inflammation. ANXA1 mediates phagocytosis of apoptotic neutrophils by macrophages 
to limit tissue injury through release of transforming growth factor β1 and changes in F-
actin reorganisation leading to localised polymerization of actin filaments to facilitate the 
formation of filopodia and ultimately result in engulfment (Maderna, Yona et al. 2005, 
Vago, Nogueira et al. 2012). ANXA1 mediates critical roles in phagocytosis and 
inhibitory roles during macrophage activation. ANXA1-/- macrophages show impaired 
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generation of ROS due to defective binding of the cells to the opsonised target and 
enhanced release of PGE2 and COX-2 (Yona, Buckingham et al. 2004). 
2.2.2.1.4 Phagosome formation 
ANXA1 interacts with profiling, a G-actin binding protein that is involved in regulating 
actin polymerisation (Lizarbe, Barrasa et al. 2013). Remodelling of the actin cytoskeleton 
is an important factor in the internalisation and the phagosome maturation process.  In 
macrophages, ANXA1 is present in actin concentrated areas and is thought to be involved 
in the formation of phagosomes, as downregulation of ANXA1 results in impaired 
phagocytosis and actin flashing (Patel, Ahmad et al. 2011).    
2.2.2.2 Adaptive immune system  
The role of ANXA1 in the adaptive immune system is less clear, as data present in the 
literature is less consistent. Lymphocytes do not appear to express large amounts of 
ANXA1 nor its receptors. B cells do not seem to express it at all and only one lymphocyte 
subset, CD56+ natural killer cells express a large amount of ANXA1 (Morand, 
Hutchinson et al. 1995, Perretti, Flower 1996). Unstimulated T cells express ANXA1 and 
FPR2/ALX receptor at low levels. However, after stimulation they increase the secretion 
of ANXA1 and upregulate their surface expression of FPR2/ALX receptor (D'Acquisto, 
Merghani et al. 2007). Previous studies suggest ANXA1 can promote T cell activation 
and T cell dependent inflammation. However, growing evidence suggests that ANXA1 is 
not solely involved in the phenomenon as TCR activation is required, but may contribute 
to induce the full T cell response (Gavins, Hickey 2012). CD4+ T cells express slightly 
more ANXA1 than CD8+ T Cells, and previous research suggests, T-cell expressing 
ANXA1 inhibit their activation in the adaptive immune response, acting as an 
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endogenous anti-inflammatory mediator (Yang, Song et al. 2013). The absence of 
ANXA1 increases CD4+ T cell activation and amplification of antigen induced 
intracellular signalling contributing to tissue inflammation (Yang, Song et al. 2013). 
However, the action of ANXA1 on T cell activation are subset specific as it promotes the 
development of Th2 and Th17 subsets and inhibits the development of the Th1 response 
(D'Acquisto, Merghani et al. 2007).  
2.2.3 Therapeutic potential of Annexin A1 and its expression in Obesity 
ANXA1 based pharmacological strategies could potentially be as effective as steroids 
without their metabolic side effects. Small ANXA1 mimetic peptides provide further 
advantages such as, protection from proteolysis during treatment and aiding delivery to 
site of injury (Sugimoto, Vago et al. 2016). The vast range of anti-inflammatory/pro-
resolving effects of ANXA1 and its peptides have shown to have significant effects in 
resolving inflammation in several disease models including, atherosclerosis, 
cardiovascular disease, inflammatory bowel disease and inflammatory arthritis (Figure 
2.11) (Sena, Grishina et al. 2013, Patel, Kornerup et al. 2012). However, the known 
effects of ANXA1 or its peptides in obesity-associated inflammation are limited.  
Previous in vivo studies of ANXA1 gene knockout in mice also report conflicting 
findings. Decreased number of fat cells and weight was observed in ANXA-/- mice 
compared to wild type (WT) (Warne, John et al. 2006). However, (Akasheh et al. 2013) 
observed significant increase in adiposity, blunted lipolysis and elevated hepatic 
lipogenesis ANXA-/- mice compared to WT. ANXA1 mRNA expression is up-regulated 
in visceral adipose tissue and subcutaneous adipose tissue of HFD induced obese mice, 
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independent of circulating leptin or IL6 levels using ob/ob knockout models (Akasheh, 
Pini et al. 2013).  
Transcriptomic analysis show increased ANXA1 expression in human adipose tissue in 
response to obesity and increased abundance of ANXA1 protein in mature adipocytes 
isolated from abdominal subcutaneous adipose tissue in old compared to young human 
obese individuals (Henegar, Tordjman et al. 2008, Alfadda, Benabdelkamel et al. 2013). 
Whereas, plasma ANXA1 levels inversely correlate with markers of adiposity such as, 
leptin and inflammation in human obesity (Kosicka, Cunliffe et al. 2013). In contrast, 
serum ANXA1 levels are elevated in obese and positively correlated with BMI, waist 
circumference and waist-to-hip ratio (Pietrani, Ferreira et al. 2018). Furthermore, higher 
levels of cleaved ANXA1 in obesity are observed, which may compromise its anti-
inflammatory and resolving actions, locally, thus ANXA1 may have an important 
pathophysiological mechanism involved in inflammatory status observed in obesity 
(Pietrani et al. 2018). 
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Figure 2.11: Therapeutic potential of Annexin A1 and it’s peptides. 
BBB=Blood brain barrier, ANXA1=Annexin A1, α-SMA=α-smooth muscle actin, TGF-β=Transforming 
growth factor-β, MMP-1=Matrix metalloproteinase-1, IBD’s= Inflammatory bowel diseases, 
EV=Extracellular vesicles, TNF-α= Tumour necrosis factor-α, NF-κB= Nuclear factor-kappa β, PGE2= 
Prostaglandin E2, COX-2= Cyclooxygenase 2, INF-γ= Interferon-γ, IL-= Interleukin-, NOX1=NADPH 
Oxidase1 and FAK=Focal adhesion kinase                 (Sheikh, Solito 2018) 
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2.3 Aims, objectives and hypotheses  
The collective aim of this project was to investigate the roles of ANXA1 in obesity and 
associated inflammation. The two main questions this project aimed to explore were; 1) 
Why is ANXA1 upregulated in adipocytes in obesity and in doing so, what role does it 
play? And 2) Are the plasma ANXA1 levels reversible with weight loss and if so, are the 
levels affected by the degree of adiposity , or by the presence of inflammation? In doing 
so, it aimed to further understand the biological significance of ANXA1 expression in 
adipocytes, the increased expression in obesity and whether the altered plasma levels in 
obesity are due to increased adiposity and/or increased inflammation and/or both.   
Study 1 (Chapter 4): Expression of obesity dysregulated genes in response to acute 
AC2-26 treatment in a using a model mimicking the inflammatory status that is 
observed during obesity of obesity  
Although, ANXA1 expression and secretion are increased in adipocytes in obesity, very 
little to no evidence is present in the literature regarding the significance of this change. 
Therefore, the aim of this study was to investigate the potential roles of ANXA1 peptide, 
AC2-26 in adipocytes using a model mimicking the inflammatory status that is observed 
during obesity. The objects of this study were: 
• To establish a model mimicking the inflammatory status that is observed 
during obesity by incubating differentiated human Simpson Golabi Behmel 
Syndrome (SGBS) adipocytes in 1%O2 for 24 hours 
• To analyse the expression of obesity dysregulated genes in response to AC2-
26 treatment using the established model mimicking the inflammatory status 
that is observed during obesity 
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It was hypothesised that ANXA1 is positively involved in regulating processes that 
improve the metabolic profile of adipocytes and dampen inflammation to reduce cellular 
stress and the risk of developing the metabolic syndrome and co-morbidities.  
Study 2 (Chapter 5): Annexin A1 regulates adipogenesis via differential MAPK 
intracellular pathways 
Results from study 1 indicated a role of ANXA1 in regulating the expression of genes 
associated with lipid accumulation, a hallmark of adipocyte differentiation. Therefore, the 
aim of this study was to investigate the role of ANXA1 in the differentiation of 
preadipocytes into mature adipocytes. The objectives of this study were: 
• To assess lipid accumulation in SGBS preadipocytes differentiated with and 
without FPR2/ALX antagonist and agonist 
• To assess the morphology of the lipid droplets in mature SGBS adipocytes 
differentiated with and without FPR2/ALX antagonist and agonist  
• To identify the intracellular signalling pathways activated in mature SGBS 
adipocytes differentiated with and without FPR2/ALX antagonist and agonist 
• To assess de-novo lipogenesis, lipolysis and glucose uptake in mature SGBS 
adipocytes differentiated with and without FPR2/ALX antagonist and agonist   
• To assess the gene expression of adipokines in mature SGBS adipocytes 
differentiated with and without FPR2/ALX antagonist and agonist     
It was hypothesised that ANXA1 regulates lipid homeostasis through modulating 
peroxisome proliferator-activated receptor γ (PPARγ) and is positively involved in 
regulating the differential process.  
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Study 3 (Chapter 6): Plasma inflammatory biomarkers, insulin sensitivity and gut 
hormones in response to rapid weight loss through Bariatric Surgery 
Bariatric surgery improves metabolic abnormalities independent of weight loss and is 
associated with altered circulatory profiles of plasma lipid, adipokine, cytokine and gut 
hormone levels. Plasma ANXA1 levels are reduced in obesity and inversely correlate 
with markers of adiposity, however, the effect of weight loss in unknown. Therefore, the 
aim of this study was to investigate the plasma ANXA1 levels in response to rapid weight 
loss induced by bariatric surgery. The objectives of this study were: 
• To analyse anthropometric and plasma lipid changes in bariatric surgery patients 
pre-operatively (pre-opt), 6 weeks and 3 months post-operatively (post-opt) 
• To analyse and correlate plasma ANXA1 levels with plasma inflammatory 
biomarkers, plasma markers of insulin sensitivity and plasma gut hormone in 
bariatric surgery patients pre-opt, 6 weeks and 3 months post-opt 
• To analyse and correlate plasma ANXA1 levels with plasma inflammatory 
biomarkers, plasma markers of insulin sensitivity and plasma gut hormone by 
types of bariatric procedures in bariatric surgery patients pre-opt, 6 weeks and 3 
months post-opt 
• To analyse and correlate plasma ANXA1 levels with plasma inflammatory 
biomarkers, plasma markers of insulin sensitivity and plasma gut hormone in 
non-T2DM and T2DM bariatric surgery patients pre-opt, 6 weeks and 3 months 
post-opt 
It was hypothesised that weight would loss significantly increase plasma ANXA1 levels, 
would inversely correlate with pro-inflammatory biomarkers and directly correlate with 
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anti-inflammatory biomarkers, markers of insulin sensitivity and plasma gut hormone, 
therefore, effectively aiding the resolution of inflammation and decreasing the risk of 
developing metabolic co-morbidities.  
Study 4 (Chapter 7): Evidence of aberrant inflammation in patients with 
Lipodystrophy 
Lipodystrophy is a group of diseases characterised by partial or total loss of adipose 
tissue. Despite being on the opposite side of the adiposity spectrum, lipodystrophy 
patients exhibit similar metabolic abnormalities such as, hypertriglyceridemia, 
dyslipidaemia and insulin resistance and onset of co-morbidities such as T2DM like obese 
individuals. Therefore, the aim of this study was to investigate the plasma ANXA1 levels 
in lipodystrophy patients. The objectives of this study were: 
• To analyse and correlate plasma ANXA1 levels in lipodystrophy and BMI 
matched controls 
• To analyse and correlate plasma C-reactive protein (CRP) levels in lipodystrophy 
and BMI matched controls 
• To correlate plasma ANXA1 levels with plasma CRP levels of lipodystrophy 
patients and BMI matched controls 
It was hypothesised that plasma ANXA1 levels are reduced in lipodystrophy patients and 
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3.1 Cell Culture 
3.1.1 Simpson-Golabi Behmel Syndrome Cells 
Simpson-Golabi-Behmel syndrome is a complex, X-linked congenital overgrowth 
syndrome characterised by an overgrowth of organs such as the adipose tissue. Genetic 
analyses show a deletion or point mutations within the glypican 3 gene which is 
responsible for encoding glycosylphosphatidylinositol-linked cell surface heparin 
sulphate proteoglycans (Fischer-Posovszky et al. 2008). SGBS preadipocytes provided 
by the Wabitsch Lab, Germany, in their proliferative stage at the 28th generation were 
used to study adipocyte physiology in this project.  
The SGBS cells were first isolated from the subcutaneous adipose tissue depot of patients 
with SBGS (Fischer-Posovszky, Newell et al. 2008). They have the capacity to proliferate 
in vitro for many generations and have the capability to differentiate into mature 
adipocytes even after 50 generations opposed to other cell lines such as, adult stem cells 
and primary human adipocytes derived from white adipose tissue (Fischer-Posovszky et 
al. 2008). Disadvantages of using primary tissue from donors include unpredictable 
variation in the characteristics of the cells and the limited availability of the tissue 
(Fischer-Posovszky et al. 2008). Thereby, the cell strain generated from the SGBS 
patients provides limitless source of cells that exhibits high differentiation capacity, yield 
fully matured adipocytes expressing adipocyte-specific genes like human adipocytes 
(Fischer-Posovszky et al. 2008). However, changes in the visceral adipose tissue depots 
are associated with significantly higher risk of developing obesity associated metabolic 
diseases therefore, data obtained using SGBS cells may not provide a true reflection.    
3.1.1.1 SGBS cell culture 
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Cell culture is a process in which cells derived from multicellular eukaryotes are grown 
under controlled conditions and often outside of their natural environment. The conditions 
may vary depending on the cell type, but they all require an artificial environment that 
regulates the physio-chemical environment and maintains the Oxygen/Carbon Dioxide 
(O2/CO2) ratio. The cells are maintained in a culture medium that supplies them with 
nutrients (carbohydrates, amino acids and vitamins), growth factors and, hormones 
essential for growth and division to mimic their natural environment. To grow, some cells 
require artificial substrates (adherent or monolayer culture), while others can grow free 
floating in the culture media (suspension culture).  
SGBS cells were maintained in 1:1 ratio of GibocTM Dulbecco’s Modified Eagle Medium 
(DMEM) and Nutrient Mixture F-12 (F-12) media, which is formulated for superior 
quality and reliability with high concentrations of glucose, amino acids and vitamins. The 
mixture contains many components including 3.2g/L glucose, 15mM HEPES, 2.5mM L-
Glutamine and Phenol Red. HEPES is used as a buffering agent and is thought to be 
largely better at maintaining the physiological pH despite changes in carbon dioxide when 
compared to bicarbonate buffers. Phenol Red is a pH indicator, a change in colour from 
red to yellow indicates a drop in pH, which directly correlates with the density of the 
culture and/or contamination. The media was further supplemented with heat treated 
Foetal Calf Serum (FCS) to provide the essential growth factors and Antibiotic-
Antimycotic solution (Anti-Anti) to prevent bacterial and fungal contamination. The 
solution contains 10,000U/mL of penicillin, 10,000µg/mL of streptomycin and 25µg/mL 
of Gibco Amphotericin B. The antibiotics penicillin and streptomycin help prevent 
bacterial contamination due to their effective dual action against gram-positive and gram-
negative bacteria and Amphotericin B prevents fungal contamination.  
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3.1.1.1.1 Methodology 
SGBS cells (passage 2-20) were seeded, maintained and incubated at 37ºC (95% O2, 5% 
CO2) in Nunc
TM cell culture treated flasks (T75 or T175) with filtered caps as monolayer 
cultures. The growth media (DMEM/F-12 (Gibco#31330-038), 10% FCS (Gibco#10270-
106), 1% Anti-Anti (Gibco#15240-062), 3.3mM Biotin (Fisher#144302) and 1.7mM 
Pantothenate (Gibco#31330-038)) was changed every 2-3 days, under sterile conditions 
in a tissue culture cabinet (wiped clean with 70% ethanol prior to and after use).  
3.1.1.2 SGBS cell subculture 
Cell subculture is a process in which some or all the cells are transferred into fresh media 
to generate or propagate a cell population from an ongoing culture or from a fresh culture. 
It is used to prolong the life and/or expand the number of cells for experimental use. 
Adherent cultures such as, SGBS cells need to be detached from the flask via 
trypsinisation before they can be passaged. TrypLETM Express, a widely used 
recombinant enzyme for dissociating adherent cells as it cleaves bonds on the C-terminal 
sides of lysine and arginine was used in this project.  
3.1.1.2.1 Methodology  
Confluent SGBS cells (50-70%) were washed with phosphate buffered saline (PBS) once 
and incubated with 3mL or 5mL of TrypLETM Express (Gibco#12605-010) in T75 or 
T175 culture flasks respectively, for 2-3 minutes at room temperature. The flasks were 
physically agitated to ensure all the cells were in suspension and 6mL or 10mL fresh 
growth media (section 3.1.1.1.1) was added respectively, to stop the reaction. The cell 
suspensions were centrifuged at 10,000 rpm for 3 minutes and the supernatants were 
discarded. The cell pellets were resuspended in fresh 5mL growth media (section 
 Chapter 3: Materials and Methods 
126 | P a g e  
 
3.1.1.1.1) by gently pipetting up and down and were seeded into fresh T75 or T175 culture 
flasks and incubated at 37ºC (95% O2/ 5% CO2) or used for experiments. 
3.1.1.3 Cell count 
Estimation of cell number is vital during cell culture experiments to quantify the 
concentration of cells and maintain consistency between the experiments. 
Haemocytometer is a thick microscope slide with chambers of defined dimensions (area 
and depth) and is commonly used to count cells using a light microscope to identify the 
cell density of a cell suspension. (Figure 3.1). It consists of nine primary squares each 
measuring at 1mm2.   
3.1.1.3.1 Methodology  
Haemocytometer and the cover slip were cleaned using 70% alcohol and the cover slip 
was affixed to the haemocytometer. 10µL of diluted SGBS cell suspension (section 
3.1.1.2.1) was loaded onto the edge of the cover slip using an automated pipette and 
allowed to run under the cover slip. Cells were counted in four 1mm square areas as 
shown in Figure 3.1 using a light microscope at 100x magnification. The cell count was 
divided by 4 to obtain an average number. The following equation was used to determine 
the number of cells per mL in the cell suspension: 
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3.1.1.4 Cryopreservation and thawing of cell stocks 
Cryopreservation is a technique used to preserve structurally intact living cells and tissues 
by making use of very low temperatures. It allows stocks of cells to be stored and prevents 
the need to have all the cell lines in culture at the same time. Thus, it aids in reducing the 
risk of microbial contamination, cross contamination with other cell lines, genetic drift 
and morphological changes and allows experiments to be conducted at similar passages 
resulting in consistency. 
Though not fully understood, it appears to work primarily by altering the physical 
conditions of both the ice and solutions immediately surrounding the cells. The main 
principle of cryopreservation follows a slow cooling at a rate of -1ºC to -3ºC per minute 
and rapid thawing at 37ºC for 3-5 minutes. Cells are frozen with cryoprotective additives 
chemicals that reduce the injury of cells during freezing (including ice crystal formation) 
   
   
   
Figure 3.1: Cell count using haemocytometer. The haemocytometer is a thick microscopic slide with 
chambers of defined dimensions and is commonly used to estimate the number of cells. The cell suspension 
is loaded, cells are counted in 4 squares (highlighted in blue) and an average is used to calculate cells per 
ml. 
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and thawing (Figure 3.2). The chemicals are separated into two broad categories based 
upon their ability to penetrate through the cellular membrane. Intracellular agents 
penetrate inside the cell preventing formation of ice crystals and extracellular agents 
(sucrose, trehalose and dextrose) do not penetrate in the cell membrane, but rather act to 
improve the osmotic imbalance that occurs during freezing. However, permeation is not 
necessary for their proper functions as protection against fast freezing is not primarily due 
to these agents but rather to the rate of freezing.  A wide range of chemicals are used as 
cryoprotective such as methyl acetamide, methyl alcohol, ethylene glycol and polyvinyl 
pyrrolidine. However, dimethylsulfoxide (DMSO) and glycerol are the most convenient 
and commonly used. DMSO makes the cell membrane porous which protects them from 
damage during thawing. It is widely used cryogenic agent; it can have toxic effects on the 
cell culture. Therefore, it is used at a final concentration of 5-15% (v/v) and diluted in the 
freezing media prior to addition to the cell suspension. Glycerol is generally used at a 
final concentration of between 5-20% (v/v) and is thought to be less toxic than DMSO. It 
protects the membrane structure and maintains the nature of internal proteins. 
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3.1.1.4.1 Methodology  
Confluent SGBS cells were trypsinised and pelleted using the above protocol (section 
3.1.1.2.1). The cell pellet (~2x106-2x107/mL of cells) was resuspended in 1mL freezing 
media (growth media (section 1.1.1.1) +10% glycerol) and transferred into labelled sterile 
cryotubes. The cryotubes were placed into a controlled cooling device (Mr Frosty; filled 
with 100% iso-prop2nol) and stored in -80ºC. This allows gradual freezing of the cells to 
prevent rapid dehydration of cells that may occur due to sudden exposure of cryogenic 
temperatures. After 24 hours, the tubes were transferred into storage boxes and stored at 
-80ºC. 
 
Frozen stocks of SGBS cells were thawed by placing the cryotubes in a water bath (37ºC) 
with gentle agitation for a few minutes. The rapid thawing causes rehydration of the cells 
without the establishment of damaging ice crystals within the cells. The cells were 
immediately diluted in 10mL of fresh growth media (section 1.1.1.1) and centrifuged at 
10,000 rpm for 3 minutes. The cell pellet was resuspended in fresh 15mL growth media 
Figure 3.2: Cryopreservation. Cryopreservation preserves structurally intact cells using low temperatures 
and cryopreservative agents and reduce the cell death from dehydration effects.  
 Chapter 3: Materials and Methods 
130 | P a g e  
 
(section 1.1.1.1) and transferred into T75 Nunc Flasks and incubated at 37ºC (95% O2/ 
5% CO2). 
3.1.1.5 SGBS cell differentiation 
Cellular differentiation is a process in which less specialised cells become more 
specialised. It occurs many times during the development of a multicellular organism as 
the organism changes from a single zygote to a complex system of cell and tissue types. 
Differentiation dramatically changes the cells size, shape, metabolic activity and 
responsiveness to signals and these changes are largely due to highly controlled 
modifications in gene expressions. Similarly, SGBS cells are a preadipocyte cell line 
which can be efficiently differentiated into mature adipocytes in the presence of 
Peroxisome proliferator-activated receptor γ agonists and in the absence of serum 
(supresses differentiation) (Fischer-Posovszky, Newell et al. 2008).  
3.1.1.5.1 Methodology 
SGBS cells were differentiated using the revised protocol supplied with the cells from the 
Wabitsch Lab, Germany. Briefly, SGBS cells were seeded in 6 well or 96 well cell culture 
plates (Table 3.1) using fresh growth media ( section 1.1.1.1) and incubated for 3 days at 
37ºC (95% O2/ 5% CO2). To induce differentiation, the cells (day 0) were washed with 
PBS twice and incubated with serum free-QuickDiff media (DMEM/F-12, 1% Anti-Anti, 
3.3mM Biotin, 1.7mM Pantothenate, 0.01mg/mL Transferrin (Sigma#T8158), 20nM 
Insulin (Sigma#19278), 100nM Cortisol (Acros#352450010), 0.2nM triiodothyronine 
(Sigma#T6397), 25nM Dexamethasone (Sigma#D1756), 250uM isobutylmethylxanthine 
(Acros#228420010), 2uM Rosiglitazone (Molekula#M34833109/Cayman#71740) for 4 
days at 37ºC (95% O2/ 5% CO2). Subsequently, the cells were incubated with serum free-
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3FC media (DMEM/F-12, 1% Anti-Anti, 3.3mM Biotin, 1.7mM Pantothenate, 
0.01mg/mL Transferrin, 20nM Insulin, 100nM Cortisol and 0.2nM triiodothyronine) for 
further 10 days at 37ºC (95% O2/ 5% CO2). The media was replaced with fresh 3FC media 
every 2-3 days. At day 14, the cells had differentiated into mature adipocytes, with visible 
















Type of seeding vessel Cells/ well Total Volume 
(mL) 
96 well plate 4000 0.1 
12 well plate 20,000 1 
6 well plate 50,000 2 
Table 3.1: SGBS cell seeding densities. In order to differentiate efficiently, SGBS cells require specific 
seeding densities. Too few cells or Too many cells seeded reduces the differentiation capacity, thereby 




Figure 3.3: Differentiation of SGBS cells. SGBS preadipocytes were differentiated over the course of 14 
days. At day 0, the cells appeared to have a fibroblast like morphology with no lipid accumulation. However, 
at day 14, the cells had accumulated lipid (indicated by white arrows) and showed a rounder morphology 
indicative of mature adipocytes. The differentiation rate was ~70-80%. X10 magnification. 
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3.2 Gene expression analysis 
Gene expression analysis is used to measure the activity of thousands of genes at once to 
create a global picture of cellular functions. Alterations in the expression of individual 
genes or groups can reflect cellular decisions relating to survival, growth and 
differentiation. It requires isolation and purification of ribonucleic acid (RNA) and 
synthesis of complementary deoxyribonucleic acid (cDNA). Subsequently, cDNA can be 
used with gene specific primers in specialised and sensitive techniques such as, 
quantitative real-time polymerase chain reactions (qRT-PCR) to assess gene expressions.   
3.2.1 RNA isolation 
Purified and intact RNA is required for gene expression analysis in target tissues and 
cells. The accuracy of the analysis is based upon isolation of high-quality RNA.  Small 
traces of protein or DNA can result in contamination and activation of ubiquitous 
enzymes such as, RNases (degrade RNA) during extraction can affect the accuracy of 
gene profiling. Therefore, it is necessary to ensure all reagents and apparatus used during 
RNA isolation are RNase free. RNA isolation involves the disruption of the cell 
membrane either mechanically by vortexing, sonication or chemically using strong 
denaturant such as; guanidine isothiocyanate, chloroform or phenol. In this project 
chemical denaturant, TRIsure was used to isolate RNA from SGBS cell samples. 
TRIsure contains a combination of thiocyanate compounds and phenol easing the 
disruption of cells during homogenization and simultaneously effectively inhibits DNase 
and RNase activity. The addition of chloroform separates the homogenate into 3 phases; 
clear aqueous phase (containing RNA), a green coloured organic phase and an interphase 
(containing protein and DNA). RNA is precipitated from the aqueous phase by addition 
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of isopropyl alcohol, washed to remove impurities and resuspended for use in 
downstream applications.  
3.2.1.1 Methodology 
Approximately 8x105/mL SGBS cells were routinely used to isolate total RNA, following 
the protocol supplied with TRIsure (Bioline#BIO-38032). Briefly, the culture media was 
removed (decanted or stored at -80ºC) and cells were lysed directly in cell culture plates 
using 1mL TRIsure (per 3 wells in 6 well plates) and cell were scarpered to ensure enough 
cell disruption. The cell homogenates were transferred into labelled DNase/RNase free 
Eppendorf tubes and stored at -80ºC or immediately processed. Chloroform at a ratio of 
1:5 to TRIsure (e.g. 0.5mL chloroform:1mL TRIsure) was added to the homogenates, 
vigorously shaken for 15 seconds and incubated for 3 minutes at room temperature. The 
homogenates were centrifuged at 12,000xg for 15 minutes at 4ºC and the aqueous phase 
was removed for RNA extraction. Iso-prop2nol at a ratio of 1:2 to TRIsure (e.g. 0.5mL 
isopropyl alcohol:1mL TRIsure) was added to the samples, incubated for 10 minutes at 
room temperature and centrifuged at 12,000xg for 15 minutes at 4ºC (followed by 
2,600xg for 30 minutes, if a pellet was not observed) to precipitate RNA. Finally, the 
pellet was washed using 75% Ethanol at 1:1 ratio to TRIsure (e.g. 1mL 75% Ethanol:1mL 
TRIsure) and centrifuged at 7,500xg for 5 minutes (this step was repeated twice). The 
pellet was air-dried for 30 minutes and resuspended in 10-20μL of DNase/RNase free 
water, concentration quantified (section 3.2.3.3) and stored at -80ºC. All the reagents used 
were of molecular biology grade to decrease the likelihood of contamination and RNA 
degradation. 
 
 Chapter 3: Materials and Methods 
134 | P a g e  
 
3.2.2 cDNA synthesis 
Reverse transcription reactions use Reverse Transcriptase (RT) enzymes, isolated RNA 
as a template, a short primer complementary to the 3’-OH end of messenger RNA 
(mRNA), deoxynucleotide triphosphates (dNTPs) and RNase inhibitor to direct synthesis 
of the first strand cDNA, which can be directly used as a template for Polymerase Chain 
Reaction (PCR).  
Several types of primers are available to generate cDNA including; oligo (dT) primers, 
random (hexamer) primers and gene specific primers. Oligo (dT) primers hybridize to the 
poly A tail (a long sequence of adenine nucleotides) at the 3’- OH end of the mRNA and 
initiate synthesis from this position helping achieve accurate cDNA. The poly A tail helps 
to distinguish between mRNA, transfer RNA and ribosomal ribonucleic acid which is 
important when using the cDNA produced for gene expression analysis.  In contrast, the 
hexamer primers consist of a mixture of oligonucleotides representing all possible 
hexamer sequences. It does not favour the 3’ -OH end and can result in truncated cDNA 
synthesis due to annealing to the 5’ end. The gene specific primers target and bind to 
mRNA transcripts of interest and reduce the complexity and yield of cDNA.  
3.2.2.1 Methodology 
In this project, SuperScript III RT enzyme kit (Invitrogen#1808044) was used to 
synthesise cDNA following the protocol provided by the manufacturer. Briefly, 1μL 
Oligo(dT) primer (Thermofisher#18418020), 1000ng or a maximum value of 4μL of 
RNA and 1μL 10mM dNTP per 10μL reaction mix were heated to 65ºC for 5 minutes 
and immediately chilled on ice, to allow the primer to anneal to the mRNA secondary 
structures. Then, 4μL 1X First Strand Buffer, 1μL 0.1M DTT and 1μL SuperScript III RT 
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were added to the reaction mix and incubated at 50ºC for 60 minutes for cDNA synthesis 
followed by 70ºC for 15 minutes to inactivate the enzyme. The concentration of the 
samples was quantified (section 2.3.3.3) and stored at -20ºC. All the reagents used were 
of molecular biology grade to decrease the likelihood of contamination and cDNA 
degradation. 
3.2.3 Nucleic acid quantification 
Quantification of nucleic acids is commonly used to estimate the concentration and the 
purity of RNA or DNA present within the sample. The traditional method of assessing 
the concentration and purity is ultraviolet-visible spectrophotometry.  
3.2.3.1 RNA 
The absorbance of diluted RNA is measured at 260nm; thus, it is possible to quantify 
RNA concentration in the sample by determining the absorbance at this wavelength 
spectrophotometrically. A reading of 1.0 at A260 is equivalent to ~40μg/mL of single 
stranded RNA diluted in pure water. Thus, RNA quantification within the sample can be 
calculated using the following equation:   A260 x dilution x 40= [RNA]µg/mL 
The purity of the RNA sample can be determined by the ratio of absorbance at 260nm 
and 280nm (A260/A280). A ratio of ~2.0 suggests pure, good quality RNA and a ratio 
less than 1.7 suggests contamination and low purity.  
3.2.3.2 DNA 
Similarly, the absorbance of diluted DNA is measured at 260nm and can be used to 
determine the concentration of DNA present within the sample. A reading of 1.0 at A260 
is equivalent to ~50μg/mL of single stranded DNA diluted in pure water. DNA 
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quantification within the sample can be calculated using the following equation: 
  
   A260 x dilution x 50= [DNA]µg/mL 
The purity of the DNA sample can be determined by the ratio of absorbance at 260nm 
and 280nm (A260/A280). A ratio of ~1.8 suggests pure, good quality DNA and a ratio 
less than 1.7 suggests contamination and low purity. Furthermore, a secondary measure 
of A260/A230 ratio is used to assess the purity of the nucleic acids. The expected ratio is 
commonly in the range of 2.0-2.2 and if the ratio is lower, it may indicate contaminants 
that absorb at 230nm such as ethylenediaminetetraacetic acid, carbohydrates and phenol.  
The ThermoFisher Scientific Nanodrop One/Onec is a UV-Vis spectrophotometer that is 
used to determine the concentration and purity of RNA and DNA within in the samples 
by measuring the absorbance at 260nm and 280nm. It can measure highly concentrated 
samples without the need for dilution, determine purity and suggest contaminants if the 
A260/A280 ratio falls below the range. 
3.2.3.3 Methodology  
The ThermoFisher Scientific Nanodrop One/Onec was used to assess the concentration 
and purity of the RNA and DNA within the samples. Briefly, the ‘Nucleic Acid’ 
application was selected from the software followed by RNA or single-stranded DNA. A 
blanking cycle was run using 1.5µL of DNase/RNase free water. Once the cycle was 
complete, the blank was wiped from the measuring pedestal and 1.5µL of the test sample 
was pipetted on. The spectral measurement was initiated using the built-in software. The 
software calculated the concentration of the sample and an A260/A280 ratio or 
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A260/A230 ratio to determine its purity. Upon completion, the sample was wiped off the 
measuring pedestal to prevent sample carryover in further measurements.  
3.2.4 Real Time Quantitative Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) uses the linearity of DNA amplification to determine 
the absolute or relative quantities of a known sequence in a sample. Relative 
quantification relates the PCR signal of a target gene in a treatment group to that of a 
control group. Millions of copies of DNA are generated by amplifying DNA fragments 
using gene specific DNA oligonucleotides (primers) as initiators. Using fluorescent 
reporter in the reaction, it is possible to measure DNA generation and statistically analyse 
gene expression.  
Like DNA replication in organisms, PCR requires a DNA polymerase enzyme to 
synthesize new strands of DNA, using existing single strands as templates. The most 
commonly used DNA polymerase in vitro is Taq polymerase; isolated from heat-tolerant 
bacterium, Thermus Aquaticus. It is very stable at high temperatures and is mostly active 
around 70ºC, deeming it ideal for PCR as elevated temperatures are required to separate 
strands of double stranded DNA and denature the template DNA.  
The key ingredients of a PCR reaction; DNA polymerase, primers, template DNA and 
nucleotides are put through repeated cycles of heating and cooling. The three key stages 
of a PCR cycle are; Denaturation (94ºC), Annealing (55-65ºC) and Extension (72ºC). The 
cycle is carried out in a regulatable heating block (thermocycler) and is repeated 25-40 
times depending on the length of the DNA region being copied. 
qRT-PCR employs the same basic principles as PCR. In addition to amplification, it 
simultaneously quantifies the target DNA present within the sample in real-time by a 
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fluorescent probe or by an intercalating dye detectable by a sensitive camera connected 
to the thermocycler. In this project, SYBR green; an intercalating dye was used to 
generate fluorescence during the PCR reaction. The dye is fluorescent on its own, but in 
the presence of double stranded DNA, it intercalates with the DNA double helix, altering 
its structure, causing it to fluoresce more. Initially, the fluorescence remains at 
background levels and increase in fluorescence is non-detectable even through the PCR 
product accumulates exponentially. Eventually, enough amplified product accumulates 
to yield a detectable fluorescence signal. The cycle at which the signal is detectable (cycle 
threshold (Ct) or quantification cycle) can be used to statistically analyse gene expression.   
3.2.4.1 Methodology used to determine the optimal concentration of cDNA in PCR 
reactions 
The protocol provided with the SensiFASTTM SYBR H-ROX kit (Bioline#BIO-92005) 
was used for two-step qRT-PCR. The SensiFASTTM SYBR H-ROX kit contains all the 
components necessary for real-time PCR, including the SYBR Green I dye, dNTP’s, 
stabilisers and enhances and is compatible to use with the BioRad CFX connect real-time 
PCR detection system (Bio-Rad, UK). Though the SensiFASTTM SYBR H-ROX kit 
suggest using 100ng cDNA per reaction mix, concentration response curves using the 
housekeeping genes; Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(Qaigen#QT00079247) and 18s RNA (Qaigen#QT00199367) were generated to 
determine the optimum concentration of cDNA to be used in PCR reactions. GAPDH and 
18s were chosen as housekeeping reference genes as their expressions were not affected 
by the hypoxic and normoxic environments nor by the agonist and antagonist treatments. 
A range of housekeeping genes were tested and, GAPDH and 18s RNA were considered 
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the best fit as they showed the least variation between treated and untreated cells in 
comparison to other housekeeping genes. 
Thus, 10μL 2x SensiFASTTM SYBR HI-ROX Mix, 2μL10x QuantiTect Primer Assay 
and 0-100ng cDNA per 20μL reaction were prepared in DNase and RNase free tubes in 
triplicates to avoid technical errors, vortexed and transferred into PCR plates. The plates 
were sealed, and the PCR machine was set up with the following: activation at 95ºC (2-
minute cycle), denaturation at 95ºC (5 seconds, 40 cycles), annealing/extension at 60ºC 
(30 seconds, 40 cycles), followed by a melt curve at 65-95ºC (5 second cycle). The Ct 
values were analysed and 80ng per reaction was determined as optimal (Figure 3.4).   
 
 















Figure 3.4: Standard curve to determine the optimal cDNA concentration for PCR. 0-100ng cDNA and 
the housekeeping genes, GAPDH and 18s RNA were used to determine the optimal cDNA concentration for 
PCR reactions. 
GAPDH= Glyceraldehyde 3-phosphate dehydrogenase, 18s RNA= 18s Ribonucleic acid, PCR= polymerase 
chain reaction and cDNA= complementary deoxyrionuleic acid 
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3.2.5 Data analysis 
The data obtained from the PCR reactions were normalised against the housekeeping gene 
(GAPDH) and analysed manually. The relative gene expression was calculated using the 
2-∆∆CT (Livak) method (Livak, Schmittgen 2001). The relative gene expression relates the 
PCR signal of the target gene in the treatment group to that of an untreated control and is 
a convenient way to analyse changes in the gene expression in response to a treatment. 
The breakdown of the equation is shown below: 
1) ∆Ct= target gene – housekeeping gene 
2) ∆∆Ct= ∆Ct sample - ∆Ct control 
3) Relative Expression= 2-∆∆Ct 
3.3 Enzyme Linked Immunosorbent Assay  
Enzyme linked immunosorbent assay (ELISA) is an analytic biochemistry assay 
technique used to detect and quantify substances such as enzymes, antigens, peptides, 
proteins and hormones in various samples including; blood, plasma, serum or supernatant. 
There are several types of ELISA assays available including direct, indirect and capture 
assays that are based on a common principle of antigen to antibody interaction. The direct 
and indirect assays require the antigen to be is adsorbed to the assay plate which is 
detected by a primary antibody. A conjugated secondary antibody is used to detect the 
primary antibody. In contrast, the antigen is ‘sandwiched’ between two antibodies in the 
capture assay.  
The capture assay, otherwise known as sandwich ELISA, is a commonly used assay to 
detect and quantify the antigen of interest. For this assay the antigen must contain at least 
two different antigenic sites that can be recognised and bound to by two different 
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antibodies; a capture antibody and a detection antibody. Monoclonal and polyclonal 
antibodies are generally used in sandwich ELISA’s. Monoclonal antibodies recognise a 
single epitope that allow quantification of small differences in the antigen providing 
specificity. Polyclonal antibodies are used as the capture antibodies to bind as much of 
the antigen as possible.  Sandwich ELISA’s are quick, efficient and remove the 
purification step before analysis and are 2-5 times more specific than direct or indirect 
ELISA’s.  
3.3.1 Typical sandwich ELISA Methodology 
ELISA’s carried out in this project were based on the sandwich technique. Briefly, for 
these assays, the capture antibody is coated onto a solid support such as, a 96 well plate. 
The antigen is incubated, followed by a wash with an appropriate buffer to remove any 
excess, unbound antigens. The antigen is incubated with a primary antibody, followed by 
a wash to remove any excess, unbound primary antibody. The complex is then incubated 
with an enzyme labelled secondary antibody, followed by a wash to remove any excess, 
unbound secondary antibody. The most widely used enzymes for detection are Horse 
Radish Peroxidise (HRP) and alkaline phosphatase (ALP). The enzymes are incubated 
with their appropriate substrates; hydrogen peroxide and P-Nitrophenyl-phosphate 
respectively. The chemical reaction result in change of colour. The amount of colour 
produced is quantified using a spectrophotometer plate reader at a target wavelength and 
is proportional to the amount of antibody/antigen present. Data obtained from the assay 
is analysed and a standard curve  is generated to determine the concentration of  biomarker 
present within the samples. The specific assays used for this project are outlined in the 
specific chapter methodologies. 
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Chapter 4: Expression of obesity 
dysregulated genes in response to acute AC2-
26 treatment a using a model mimicking the 
inflammatory status that is observed during 
obesity 
Dysregulated expansion of the adipose tissue during obesity and the presence of local 
tissue hypoxia leads to changes in expression of genes associated with several cellular 
processes including stress, metabolism and inflammation. Though the expression and 
secretion of Annexin A1 by adipocytes is increased in obesity, the effect of this change 
in unknown. Therefore, the objective of this study was to investigate the effect of Annexin 
A1 agonist, AC2-26 on the expression of genes known to be dysregulated in obesity to 
identify genes, cellular processes and pathways which are potentially regulated by 
Annexin A1.   
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4.1 Abstract  
Introduction: Adipose tissue oxygen consumption and blood flow are altered in obesity 
inducing local tissue hypoxia. Hypoxia affects several biological functions including 
angiogenesis, cell proliferation, adipogenesis, apoptosis, inflammation, insulin resistance 
and mitochondrial dysfunction affecting the overall degree of adiposity (Wood, de 
Heredia et al. 2009). Though the expression of Annexin A1 (ANXA1) are dysregulated 
in the adipose tissue in response to obesity, its roles in the adipose tissue or obesity are 
unclear (Henegar, Tordjman et al. 2008, Alfadda, Benabdelkamel et al. 2013). 
Aim: The aim of this study was to investigate the potential roles of ANXA1 in adipocytes 
using a model mimicking the inflammatory status that is observed during obesity.  
Methodology: Simpson Golabi Behmel Sydrome (SGBS) preadipocytes were 
differentiated over 14 days in normoxia (95% O2/ 5% CO2) to reach a mature adipocyte 
phenotype. On day 14, mature adipocytes were treated with 10µM AC2-26 and incubated 
in hypoxia (1% O2/5% CO2/94% N2) for 24 hours and the gene expressions were 
analysed. The results were statistically analysed using GraphPad prism 5.0. Statistical 
significance at 95% was determined using One-tailed unpaired students T-test. 
Results: As expected, mRNA expressions of HIF and SLC2A were upregulated in mature 
adipocytes incubated in hypoxia for 24 hours, indicative of cellular hypoxia. Treatment 
with AC2-26 significantly upregulated the mRNA expressions of BAX, PER3, PPARA, 
ADIPOQ, IL6 and ACHE, and downregulated the mRNA expressions of CD36, DPP4, 
ACOX1, PPP3CC, LEP, NAMPT, RETN, CFD, TNF, IRS1, SLC2A4, IGFR1, JUN and 
VEGFA.  
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Summary: The regulation of genes in response to acute AC2-26 treatment indicate a 
protective role of ANXA1 in obesity and inflammation and may provide a novel strategy 
to prevent the development of obesity associated inflammation and metabolic diseases. 
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4.2 Introduction 
The dysregulated development and expansion of the adipose tissue and/or adipocyte in 
obesity, alters their functions contributing to the onset of associated co-morbidities and 
metabolic diseases. These functions include; 1) changes in the lipid storing and lipid 
mobilization processes in mature adipocytes, inducing lipotoxicity (Virtue, Vidal-Puig 
2010, Unger, Clark et al. 2010), 2) Impaired synthesis and secretion of cytokines, 
chemokines and adipokines from hypertrophic adipocytes and adipose tissue resident 
immune cells, 3) Recruitment and infiltration of macrophages and immune cells into the 
adipose tissue and 4) Impaired extracellular matrix remodelling and angiogenesis. Altered 
adipose tissue blood flow (ATBF) is thought to play an important role in the dysregulated 
function of the adipose tissue  and/or adipocytes in obesity and type 2 diabetes mellitus 
(T2DM) (Sotornik, Brassard et al. 2012). Altered adipose tissue perfusion is associated 
with dysregulated hormone signalling and flux of various metabolic substrates (Lafontan 
2014).                                                                                                                                                                                                                                                                                                     
4.2.1 Hypoxia and Obesity 
Hypoxia is defined as deficiency of oxygen within cells and tissues and is often associated 
with high altitude, ischaemic injury or tumour development (Wood, de Heredia et al. 
2009). It is a highly conserved evolutionary defence mechanism that adapts to low oxygen 
(O2) levels and is required for normal physiological functions such as embryogenesis and 
wound health (Hosogai, Fukuhara et al. 2007). The response to low O2 is mediated by the 
hypoxia-inducible transcription factors; the best known is the hypoxia inducible factor 1 
(HIF-1). HIF-1 is composed of two subunits, HIF-1α; the oxygen sensing subunit and 
HIF-1β; a constitutively-expressed protein that is O2 insensitive (Wood, de Heredia et al. 
 Chapter 4: Expression of obesity dysregulated genes in response to acute AC2-26 
treatment using a model mimicking the inflammatory status that is observed during 
obesity 
 
146 | P a g e  
 
2009). HIF-1α is continuously synthesised but is readily ubiquitinated and degraded via 
the proteasome pathway under normoxic conditions (Figure 4.1) (Wang, B., Wood et al. 
2007). However, under low O2 concentrations, HIF-1β binds to HIF-1α to form an active 
transcription factor (Figure 4.1) that is involved in inducing the transcription of many 
genes involved in multiple biological functions including, angiogenesis, glucose 
metabolism, apoptosis, cellular stress, extracellular matrix re-modelling and 
inflammation (Semenza 2003).   
 
Figure 4.1: Regulation and activity of hypoxia inducible factor -1α. Under normal oxygen levels, HIF-1α is 
hydroxylated twice by PHD to provide sites for binding of the VHL, enabling ubiquitination and proteasomal 
degradation. However, when the oxygen levels are low, the activity of PHD is markedly reduced and the 
accumulating HIF-1α combines with HIF-1β to form a heterodimer to bind to DNA and interact with its 
cofactors p300/CBP to drive transcription of HIF-1α inducible genes.     
PHD; Prolyl Hydroxylase domain Dioxygenases, VHL; con Hippel-Lindau protein, HIF; Hypoxia inducible 
factor, DNA; Deoxyribose nucleic acid       (Tal 2012) 
Some materials have been removed from this thesis due to Third Party Copyright. Pages where material has been 
removed are clearly marked in the electronic version. The unabridged version of the thesis can be viewed at the 
Lanchester Library, Coventry University.
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The altered adipose tissue perfusion and enlarged adipocytes in obesity trigger tissue 
hypoxia, initiating a cascade of events leading to chronic “low-grade” inflammation in 
the adipose tissue in obesity (Spite, Claria et al. 2014). The hypoxia-induced 
inflammation hypothesis in obesity is based on the following prepositions; 1) cardiac 
output and blood flow are not increased, 2) blood flow to the adipose tissue is not 
increased postprandially and 3) the size of the adipocytes is larger (150-200μM) than the 
diffusion distance of O2 (100-200μM) in obese compared to lean (Trayhurn 2013). Other 
theories suggest that endoplasmic reticulum stress, oxidative stress and gut microbiota 
may play roles in the inflammatory response (Gregor, Hotamisligil 2007, Houstis, Rosen 
et al. 2006, Cani, Bibiloni et al. 2008). However, low O2 tension and/or hypoxia can lead 
to endoplasmic reticulum and oxidative stress, thus they could work together to amplify 
the inflammatory response.  
HIF-1 subunits are directly linked to adiposity as well as in the response to hypoxia. Loss 
of HIF-1α in adipose tissue leads to elevated body weight and increased obesity, whereas, 
loss of HIF-β in the adipose tissue reduces weight gain and resistance to developing 
obesity in mice (Zhang 2010, Lee 2011). Mild hypoxia is reported in the adipose tissue 
of obese human individuals (Ye 2009). Exposure of mature human adipocytes to hypoxic 
conditions (1% O2 v/v) substantially induce HIF-1α activity with significant increase in 
mRNA and protein levels of a key hypoxia marker (glucose transporter 1 (SLC2A1)),  
pro-inflammatory markers and a significant decrease in mRNA and protein levels of an 
anti-inflammatory marker (Wood, de Heredia et al. 2009). These findings are in line with 
those observed in mouse 3T3-L1 and 3T3-F442A fat cells, further implying that hypoxia 
may be the underlaying cause of inflammation and cellular dysfunction in obesity (Figure 
4.2) (Hosogai, Fukuhara et al. 2007, Chen, Lam et al. 2006).  
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Though ANXA1 mRNA expression is significantly increased in human adipose tissue in 
response to obesity and increased abundance of ANXA1 protein in mature adipocytes 
was isolated from abdominal subcutaneous adipose tissue in old compared to young 
human obese, its role in adipocyte biology or obesity is unclear individuals (Henegar, 
Tordjman et al. 2008, Alfadda, Benabdelkamel et al. 2013).  
 
 
Figure 4.2: Adipose tissue hypoxia and inflammation. In lean individuals, the adipose tissue exhibits an 
anti-inflammatory profile with normal metabolic function, normal vascularisation and presence of anti-
inflammatory, insulin sensitising immune cells. However, dysregulated expansion of the adipose tissue 
during obesity alters the anti-inflammatory profile into a pro-inflammatory profile with metabolic 
dysfunction, severe hypoxia, adipocyte necrosis and presence of pro-inflammatory immune cells further 
contributing to metabolic dysfunction and insulin resistance.  (Catalan, Gomez-Ambrosi et al. 2013)  
Some materials have been removed from this thesis due to Third Party Copyright. Pages where material 
has been removed are clearly marked in the electronic version. The unabridged version of the thesis can 
be viewed at the Lanchester Library, Coventry University.
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4.3 Aim, objectives and hypothesis 
The aim of this study was to investigate the potential roles of ANXA1 in adipocytes using 
a model mimicking the inflammatory status that is observed during obesity. The 
objectives of this study were: 
• To establish a model mimicking the inflammatory status that is observed in 
obesity by incubating differentiated human Simpson Golabi Behmel 
Syndrome (SGBS) adipocytes in 1% O2 for 24 hours 
• To analyse the expression of obesity dysregulated genes in response to AC2-
26 treatment using the established model 
It was hypothesised that ANXA1 is positively involved in regulating processes that 
improve the metabolic profile of adipocytes and dampen inflammation to reduce cellular 
stress and the risk of developing the metabolic syndrome and co-morbidities.   
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4.4 Materials and Methods  
4.4.1 Model mimicking the inflammatory status  Obesity 
Rapid increase in adipose tissue depots is thought to lead to hypoxia. As the tissue mass 
expands, the cultures of adipocytes become distant from the vasculature, initiating the 
inflammatory processes and alterations in insulin sensitivity as exhibited in obesity 
(Trayhurn 2013). Previous studies have shown that the partial pressure of oxygen (PO2) 
in the white adipose tissue of obese mice (15 mmHg) was 3 folds lower than in the lean 
mice (47.9 mmHg), indicative of sever hypoxia. To meet the aims of this chapter, a 
hypoxic environment (1% O2) were used to mimic the conditions within the adipose tissue 
as closely as possible in an in vitro cellular model. Published methodologies demonstrate 
the dropped in oxygen levels from 21% O2 (normoxia) to 1% O2 (hypoxia) show similar 
inflammatory marker profiles and alterations in insulin sensitivity to obesity (Trayhurn 
2013).  
4.4.1.1 Methodology  
Simpson Golabi Behmel Sydrome (SGBS) preadipocytes were differentiated into mature 
adipocytes in a normoxic incubator (95% O2/5% CO2) following the methodology 
described in section 3.1.1.1.1. On day 14, mature adipocytes were incubated in an 
incubator chamber flushed with 1% O2, 5% CO2 and 94% Nitrogen (N2), sealed and 
incubated at 37ºC for 24 hours to mimic adipose tissue hypoxia and generate obesogenic 
cell phenotype.  
4.4.2 AC2-26 peptide treatment  
AC2-26 peptide is an N-terminal peptide of ANXA1 which mimics the activity of the 
full-length protein. It exhibits anti-inflammatory properties as it inhibits leukocyte 
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extravasation; reduces neutrophil adhesion, emigration, promotes detachment and 
accelerates wound repair after an injury (Dalli, Montero-Melendez et al. 2012)..4.2.1 
Methodology 
SGBS preadipocytes were differentiated into mature adipocytes in a normoxic incubator 
(95% O2/5% CO2) following the methodology described in section 3.1.1.1.1. On day 14, 
mature adipocytes were treated with 10µM AC2-26 peptide 
(Pepcceuticals#SSCU100417) or vehicle control (DMSO) and incubated in an incubator 
chamber flushed with 1% O2, 5% CO2 and 94% Nitrogen (N2), sealed and incubated at 
37ºC for 24 hours to mimic adipose tissue hypoxia and generate obesogenic cell 
phenotype. After 24 hours, the cells were homogenised (section 3.2.1.1) for analysis.  
4.4.3 Lactate assay 
Lactate is secreted by cells into the cell culture media and is a convenient measure to 
assess hypoxia. It is a metabolic compound formed by the action of Lactate 
Dehydrogenase in cells under various conditions and is increased in hypoxia (Wang, D., 
Wang et al. 2018).  
4.4.3.1 Methodology 
The Lactate assay (Sigma-Aldrich#MAK064) was carried out following the protocol 
provided by the manufacturer. Briefly, 50µL of prepared lactate standards (0-10nmole) 
and cell culture medium from cells prepared in section 4.4.1.1 was filtered through a 10 
kDa cut-off spin filter and plated into a 96 well flat bottom plate. 50µL of reaction mix 
(46µL Lactate Assay Buffer + 2µL Lactate Enzyme Mix + 2µL Lactate Probe) was added 
per well and mixed on a horizontal shaker for 30 minutes at room temperature protected 
from light. The absorbance of the reaction was measured using a spectrophotometer at 
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570nm. The average absorbance measurement of blank standard was subtracted from the 
average absorbance measurements of all individual standards and unknown samples. A 
standard curve was generated, and the trend line equation used to determine the protein 
concentration of each unknown sample. The concentration of Lactate was calculated 
using the following equation:  
(Amount of Lactate in unknown sample from standard curve/Sample Volume added 
into the wells) * Lactate molecular weight=89.07g/mole 
4.4.4 Gene Expression analysis 
Cells homogenised in section 4.4.2.1 were used to isolate RNA and synthesise cDNA (as 
described in section 3.2.1.1 and 3.2.2.1) to analyse the gene expression of an array of 
different genes in response to AC2-26 treatment in obesogenic cells. 
4.4.4.1 Methodology  
The BioRad obesity plate (Biorad#10038460) used in this study is pre-coated with 
lyophilized primers (negative and positive controls) and just requires the addition of 
SYBR green PCR master mix and cDNA per well. Thus, 5μL 2x SensiFASTTM SYBR 
HI-ROX Mix and 80μg of cDNA per 10μL reaction were added to each well. Additional 
primer assays (listed in section 5.4.4) were prepared. The plates were sealed, and the PCR 
machine was set up with the following: activation at 95ºC (2-minute cycle), denaturation 
at 95ºC (5 seconds, 40 cycles), annealing/extension at 60ºC (30 seconds, 40 cycles), 
followed by a melt curve at 65-95ºC (5 second cycle). The Ct values were used to calculate 
the relative gene expression in response to AC2-26 treatment using the methodology 
described in section 3.2.5. 
 Chapter 4: Expression of obesity dysregulated genes in response to acute AC2-26 
treatment using a model mimicking the inflammatory status that is observed during 
obesity 
 
153 | P a g e  
 
4.4.5 Data and statistical analysis 
 The data in this study is presented as Mean ± Standard Error of the Mean (SEM). One 
tailed, unpaired student’s T-test was used to statistically analyse the data and to assess the 
differences in the data sets, a p value of p<0.05 was considered statistically significant. 
GraphPad Prism 5 was used to statistically analyse the data and produce the graphs. R 
studio, version 1.1.453 was used to produce the heatmaps using commands provided by 
Kevin Blighe (https://www.biostars.org/p/299161/).   
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4.5 Results  
4.5.1 Model mimicking the inflammatory status that is observed during Obesity 
mRNA expression of hypoxia markers; HIF (HIF-1α) (22.6 ±5.7-fold, p=0.0097, n=3) 
and SLC2A (GLUT1) (3.8 ±0.4-fold, p=0.0014, n=4) were significantly upregulated in 
adipocytes incubated in a hypoxic environment compared to adipocytes incubated in a 
normoxic environment (21% O2), as shown in Figure 4.3a (Trayhurn, Wood 2004).  
Furthermore, lactate secretion was significantly increased in cell culture medium from 
cells incubated in hypoxic compared to normoxic environment (1.8 ±0.01 ng/µL vs 1.73 
±0.02 ng/µL, p=0.0009, n=5, respectively), as shown in Figure 4.3b, indicative of  cellular 
hypoxia being achieved.   
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Figure 4.3: Markers of hypoxia in mature adipocytes. SGBS cells were differentiated over 14 days to reach 
a mature adipocyte phenotype in normoxic environment. Mature adipocytes were incubated in hypoxic 
environment (1% O2) for 24 hours. a) mRNA was extracted using Trisure and cDNA synthesised. 80ng of 
cDNA was used in SYBR green mediated quantitative PCR. Ct values were obtained and used to calculate 
normalised gene expression using the Livak 2-CT equation (as described in Chapter 3). One-tailed unpaired 
student’s T-test was used to statistically analyse the data. mRNA expression of HIF (HIF-1α) (p=0.097, 
n=3) and SLC2A (GLUT1) (p=0.0014, n=4) were significantly upregulated in adipocytes incubated in a 
hypoxic environment compared to a normoxic environment. Normoxia normalised to 1. b) Lactate secretion 
was significantly increased in cell culture medium of cells incubated in hypoxic compared to normoxic 
conditions (p=0.0009, n=5). Data presented as Mean±SEM. P value was set at P<0.05 and is denoted by * 
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4.5.2 Gene-annotation enrichment analysis  
Genome-wide gene expression analyses are commonly used to gain an insight into 
molecular events that occur within specific tissues and/or cells to understand human 
diseases (Hao, Yang et al. 2018). Obesity is associated with significant changes in the 
expression of genes involved in various cellular processes (Attie, Scherer 2009). The 
expression of these genes was analysed in response to acute AC2-26 treatment in a model 
mimicking the inflammatory status that is observed during obesity. mRNA expression of 
known genes dysregulated in obesity were analysed. The genes were categorised into 
biological processes using the Protein ANalysis THrough Evolution Relationships 
(PANTHER) classification system (http://www.pantherdb.org/). It classifies proteins 
according to family and subfamily, molecular function, biological processes and 
pathways. It organises sets of genes accordingly into broad categories, rather than specific 
niche categories, allowing for general overview of the biological processes (Figure 4.4). 
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Figure 4.4: Biological processes of known genes dysregulated in obesity. Known genes dysregulated in 
obesity were categorised based on their biological processes using the Protein ANalysis THrough Evolution 
Relations (PANTHER) Classification System. The pie chart presents % of genes investigated involved in sub 
biological processes such as cellular processes, metabolic processes and response to stimuli. 
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Genes in the top 3 biological processes were analysed. 45.7% of the genes are invovled 
in cellular processes such as, cell communication (45.9%), cell cycle (5.9%), cell 
proliferation (2.4%) and cellular component movement (5.9%), as shown in Figure 4.5. 
mRNA expression of 13 genes invovled in cellular processes were signficantly regulated 
in response to acute AC2-26 treatment compared to vehicle control are shown in Figure 
4.6. ACHE (1.62 ±0.2-fold, p=0.0317, n=3) and BAX (2.8 ±0.2-fold, p=0.0004, n=3) were 
significantly upregulated. CALU (0.6 ±0.1-fold, p=0.0019, n=3), DPP4 (0.72 ±0.1-fold, 
p=0.0170, n=3), F2R (0.56 ±0.1-fold, p=0.0084, n=3), GABRB3 (0.51 ±0.2-fold, 
p=0.0437, n=3), IGF1R (0.60 ±0.1-fold, p=0.0174, n=3), IRS1 (0.21 ±0.03-fold, 
p<0.0001, n=3), MME (0.55 ±0.1-fold, p=0.0076, n=3), SSTR1 (0.59 ±0.1-fold, 
p=0.0176, n=3), TNF (0.4 ±0.3-fold, p=0.0429, n=3), PPP3CC (0.66 ±0.1-fold, 
 
 
Cell communication (45.9%) 
 
 
Cell cycle (5.9%) 
 
 
Cell proliferation (2.4%) 
 
 
Cellular component movement (5.9%) 
Figure 4.5: Cellular processes of known genes dysregulated in obesity. Known genes dysregulated in  
obesity were categorised based on their biological processes using the Protein ANalysis THrough Evolution 
Relations (PANTHER) Classification System. The pie chart presents % of genes investigated involved in 
cellular processes. 
 Chapter 4: Expression of obesity dysregulated genes in response to acute AC2-26 
treatment using a model mimicking the inflammatory status that is observed during 
obesity 
 
158 | P a g e  
 
p=0.0062, n=3) and VEGFA (0.50 ±0.2-fold, p=0.0449, n=3) were significantly 
downregulated.  
 
44.1% of the genes are invovled in metabolic processes such as, biosynthetic process 
(37.8%), catabolic process (25.6%) and primary metabolic processes (69.5%) (Figure 
4.7a), of which 35.% are invovled in lipid metabolic processes, 7% invovled in 
carbohydrate metabolic processes and 21.1% invovled in protein metabolic processes 
(Figure 4.7b). mRNA expression of 12 genes invovled in metabolism were signficantly 
regulated in response to acute AC2-26 treatment compared to vehicle control are shown 
in Figure 4.8. HPRT1 (1.84 ±0.4-fold, p=0.0480, n=3), MLH1 (1.5 ±0.04-fold, p=0.0004, 
Figure 4.6: Genes involved in cellular processes that were significantly regulated in response to acute 
AC2-26 treatment in using a model mimicking the inflammatory status that is observed during obesity. 
SGBS cells were differentiated into mature adipocytes and treated with 10μM AC2-26 or vehicle control and 
incubated in hypoxic (1% O2) environment for 24 hours. mRNA was extracted using Trisure and cDNA was 
synthesised. 80ng of cDNA was used in SYBR green mediated quantitative PCR.  mRNA expression of genes 
known to be dysregulated in obesity were analysed. Ct values were obtained and used to calculate normalised 
gene expression using the Livak 2-CT equation (as described in Chapter 3). One-tailed unpaired student’s 
T-test was used to statistically analyse the data. 13 genes involved in cellular processes were significantly 
regulated in response to acute AC2-26 treatment compared to vehicle control.  ACHE (p=0.0317, n=3) and 
BAX (p=0.0004, n=3) were significantly upregulated. CALU (p=0.0019, n=3), DPP4 (p=0.0170, n=3), F2R 
(p=0.0084, n=3), GABRB3 (p=0.0437, n=3), IGF1R (p=0.0174, n=3), IRS1 (p<0.0001, n=3), MME (p-
0.0076, n=3), SSTR1 (p=0.0176, n=3), TNF (p=0.0429, n=3), PPP3CC (p=0.0062, n=3) and VEGFA 
(p=0.0449, n=3) were significantly downregulated. Vehicle control normalised to 1. Data presented as 
Mean±SEM. P value was set at P<0.05 and is denoted by * vs 1. Housekeeping gene: GAPDH 
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n=3), PER3 and TBP (1.23 ±0.1-fold, p=0.0084, n=3) were significantly upregulated. 
ACOX1 (0.78 ±0.1-fold, p=0.030, n=3), CTSA (0.7 ±0.1-fold, p=0.0298, n=3), CTSK (0.7 
±0.01-fold, p<0.0001, n=3), DPP4, IRS1, LPIN1 (0.83 ±0.02, p=0.0010, n=3) and SIRT1 
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Figure 4.7: Metabolic processes of known genes dysregulated in obesity. Known genes dysregulated in 
obesity were categorised based on their biological processes using the Protein ANalysis THrough Evolution 
Relations (PANTHER) Classification System. The pie chart presents % of genes investigated involved in a) 
metabolic processes and b) primary metabolic processes. 
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27.4% of the genes are invovled in responding to stimuli, such as, response to endogenous 
stimuli (37.3%), response to external stimulus (23.5%) and response to stress (25.5%), as 
shown in Figure 4.9. mRNA expression of 9 genes invovled in responding to stimuli were 
signficantly regulated in response to acute AC2-26 treatment compared to vehicle control 
are shown in Figure 4.10. ACHE, BAX and PER3 (3.4 ±1.0-fold, p=0.0370, n=3) were 
significantly upregulated, DPP4, IGF1R, IRS1, JUN (0.48 ±0.2-fold, p=0.0206, n=3), 
TNF and VEGFA were significantly downregulated.  
Figure 4.8: Genes involved in metabolism that were significantly regulated in response to acute AC2-26 
treatment in using a model mimicking the inflammatory status that is observed during obesity. SGBS cells 
were differentiated into mature adipocytes and treated with 10μM AC2-26 or vehicle control and incubated 
in hypoxic (1% O2) environment for 24 hours. mRNA was extracted using Trisure and cDNA was synthesised. 
80ng of cDNA was used in SYBR green mediated quantitative PCR.  mRNA expression of genes known to be 
dysregulated in obesity were analysed. Ct values were obtained and used to calculate normalised gene 
expression using the Livak 2-CT equation (as described in Chapter 3). One-tailed unpaired student’s T-test 
was used to statistically analyse the data. 13 genes involved in cellular processes were significantly regulated 
in response to acute AC2-26 treatment compared to vehicle control.  HPRT1 (p=0.0480, n=3), MLH1 (p-
0.0004, n=3), PER3 (p=0.0370, n=3) TBP (p=0.0084, n=3) were significantly upregulated. ACOX1 
(p=0.030, n=3), CTSA (p=0.0298, n=3), CTSK (p<0.0001, n=3) DPP4 (p=0.0170, n=3), IRS1 (p<0.0001, 
n=3) LPIN1 (p=0.0010, n=3) and SIRT1 (p=0.0176, n=3) were significantly downregulated. Vehicle control 
normalised to 1. Data presented as Mean±SEM. P value was set at P<0.05 and is denoted by * vs 1. 
Housekeeping gene: GAPDH 










































 Chapter 4: Expression of obesity dysregulated genes in response to acute AC2-26 
treatment using a model mimicking the inflammatory status that is observed during 
obesity 
 









Cellular defence response (3.9%) 
 
 
Immune response (7.8%) 
 
 
Response to abiotic stimulus (5.9%) 
 
 
Response to biotic stimulus (5.9%) 
 
 
Response to endogenous stimulus (37.7%) 
 
 
Response to external stimulus (23.5%) 
 
 
Response to stress (25.5%) 
Figure 4.9: Response to varies stimuli of known genes dysregulated in obesity. Known genes dysregulated 
in obesity were categorised based on their biological processes using the Protein ANalysis THrough 
Evolution Relations (PANTHER) Classification System. The pie chart presents % of genes investigated 
involved in responding to various stimuli. 
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Figure 4.10: Genes involved in responding to stimuli that were significantly regulated in response to acute AC2-
26 treatment in using a model mimicking the inflammatory status that is observed during obesity. SGBS cells were 
differentiated into mature adipocytes and treated with 10μM AC2-26 or vehicle control and incubated in hypoxic 
(1% O2) environment for 24 hours. mRNA was extracted using Trisure and cDNA was synthesised. 80ng of cDNA 
was used in SYBR green mediated quantitative PCR.  mRNA expression of genes known to be dysregulated in obesity 
were analysed. Ct values were obtained and used to calculate normalised gene expression using the Livak 2 -CT 
equation (as described in chapter 3). One-tailed unpaired student’s T-test was used to statistically analyse the data. 
13 genes involved in cellular processes were significantly regulated in response to acute AC2-26 treatment 
compared to vehicle control.  ACHE (p=0.0317, n=3) and BAX (p=0.0004, n=3) were significantly upregulated. 
DPP4 (p=0.0170, n=3), IGF1R (p=0.0174, n=3), IRS1 (p<0.0001, n=3), JUN (p=0.0206, n=3), PER3 (p=0.0370, 
n=3), TNF (p=0.0429, n=3), PPP3CC (p=0.0062, n=3) and VEGFA (p=0.0449, n=3) were significantly 
downregulated. Vehicle control normalised to 1. Data presented as Mean±SEM. P value was set as P<0.05 and is 
denoted by * vs 1. Housekeeping gene: GAPDH 
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4.5.3 KEGG Pathway mapping  
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
bioinformatics resources 6.7 (https://david-d.ncifcrf.gov/home.jsp) was used to 
categorise the genes using the Kyoto Encyclopedia of genes and genomes (KEGG) 
database into pathways for analysis. The genes were grouped into 22 biological pathways, 
as listed in table 4.1. The DAVID annotation tool uses Fisher Exact to measure the gene-
enrichment in annotation terms (these consist of information such as biochemical 
Pathway Count P-Value 
hsa04920: Adipocytokine signalling pathway 17 8.03E-13 
hsa03320: PPAR signalling pathway 11 2.83E-06 
hsa04620: Toll-like receptor signalling pathway 12 1.53E-05 
hsa04621: NOD-like receptor signalling pathway 9 6.96E-05 
hsa04930: Type II diabetes mellitus 8 7.92E-05 
hsa04910: Insulin signalling pathway 12 2.24E-04 
hsa05010: Alzheimer's disease 12 1.12E-03 
hsa05014: Amyotrophic lateral sclerosis (ALS) 7 1.19E-03 
hsa04060: Cytokine-cytokine receptor interaction 15 2.34E-03 
hsa05200: Pathways in cancer 17 2.90E-03 
hsa04660: T cell receptor signalling pathway 9 3.03E-03 
hsa05210: Colorectal cancer 7 1.19E-02 
hsa04080: Neuroactive ligand-receptor interaction 13 1.32E-02 
hsa04640: Hematopoietic cell lineage 7 1.32E-02 
hsa04960: Aldosterone-regulated sodium reabsorption 5 1.36E-02 
hsa05219: Bladder cancer 5 1.48E-02 
hsa04722: Neurotrophin signalling pathway 8 2.25E-02 
hsa04662: B cell receptor signalling pathway 6 2.76E-02 
hsa04623: Cytosolic DNA-sensing pathway 5 3.59E-02 
hsa04510: Focal adhesion 10 3.91E-02 
hsa05215: Prostate cancer 6 5.17E-02 
hsa04062: Chemokine signalling pathway 9 6.27E-02 
Table 4.1: KEGG pathways. Genes known to be dysregulated in obesity were categorised into biological 
pathways using DAVID resource. DAVID uses the KEGG database to categorise the genes into pathways 
based on their enrichment. The Fisher Exact P-value is used to measure gene enrichment; the smaller the P-
value, the more enriched the gene. For example, genes within the top 3 signalling pathways; adipocytokine 
signalling pathway, PPAR signalling pathway and Toll-like receptor signalling pathway are specifically 
associated (enriched) with these pathways than random chance.  
 Chapter 4: Expression of obesity dysregulated genes in response to acute AC2-26 
treatment using a model mimicking the inflammatory status that is observed during 
obesity 
 
164 | P a g e  
 
function, biological function, involved regulations and interactions and expression), 
therefore, the P-Value was used to identify top pathways with specifically enriched genes.  
 
Figure 4.11 shows 11 pathways with P-Value <0.01, the genes within the pathways and 
their expression in response to acute AC2-26 treatment compared to vehicle control.  
Figure 4.12 shows genes that were significantly regulated in response to acute AC2-26 
treatment compared to vehicle control in the top 11 pathways. ACOX1, CDKN2A (0.74 
±0.2-fold, p=0.0846, n=3), FASN (0.68 ±0.1-fold, p=0.0125, n=3), IFGR1 (0.64 ±0.2-
fold, p=0.0394, n=3), LRP1 (1.59 ±0.2-fold, p=0.0300, n=3), MALT1 (1.90 ±0.4-fold, 
p=0.0568, n=3), MLH1 (1.45 ±0.05-fold, p=0.0004, n=3), MME, NR1H3 (0.76 ±0.1-fold, 
p=0.0197, n=3), PSEN1 (0.73 ±0.1-fold, p=0.0102, n=3), PSEN2 (2.48 ±0.5-fold, 
p=0.0214, n=3), SPP1 (0.62 ±0.2-fold, p=0.0647, n=3), SREBF1 (0.79 ±0.1-fold, 
p=0.0253, n=3) are involved in a pathway (Figure 3.13). BAX, CD36 (0.55 ±0.2-fold, 
p=0.0305, n=3), LEP (0.56 ±0.2-fold, p=0.0400, n=3), PPARA (2.8 ±0.7-fold, p=0.0303, 
n=3), VEGFA are involved in 2 pathways (Figure 3.14). ADIPOQ (2.0 ±0.3-fold, 
p=0.0073, n=3), IRS1, IL6 (1.4±0.1-fold, p=0.0072, n=3), JUN, PPP3CC, SLC2A4 (0.67 
±0.1-fold, p=0.0278, n=3) and TNF are involved in 3 or more pathways (Figure 4.15).   
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Figure 4.11: Clustering of DAVID gene enrichment results (KEGG pathways) and gene expression in 
response to acute AC2-26 treatment using a model mimicking the inflammatory status that is observed 
obesity. SGBS cells were differentiated into mature adipocytes and treated with 10μM AC2-26 or vehicle 
control and incubated in hypoxic (1% O2) environment for 24 hours. mRNA was extracted using Trisure and 
cDNA was synthesised. 80ng of cDNA was used in SYBR green mediated quantitative PCR.  mRNA 
expression of genes known to be dysregulated in obesity were analysed. Ct values were obtained and used 
to calculate normalised gene expression using the Livak 2-CT equation (as described in Chapter 3). The 
Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources 6.7 was 
used to categorise the genes using the Kyoto Encyclopaedia of genes and genomes (KEGG) database. R was 
used to generate a graphical presentation of gene expression in response to acute AC2-26 treatment and 
their involvement in different biological pathways. The graph shows the highly significantly enriched 
pathways (Fisher exact P-value <0.01. Vehicle control normalised to 1. Housekeeping gene: GAPDH 
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Figure 4.12: Clustering of DAVID gene enrichment results (KEGG pathways) and significant regulation 
of gene expression in response to acute AC2-26 treatment using a model mimicking the inflammatory 
status that is observed obesity. SGBS cells were differentiated into mature adipocytes and treated with 10μM 
AC2-26 or vehicle control and incubated in hypoxic (1% O2) environment for 24 hours. mRNA was extracted 
using Trisure and cDNA was synthesised. 80μg of cDNA was used in SYBR green mediated quantitative 
PCR.  mRNA expression of genes known to be dysregulated in obesity were analysed. Ct values were 
obtained and used to calculate normalised gene expression using the Livak 2-CT equation (as described in 
Chapter 3). One-tailed unpaired student’s T-test was used to statistically analyse the data. The Database 
for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources 6.7 was used to 
categorise the genes using the Kyoto Encyclopaedia of genes and genomes (KEGG) database. R was used 
to generate a graphical presentation of gene expression in response to acute AC2-26 treatment and their 
involvement in different biological pathways. The graph shows the highly significantly enriched pathways 
(Fisher exact P-value <0.01 and genes that were significantly regulated in response to acute AC2-26 
treatment. Vehicle control normalised to 1. Housekeeping gene: GAPDH 
 Chapter 4: Expression of obesity dysregulated genes in response to acute AC2-26 
treatment using a model mimicking the inflammatory status that is observed during 
obesity 
 
167 | P a g e  
 
  
Figure 4.13: Genes involved in a biological pathway that were significantly regulated in response to acute 
AC2-26 treatment using a model mimicking the inflammatory status that is observed obesity. SGBS cells 
were differentiated into mature adipocytes and treated with 10μM AC2-26 or vehicle control and incubated 
in hypoxic (1% O2) environment for 24 hours. mRNA was extracted using Trisure and cDNA was synthesised. 
80ng of cDNA was used in SYBR green mediated quantitative PCR.  mRNA expression of genes known to be 
dysregulated in obesity were analysed. Ct values were obtained and used to calculate normalised gene 
expression using the Livak 2-CT equation (as described in Chapter 3). One-tailed unpaired student’s T-test 
was used to statistically analyse the data. mRNA expressions of LRP1 (p=0.0300, n=3), MALT1 (p=0.0568, 
n=3), MLH1 (p=0.0004, n=3) and PSEN2 (p=0.0102, n=3) were upregulated, whereas, ACOX1 (p=0.030, 
n=3), CDKN2A (p=0.0846, n=3), FASN (0.0125, n=3), IGFR1 (0.0394, n=3), MME (p=0.0076, n=3), 
NR1H3 (p=0.0197, n=3), PSEN1 (p=0.0102, n=3), SPP1 (p=0.0647, n=3) AND SREBF1 (p=0.0253, n=3) 
were downregulated in response to acute AC2-26 treatment compared to vehicle control. Vehicle control 
normalised to 1. Data presented as Mean±SEM. P value was set as P<0.05 and is denoted by * vs 1. 
Housekeeping gene: GAPDH 
 
Figure 4.14: Genes involved in 2 biological pathways that were significantly regulated in response to 
acute AC2-26 treatment using a model mimicking the inflammatory status that is observed obesity. SGBS 
cells were differentiated into mature adipocytes and treated with 10μM AC2-26 or vehicle control and 
incubated in hypoxic (1% O2) environment for 24 hours. mRNA was extracted using Trisure and cDNA was 
synthesised. 80ng of cDNA was used in SYBR green mediated quantitative PCR.  mRNA expression of genes 
known to be dysregulated in obesity were analysed. Ct values were obtained and used to calculate 
normalised gene expression using the Livak 2-CT equation (as described in Chapter 3). One-tailed unpaired 
student’s T-test was used to statistically analyse the data.  mRNA expressions of BAX (p=0.0004, n=3) and 
PPARA (p=0.0303, n=3) were significantly upregulated, whereas, CD36 (p=0.0305, n=3), LEP (p=0.0400, 
n=3) and VEGFA (p=0.0449, n=3) were significantly downregulated in response to acute AC2-26 treatment 
compared to vehicle control. Vehicle control normalised to 1. Data presented as Mean±SEM. P value was 
set as P<0.05 and is denoted by * vs 1. Housekeeping gene: GAPDH 
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Figure 4.15: Genes involved in 3 or more biological pathways that were significantly regulated in response 
to acute AC2-26 treatment using a model mimicking the inflammatory status that is observed obesity. 
SGBS cells were differentiated into mature adipocytes and treated with 10μM AC2-26 or vehicle control and 
incubated in hypoxic (1% O2) environment for 24 hours. mRNA was extracted using Trisure and cDNA was 
synthesised. 80ng of cDNA was used in SYBR green mediated quantitative PCR.  mRNA expression of genes 
known to be dysregulated in obesity were analysed. Ct values were obtained and used to calculate normalised 
gene expression using the Livak 2-CT equation (as described in Chapter 3). One-tailed unpaired student’s 
T-test was used to statistically analyse the data.  mRNA expression of ADIPOQ (0.0073, n=3) was 
significantly upregulated and mRNA expressions of IRS1 (p<0.0001, n=3), IL6 (p=0.0072, n=3), JUN 
(p=0.0206, n=3), PPP3CC (p=0.0062, n=3), SLAC2A4 (p=0.0278, n=3) and TNF (p=0.0429, n=3) were 
significantly downregulated in response to acute AC2-26 treatment compared to vehicle control. Vehicle 
control normalised to 1. Data presented as Mean±SEM. P value was set as P<0.05 and is denoted by * vs 
1. Housekeeping gene: GAPDH 
 






































 Chapter 4: Expression of obesity dysregulated genes in response to acute AC2-26 
treatment using a model mimicking the inflammatory status that is observed during 
obesity 
 
169 | P a g e  
 
4.5.3.1 Adipocytokine Signalling Pathway 
The adipocytokine pathway is the most significantly gene enriched pathway dysregulated 
in obesity (Figure 4.12), therefore, mRNA expression of additional adipokines were 
analysed in response to acute AC2-26 treatment.  mRNA expression of ADIPOQ (Figure 
4.15) was significantly upregulated in response to acute AC2-26 treatment compared to 
vehicle control. Similarly, mRNA expression of LEP (Figure 4.14), RETN (0.14 ±0.04-
fold, p<0.0001, n=4), NAMPT (0.41 ±0.1-fold, p=0.0039, n=3) and CFD (0.33 ±0.2, 
p=0.0096, n=4) were significantly downregulated in response to acute AC2-26 treatment 
compared to vehicle control, as shown in Figure 4.16.  
  
Figure 4.16: mRNA expression of adipocytokines in response to acute AC2-26 using a model mimicking 
the inflammatory status that is observed obesity. SGBS cells were differentiated into mature adipocytes and 
treated with 10μM AC2-26 or vehicle control and incubated in hypoxic (1% O2) environment for 24 hours. 
mRNA was extracted using Trisure and cDNA was synthesised. 80ng of cDNA was used in SYBR green 
mediated quantitative PCR. Ct values were obtained and used to calculate normalised gene expression using 
the Livak 2-CT equation (as described in Chapter 3). One-tailed unpaired student’s T-test was used to 
statistically analyse the data. RETN (p<0.0001, n=4), NAMPT (p=0.0039, n=3) and CFD (p=0.0096, n=4) 
were significantly downregulated in response to acute AC2-26 treatment compared to vehicle control. 
Vehicle control normalised to 1. Data presented as Mean±SEM. P value was set as P<0.05 and is denoted 
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4.6 Discussion 
In the current study, the potential roles of ANXA1 in adipocyte biology were screened 
using a model mimicking the inflammatory status observed in obesity. 186 known genes 
dysregulated in obesity were analysed in response to acute AC2-26 treatment and 
categorised into groups based on their biological functions and biological pathways. 
Table 4.2 lists the regulation of genes (or protein level) in obesity that were significantly 
altered in response to acute AC2-26 treatment. The implications of genes involved in 2 
or more biological processes, biological pathways and adipokines in obesity are discussed 
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Gene Protein KEGG Orthology Obesity Reference 





Sherf-Dagan et al. 
2018) 
ACOX1 Acyl-CoA oxidase 1 Lipid metabolism 
PPAR signalling 
pathway 
ACOX-/- mice have a 
lean body phenotype 
(Huang, Jia et al. 2012) 




(Makki, Froguel et al. 
2013) 
BAX BCL2- associated X protein Apoptosis Increased in adipose 
tissue of obese mice and 
humans 
(Alkhouri, Gornicka et 
al. 2010) 
 
CALU Calumenin Ca2+ binding protein Not known  
CD36 Fatty acid translocase  Immune system 
Metabolism 
Upregulated in SAT in 
human obesity 
(Bonen, Tandon et al. 
2006) 
CFD Adipsin Complement and 
coagulation cascade 
Lipid metabolism 
Decreased expression in 
obese  
(Song, Kim et al. 2016) 
CTSA Cathepsin A Lysosome  Not known  




(Xiao, Junfeng et al. 
2006) 
DPP4 Dipeptidyl peptidase 4 Metabolism Positively correlates 
with BMI 
(Sell, Bluher et al. 
2013) 
F2R Coagulation Factor II 







FASN Fatty acid synthase  Lipid metabolism 
Insulin signalling 
pathway 
Increased expression in 
adipose tissue with 
obesity 
(Berndt, Kovacs et al. 
2007) 
GABRB3 Gamma-aminobutyric acid 
type A receptor β3 subunit 




Metabolism Not known (Kamal, Kim et al. 
2013) 
IGF1R Insulin like growth factor 1 
receptor 
Cell growth and survival 
Metabolism 
Increased in obese 
children 
(Ricco, Ricco et al. 
2018) 
IRS1 Insulin receptor substrate 1 Metabolism Reduced in adipocytes 
of obese Pima Indians  
(Kovacs, Hanson et al. 
2003) 
IL6 Interleukin 6 Inflammation  
Metabolism 
 
Mice lacking display 
obesity 
(Matthews, Allen et al. 
2010) 
JUN JunD proto-oncogene Immune system 
Transcription Factor 
JunD-/- mice display 
reduced adiposity 
(Hasenfuss, Bakiri et al. 
2014) 
LEP Leptin Metabolism 
 
Positively correlates 
with fat mass; increased 
in obesity 
(Ozata, Ozdemir et al. 
1999) 
LPIN1 Lipin 1 Lipid metabolism Enhanced expression 
promotes obesity in 
mice 
(Phan, Reue 2005) 
LRP1 Low-density lipoprotein 
receptor-related protein 1 
Cholesterol metabolism Expression upregulated 
in human and mouse 
obese adipose tissue 
(Masson, Chavey et al. 
2009) 
MALT1 Mucosa associated 
lymphoid tissue lymphoma 
translocation protein 1 
Immune system Not known  
MLH1 mutL homolog 1 DNA repair Not known  
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Levels increased in 
obesity 
(Standeven, Hess et al. 
2011) 
NAMPT Visfatin Metabolism  
Immune system 
Increased levels in 
obesity 
(Kaminska, 
Kopczynska et al. 2010) 
NR1H3 Liver X receptor α Metabolism 
PPAR signalling 
Levels in subcutaneous 




PDK4 Pyruvate dehydrogenase 
kinase 4 
Metabolism 
Fatty acid restriction 
Not known  
PPARA Peroxisome proliferator-
activated receptor α 
Metabolism 
 
Protects against obesity (Araki, Nakagawa et al. 
2018) 
PER3 Period circadian regulator 3 Circadian rhythm  Methylation positively 
correlated with BMI and 
insulin resistance  
(Ramos-Lopez, 
Samblas et al. 2018) 
PPP3CC Calcineurin Metabolism 
Immune system 
Upregulated in bariatric 
patients  
(Berisha, Serre et al. 
2011) 
PSEN1 Presenilin 1 Signal transduction Levels positively 
correlate with BMI 
(Luciano, Barraco et al. 
2015) 
PSEN2 Presenilin 2 Signal transduction Not known  
RETN Resistin Adipocytokine 
signalling pathway 
Increased levels in 
obesity 
(De Luis, Gonzalez 
Sagrado et al. 2010) 
SIRT1 Sirtuin 1 Signal transduction Decreased in adipose 
tissue of obese 
(Stefanowicz, 
Nikolajuk et al. 2018) 
SLC2A4 Glucose transporter 4 Metabolism Reduced expression in 
fat of obese 
(Poletto, David-Silva et 
al. 2015) 
SREBF1 Sterol regulatory element-
binding protein -1 
Energy homeostasis mRNA levels decreased 
in adipose tissue of mice 
and humans 
(Kolehmainen, Vidal et 
al. 2001) 
SSTR1 Somatostatin receptor 1 cAMP signalling 
pathway 
Not known  
TBP TATA box binding protein Metabolism Not known  




VEGFA Vascular endothelial 




Positive correlation with 
BMI 







Table 4.2: Gene expression and/or protein levels in obesity. Out of 186 genes analysed, the expression of 
genes presented in this table were significantly regulated in response to acute AC2-26 treatment. The KEGG 
ortholog (biological function) and their expression in obesity are presented. 
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Cell survival is regulated through appropriate control of programmed cell death 
(apoptosis) as it is essential for homeostatic maintenance of cell number in many tissues. 
Impaired apoptosis contributes to tumourigenesis, autoimmunity and inflammatory 
disorders (Elmore 2007). The control of cell survival and cell death are balanced by the 
activation of pro-apoptotic and pro-survival signalling pathways.  
4.6.1 Bcl-2-associated X protein  
High circulating levels (and intracellular levels) of triglycerides and free fatty acids (FFA) 
are common in overweight and obese individuals (Campbell, Carlson et al. 1994). FFA’s 
engage directly with the core apoptotic machinery by activating pro-apoptotic Bcl-2-
associated X protein (BAX) (Zhu, Han et al. 2015). Adipocyte death has been reported in 
both obese humans and rodents and data suggests that adipocyte apoptosis is a key initial 
event that contributes to macrophage infiltration into the adipose tissue, insulin resistance 
and hepatic steatosis (Alkhouri, Gornicka et al. 2010). Hyperinsulinemia associated with 
obesity may serve to balance the anti-apoptotic signal and promote adipocyte survival 
(Loftus, Kuhajda et al. 1998). Therefore, inhibiting adipocyte apoptosis is suggested as a 
therapeutic strategy. However, (Zhu, Han et al. 2015) have reported induction of 
apoptosis as a novel strategy to treat obesity. This proposal coincides with the results of 
the current study as acute AC2-26 treatment significantly upregulated mRNA expression 
of BAX, suggestive of increased apoptosis in obesogenic adipocytes. Similar effects are 
observed in neutrophils as ANXA1 augments neutrophil apoptosis by activating BAX to 
resolve inflammation (Vago, Nogueira et al. 2012). Furthermore, siRNA knockout of 
ANXA1 in rat trophoblasts downregulated BAX expression supressing apoptosis in a 
preeclampsia model (Feng, Wang et al. 2018). However, further investigation at the 
proteomic level needs to be carried out to appropriately identify the expression of BAX in 
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response to acute AC2-26 treatment and the implications of increased apoptosis in obesity 
as a therapeutic strategy.  
All aspects of physiology including cardiovascular activity, the endocrine system and 
metabolism are influenced by the circadian clock to ensure the physiological processes 
are carried out at the correct time (Froy 2012). The central suprachiasmatic clock located 
in the suprachiasmatic nucleus of the anterior hypothalamus resets signals in peripheral 
tissues such as muscle, digestive tract, liver and adipose tissue (Froy 2012). Enzymes and 
transport systems involved in various metabolic pathways such as, cholesterol 
metabolism and glucose metabolism are influenced by the circadian genes (Froy 2012). 
Animals with mutations within the clock genes provide evidence for relationship between 
circadian clock and metabolic homeostasis and clinical studies in shift workers and obese 
patients further supports these association (Froy 2012). Furthermore, the clock genes and 
adipokines show circadian rhythmicity and dysfunctions of genes involved in the 
circadian rhythm alter the levels of adipokines during the development of obesity (Engin 
2017).   
4.6.2 Period circadian protein homolog 3 
The period circadian protein homolog 3 (PER3) is member of the period proteins that 
form the clock genes and negatively regulate the circadian clock. mRNA expression of 
PER3 was significantly upregulated in response to acute AC2-26 treatment, in the current 
study. Daytime rhythm is evident for salivary ANXA1 and positively correlates with 
salivary cortisol in healthy human participants (Fowkes, Moradi-Bidhendi et al. 2013).  
PER3 negatively influence adipogenesis as deletions of PER3 in mouse preadipocytes 
promote adipogenesis by directly regulating Kruppel like factor -15 (Aggarwal, Costa et 
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al. 2017, Costa, So et al. 2011). Weight cycling promotes weight gain and mice 
completing weight cycling were characterised by a downregulation of several clock genes 
including, PER3 in the adipose tissue (Dankel, Degerud et al. 2014). Furthermore, high 
fat diet (HFD) fed PER3-/- mice developed significant obesity even though the food 
consumption was similar during light and dark periods (Yang, Liu et al. 2009). ANXA1 
may play a role in resetting the biological clock to restore functionality of physiological 
system and negatively regulating adipocyte differentiation preventing the onset of 
metabolic disorders.  
The adipose tissue regulates various metabolic processes including, lipid metabolism, 
glucose homeostasis and inflammation. Three links between adipocyte biology and the 
onset of the metabolic syndrome in obese have been identified (Attie, Scherer 2009). 
These include; 1) increased recruitment and infiltration of macrophages that produce and 
secrete pro-inflammatory cytokines dysregulating insulin signalling (Lumeng, Deyoung 
et al. 2007). 2) Blunted insulin signalling in adipocytes leading to increased lipolysis and 
efflux of FFA’s from adipocytes to other tissues leading to whole body glucose 
intolerance (Duncan, Ahmadian et al. 2007). 3) Altered balance of synthesis and secretion 
of adipokines contributing to impaired glucose tolerance and insulin resistance (Kwon, 
Pessin 2013).  Most of the genes analysed in the current study are involved in regulating 
the metabolic processes in adipocytes and are also thought to contribute to the onset of 
the metabolic syndrome and obesity associated co-morbidities.  
4.6.3 Fatty acid translocase-CD36 
The membrane receptor fatty acid translocase (FAT)-CD36 is a key transporter that 
facilitates the movement of long chain fatty acids across the cellular membrane in the 
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heart, skeletal muscle and the adipose tissue (Noushmehr, D'Amico et al. 2005). CD36 
expression is upregulated in the SAT in obese humans (Bonen, Tandon et al. 2006). Acute 
AC2-26 treatment significantly downregulated the mRNA expression of CD36 in 
adipocytes, in the current study. CD36-/- HFD induced obese mice show reduced adipose 
size and increased number of preadipocytes, suggesting it is involved in adipocyte 
differentiation (Vroegrijk, van Klinken et al. 2013). These mice are protected against the 
development of obesity possibly due to increased basal lipolysis and insulin 
responsiveness (Vroegrijk, van Klinken et al. 2013). Though, the data suggest a negative 
role of CD36 in obesity and associated metabolic diseases, impaired uptake of fatty acid 
in the adipose tissue of CD36-/- mice, result in increased plasma concentration of  fatty 
acids and triglycerides  and chronically elevated levels of circulating fatty acids are 
determinants of insulin resistance (Coburn, Knapp et al. 2000)(Karpe, Dickmann et al. 
2011, Kennedy, Kuchibhotla et al. 2011).  
Furthermore, CD36 dependent inflammatory paracrine loop between adipocytes and 
macrophages facilitates chronic inflammation contributing to the development of insulin 
resistance (Kennedy, Kuchibhotla et al. 2011). However, whole-body insulin mediated 
glucose uptake is increased in CD36-/- mice and was concluded to be due to an increase 
in muscle sensitivity, though, these mice exhibit insulin resistance in the liver (Goudriaan, 
den Boer et al. 2005). Therefore, CD36 expression and its role in insulin signalling may 
be organ dependent and ANXA1 may contribute towards increasing whole-body insulin 
sensitivity by downregulating its expression. 
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4.6.4 Dipeptidyl peptidase-4 
Dipeptidyl peptidase-4 (DPP4) is an exopeptidase (catalyses the cleavage of the terminal 
peptide bond to release an amino acid or dipeptide from a polypeptide chain) expressed 
on the surface of most cell types and is associated with immune regulation, signal 
transduction, apoptosis and glucose metabolism. It is a universally expressed 
transmembrane glycoprotein that cleaves the N-terminal dipeptides from a variety of 
substrates including growth factors, hormones, neuropeptides and chemokines (Yazbeck, 
Howarth et al. 2009). It is released from the plasma membrane as a soluble protein after 
proteolytic cleavage and it functions as a regulatory protease and a binding protein (Iwaki-
Egawa, Watanabe et al. 1998). mRNA expression of DPP4 was significantly 
downregulated in response to acute AC2-26 treatment, in the current study. Glucagon-
like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are released from the 
intestine and are responsible for ~60% of postprandial insulin secretion and supress 
glucagon secretion (Drucker, Nauck 2006). Both GLP-1 and GIP are proteolytically 
cleaved by DPP4 inhibiting their ‘incretin effect’(Bae 2016). DPP4 levels are lower in 
obese insulin sensitive compared to matched obese insulin resistant individuals further 
implicating its role in insulin sensitivity (Sell, Bluher et al. 2013). Inhibition of DPP4 
activity enhances glucose stimulated insulin secretion, enhances cellular glucose uptake, 
decreases hepatic glucose output and is an established target for treatment for T2DM 
(Ahren 2007). Furthermore, peripheral infusions of GLP-1 significantly enhance satiety 
and decrease food intake in lean, obese non-T2DM and T2DM humans (Flint, Raben et 
al. 1998, Naslund, Barkeling et al. 1999, Gutzwiller, Drewe et al. 1999).  
In addition, DPP4 is a newly identified adipokine and it may provide the missing link 
between obesity and metabolic diseases, as it positively correlates with an increasing risk 
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score for the metabolic syndrome (Lamers, Famulla et al. 2011)(Lamers, Famulla et al. 
2011). Obesity induces DPP4 abundance in subcutaneous and visceral adipose tissue, 
with visceral adipose tissue exhibiting the highest level of DPP4 (Lamers, Famulla et al. 
2011). DPP4 secretion from the adipose tissue positively correlates with BMI, percent 
body fat, triglycerides, homeostatic model assessment and adipocyte volume in human 
individuals (Lamers, Famulla et al. 2011). Furthermore, it positively correlates with pro-
inflammatory adipokines such as, leptin and negatively with anti-inflammatory 
adipokines such as, adiponectin (Sell, Bluher et al. 2013). It is speculated that the pro-
inflammatory adipokines may regulate its release (Sell, Bluher et al. 2013). Moreover, 
DPP4 expression is increased during monocyte to macrophage differentiation and is 
significantly increased in M1 macrophages found around crown like structures in the 
adipose tissue (Zhong, Rao et al. 2013). Pharmacological inhibitors reduce insulin 
resistance and inflammation by regulating macrophage status; inhibiting DPP4 induces a 
phenotypic change from an insulin resistance (M1) to insulin sensitive (M2) phenotype 
(Zhuge, Ni et al. 2016). Therefore, in addition to direct anti-inflammatory effects, 
ANXA1 may induce indirect effects via modulating the expression of DPP4 to enhance 
its pro-resolving properties to reduce inflammation and improve insulin sensitivity.  
4.6.5 Peroxisome proliferator-activated receptor α and peroxisomal acyl-coenzyme 
A oxidase 1 
Peroxisome proliferator-activated receptor α (PPARα) is a transcription factor, involved 
in regulating lipid metabolism with important roles in mediating energy release through 
lipolysis and lipid oxidation and energy homeostasis (Den Broeder, Kopylova et al. 
2015). It is highly expressed in tissues with mitochondrial and peroxisomal β oxidation 
such as the brown adipose tissue and the liver (Escher, Braissant et al. 2001).  
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Acyl-CoA oxidase 1 (ACOX1) participates in 3 metabolic pathways; fatty acid 
metabolism, polyunsaturated fatty acid biosynthesis and peroxisome proliferator-
activated receptor signalling pathway. mRNA expression of ACOX1 was significantly 
downregulated and PPARα was significantly upregulated in response to AC2-26 
treatment, in the current study. Inhibition of ACOX1 by a specific inhibitor increases 
hepatic mitochondrial fatty acid oxidation, PPARα expression, decreases body weight 
gain, circulating triglycerides and insulin levels in HFD fed rats (Zeng, Deng et al. 2017). 
Sustained activation of PPARα increases fatty acid oxidation, restores glucose 
homeostasis and attenuates obesity in ACOX1-/- ob/ob mice (Huang, Jia et al. 2012). 
PPARα agonists and drugs for dyslipidaemia promote peroxisomal and mitochondrial β 
oxidation and inhibit fatty acid synthesis in the liver, improving insulin sensitivity by 
decreasing ectopic lipid accumulation in peripheral and adipose tissue (Shiomi, 
Yamauchi et al. 2015). PPARα activation by receptor agonists prevents the development 
of obesity induced insulin resistance without inducing weight gain in rats (Guerre-Millo, 
Gervois et al. 2000). Furthermore, PPARα activation supresses obesity-induced increases 
in inflammatory cytokines such as, TNFα by inhibiting the nuclear factor kappa β (NF-
κβ) signalling pathway and reduce macrophage derived inflammation in cultured 
adipocytes (Tsuchida, Yamauchi et al. 2005, Murakami, Bujo et al. 2007). 
Additionally, activation of PPARα prevents adipocyte hypertrophy by increasing energy 
expenditure via inducing molecules involved in fatty acid combustion such as, uncoupling 
protein 1 in brown adipocytes and β3 adrenergic receptor in white adipocytes as they play 
important roles in lipolysis and thermogenesis (Atgie, D'Allaire et al. 1997). Trans-
differentiation from white to brown adipocytes (brite) or brown-like differentiation in 
white adipose tissue depots is suggested to have significant implications in the treatment 
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of obesity and associated metabolic disorders (Patil, Sharma et al. 2017). ANXA1 may 
induce this transformation (increased thermogenesis in non-brown adipose tissue depots) 
or decrease adipocyte hypertrophy by regulating PPARα activity, therefore, it would be 
of significant interest to further understand the implications of PPARα activation by AC2-
26 and/or ANXA1 in an obesogenic adipocyte model.        
4.6.6 Calcineurin 
Calcineurin is a ubiquitously expressed calcium-sensitive serine-threonine phosphatase 
is composed of a calmodulin-binding catalytical subunit A (encoded by 3 isoforms; 
PPP3CA (isoform α), PPP3CB (isoform β) or PPP3CC (isoform γ)) and a binding 
regulatory subunit B (Klee, Crouch et al. 1979, Rusnak, Mertz 2000). It is activated by 
an influx of intracellular calcium and is involved in conveying environmental stimuli in 
multiple tissues and organs. Adipocyte differentiation is influenced by many extrinsic 
factors and intracellular signalling pathways; including intracellular calcium 
concentrations. Increase in intracellular calcium concentrations during early phases of 
preadipocyte differentiation show to inhibit preadipocyte differentiation into fully mature 
adipocytes by blocking the post confluent mitotic phase of differentiation by mediating 
c-myc gene expression (Ntambi, Takova 1996). However, increased concentration during 
the later stages of differentiation enhance the expression of markers of mature adipocytes, 
such as PPAR-γ (Shi, Halvorsen et al. 2000). Calcineurin mediates calcium dependent 
inhibition of adipocyte differentiation in 3T3-L1 cells, as inhibition of calcineurin 
enhances the efficiency of adipogenesis (Neal, Clipstone 2002).  mRNA expression of 
PPP3CC is downregulated in response to acute AC2-26 treatment, in the current study, 
indicating a pro-adipogenic effect. However, it is possible that ANXA1 may mediate its 
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anti-adipogenic effect in the later stages of adipocyte differentiation adipocytes opposed 
to the early stages.  
High dose of calcineurin inhibitors are prescribed to organ transplant patients as 
immunosuppression therapy, but they cause posttransplant T2DM, hypercholesterolemia 
and hypertension, however, their effect on body weight is conflicting (Benhamou, 
Penfornis 2002). Rats treated with low doses of calcineurin inhibition show reduced body 
weight gain (Ishida, Mitamura et al. 1997). Furthermore, mice with a global knockout of 
isoform β have diminished fat mass; protection from body weight gain, altered food 
intake, feeding efficiency and energy expenditure (Pfluger, Kabra et al. 2015). ANXA1 
may mediate anti-obesogenic phenotype by regulating the expression of PPP3CC; 
isoform γ in mature adipocytes. 
4.6.7 Adipocytokines (Leptin, Visfatin, Resistin, Adipsin and Adiponectin) and 
Cytokines (IL6 and TNFα)  
Adipokines include inflammatory mediators, angiogenic proteins and metabolic 
regulators. They mediate crosstalk between the adipose tissue and other metabolic organs 
including the liver, muscle, pancreas and the central nervous system (Rosen, Spiegelman 
2006) and impaired communication is a critical pathological component in the 
development of the metabolic syndrome (Trujillo, Scherer 2006). mRNA expression of 
‘pro-inflammatory’ adipokines and cytokine; LEP, NAMPT, RETN, CFD and TNFα were 
significantly downregulated and the mRNA expression of ‘anti-inflammatory’ adipokine; 
ADIPOQ was significantly upregulated in response to acute AC2-26 treatment, in the 
current study.  
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Hyperphagia, obesity and insulin resistance are observed in mice lacking leptin, and 
administration of leptin in ob/ob mice and lipoatrophic mice improves these metabolic 
abnormalities (Friedman, Halaas 1998, Shimomura, Hammer et al. 1999). Leptin levels 
positively correlate with BMI and are increased in obesity but do not exert the anorexic 
response, therefore, contribute to the development of the metabolic syndrome by affecting 
insulin sensitivity (Friedman, Halaas 1998, Bakker, Van Dielen et al. 2004). Similarly, 
Visfatin positively correlates with visceral adiposity in human and mouse models of 
obesity and in T2DM patients (Fukuhara, Matsuda et al. 2005, El-Mesallamy, Kassem et 
al. 2011). The expression and secretion of visfatin positively correlates with circulating 
levels of inflammatory markers such as, IL6 and C-reactive protein (Oki, Yamane et al. 
2007).  Furthermore, these inflammatory markers induce the secretion of resistin (Kaser, 
Kaser et al. 2003). It may induce insulin resistance by activating suppressor of cytokine 
signalling 3 (SOCS3); an inhibitor of insulin signalling in adipocytes (Steppan, Wang et 
al. 2005, Rajala, Obici et al. 2003). mRNA expression of SOCS3 was significantly 
downregulated in response to AC2-26 treatment in the current study (Figure 3.11), 
suggesting ANXA1 may resolve insulin resistance through this mechanism. Furthermore, 
mice lacking resistin have low blood glucose levels post fasting (Banerjee, Rangwala et 
al. 2004) and ob/ob deficient mice are more obese but have improved glucose tolerance 
and insulin sensitivity (Steppan, Wang et al. 2005). Adipsin is involved in triacylglycerol 
synthesis and promotes differentiation, whereas, deficiency is associated with partial 
lipodystrophy (Sissons, West et al. 1976). Adiponectin negatively correlates with obesity 
and overexpression improves glucose metabolism, reduces macrophage numbers, 
decreases TNFα and improves vascularisation in ob/ob mice (Kim, van de Wall et al. 
2007).  TNFα is increased in the adipose tissue of humans and mice models of obesity 
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and T2DM (Hotamisligil, Shargill et al. 1993, Kern, Saghizadeh et al. 1995). In addition, 
TNFα contributes to dysregulated secretion of adipokines, as obese subjects overproduce 
adipokines due to hyperactivation of NF-κB pathway. Overexpression of adipokines and 
cytokines in adipocytes of obese subjects can be prevented by inhibiting NF-κB activity. 
Therefore, ANXA1 may prevent adipokine dysregulation and reduce inflammation as it 
mediates its activity by binding to and inhibiting NF-κB activity, enhancing apoptosis (as 
described above) and inhibiting cell growth (Zhang, Huang et al. 2010). 
Interestingly, mRNA expression of IL6 was upregulated in response to acute AC2-26 
treatment. IL6 induces the expression of ANXA1, which may act in an autocrine and 
paracrine manner to regulate the expression of IL6 in a positive feedback loop (Sheikh 
2018). IL6 bears both anti- and pro-inflammatory properties. In addition to its role in 
inflammation and infection responses, it is involved in regulating metabolic, regenerative 
and neural processes (Scheller, Chalaris et al. 2011).  Mice lacking IL6 display obesity, 
hepatosteatosis, liver inflammation and insulin resistance compared to control on a 
standard chow diet, with increased glucose intolerance and insulin resistance in mice fed 
a HFD compared to control (Matthews, Allen et al. 2010). Thus, reflecting the anti-
inflammatory and insulin sensitising role of ANXA1.   
4.6.8 Insulin dependent glucose uptake; Insulin Receptor Substrate 1 and Glucose 
transporter 4  
Insulin receptor substrate 1 (IRS1) and Glucose transporter 4 (GLUT4) (encoded by the 
SLC2A4 gene) are involved in insulin dependent glucose uptake in adipocytes. Binding 
of insulin to its receptor initiates an intracellular cascade inducing the activation and 
phosphorylation of IRS1 and translocation of GLUT4 vesicles to the plasma membrane, 
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allowing glucose to enter the cell. The expression of GLUT4 is tissue specific (adipose 
tissue, skeletal muscle and cardiac muscle) and is regulated by hormones and/or metabolic 
cues (Griesel, Weems et al. 2010). GLUT4 has significant effects on the whole-body 
glucose homeostasis, suggesting it is important for adaptation to extreme physiological 
states such as, fasting and chronic over feeding (Griesel, Weems et al. 2010). Changes in 
the expression of GLUT4 mRNA are dependent on the physiological state of the organism 
and occurs at a steady state, tissue specific manner as, chronic fasting significantly 
reduces its expression in the adipose tissue, but no change is observed in the skeletal 
muscle (Olson 2012). However, expression of GLUT4 mRNA and protein levels do not 
increase proportionately in response to chronic overfeeding and instead decreased 
expression is observed in the adipose tissue of obese phenotype (Poletto, David-Silva et 
al. 2015). The reduction in the expression of GLUT4 is suggested to occur as an adaptive 
response to protect the brain against hypoglycaemia in response to adipose tissue 
expansion in obesity, as if GLUT4 increase proportionally, glucose clearance by adipose 
tissue would divert glucose from the nervous system  (Garvey, Maianu et al. 1991, 
Ikemoto, Thompson et al. 1995). Furthermore, its expression is altered due to 
dysregulated glucose homeostasis in diseases such as, T2DM (reduced) and therefore, it 
has been a target of intensive research on the cause and prevention of T2DM (Kouidhi, 
Berrhouma et al. 2013). Similarly, reduced mRNA of IRS1 are observed in obesity and 
T2DM (Wang, Y., Nishina et al. 2009, Kovacs, Hanson et al. 2003). Interestingly, the 
mRNA expression of GLUT4 and IRS1 were significantly downregulated in response to 
AC2-26, in the current study, suggesting ANXA1 plays a negative role in insulin 
stimulated glucose uptake in adipocytes, even though other genes investigated in this 
study indicate an insulin sensitising effect of ANXA1. Annexin A2 (ANXA2), another 
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member of the Annexin family, is highly expressed in insulin resistant HFD mouse 
models. Knockout down of ANXA2 in these mice, increased the expression of IRS1 and 
glucose uptake, suggesting the Annexin family may negatively regulate insulin mediated 
glucose uptake and/or glucose homeostasis (Wang, Y., Cheng et al. 2018). As high 
glucose levels promote adipocyte differentiation (Jackson, Griesel et al. 2017), the 
expression levels of GLUT4 and IRS1 may be downregulated in mature adipocytes due 
to the possible ‘anti-adipogenic’ effect of ANXA1 in mature adipocytes (as concluded in 
Chapter 5), to reduce hypertrophy and associated inflammation and may favour adipocyte 
hyperplasia.   
4.6.9 Insulin growth factor receptor 1 
The insulin growth factor receptor 1 (IGFR1) ligand insulin growth factor 1 (IGF-1) is a 
liver derived endocrine hormone that provides signals to macrophages that are involved 
in muscle regeneration, neuronal survival and adipose tissue function (Spadaro, Camell 
et al. 2017). Insulin and IGF-1 are essential for the development of both white and brown 
adipose tissues. Insulin mediates glucose uptake and lipid metabolism and IGF-1 plays 
important roles in the stimulation of adipocyte differentiation and preadipocyte survival 
(Xu, J., Liao 2004, Sakaguchi, Fujisaka et al. 2017). mRNA expression of IGFR1 was 
downregulated in response to acute AC2-26 treatment, in the current study. Inhibition of 
IGFR1 in rats attenuates its pro-adipogeneic role (Wang, Y., Mak et al. 2018) and deletion 
in macrophages is associated with reduced adipose tissue inflammasome activation 
(Spadaro, Goldberg et al. 2016). Therefore, ANXA1 may regulate expression of IGFR1 
to regulate adipocyte differentiation and hypertrophy to manage obesity induced 
inflammation in the adipose tissue.   
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In obesity, adipocytes face various stress insults including mechanical, metabolic and 
oxidative, so it is not surprising that many genes involved in responding to stress are 
dysregulated. Oxidative stress is considered to encourage obesity by stimulating white 
adipose tissue deposition and altering food intake (Furukawa, Fujita et al. 2004). 
Oxidative stress increases preadipocyte proliferation, adipocyte differentiation and the 
size of mature adipocytes in both in vivo and in vitro animal studies (Lee, Lee et al. 2009, 
Higuchi, Dusting et al. 2013). However, metabolic changes observed in obesity such as 
hyperglycaemia, elevated tissue lipid levels, hyperleptinemia and chronic inflammation 
further contribute to oxidative stress, inducing positive feedback loop (Manna, Jain 2015).  
4.6.10 Transcription factor Jun-D 
Jun (c-Jun, Jun-B and Jun-D) and Fos (c-Fos, Fos-B, Fra-1 and Fra-2) are members of the 
transcription factor activator protein (AP-1) family that play a central role in regulating 
gene transcription in various biological processes. Jun and Fos proteins form AP-1 dimers 
that bind at AP-1 sites and regulate transcription of AP-1 dependent genes that are 
involved in development, differentiation, inflammation and cancer (Hasenfuss, Bakiri et 
al. 2014, Halazonetis, Georgopoulos et al. 1988, Wang, H., Xie et al. 1996, Eferl, Ricci 
et al. 2003). In addition, they modulate the response to acute cellular insults such as 
oxidative stress and DNA damage (Shaulian, Karin 2002).  Reactive oxygen species 
activate inflammatory pathways by modulating the expression of cytokines via activation 
of redox-sensitive transcription factors (Cho, Kim et al. 2018). AP-1 and other 
transcriptional factors such as NF-κB and signal transducer and activator of transcription 
3 increase monocyte colony proliferating factor 1 and decrease adiponectin (Cho, Kim et 
al. 2018). Therefore, in addition to inhibiting NF-κB activity, ANXA1 may be involved 
in regulating AP-1 activity to reduce cellular stress.   
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Jun-D is expressed in differentiated 3T3-L1 cells and it heterodimerises with Fos-related 
antigen 1 (Fra-1); a component of the AP-1 transcription factor and binds to promoter 
regions of genes that are important for the development and/or maintenance of adipocyte 
phenotype (Albrektsen, Fleckner 2001). mRNA expression of JUN was significantly 
downregulated in response to acute AC2-26 treatment, in the current study and this 
finding further emphasis the anti-adipogenic role of ANXA1. Furthermore, Jun-D may 
be involved in the antidiabetic activity of thiazolidinedione as they activate PPARγ by 
inducing Jun-D/Fra-1 heterodimerisation and improve glycemia (Albrektsen, Fleckner 
2001). However, in the liver, Jun-D induces hepatic PPARγ signalling and lipid 
accumulation and is essential for efficient non-alcoholic fatty liver disease (Hasenfuss, 
Bakiri et al. 2014, Halazonetis, Georgopoulos et al. 1988).  
4.6.11 Vascular endothelial growth factor α 
Vascular endothelial growth factor α (VEGFα) is a key regulator of angiogenesis in the 
adipose tissue. Poor vascularisation during adipose tissue proliferation causes fibrosis, 
local tissue inflammation and insulin resistance. VEGFα levels are regulated by exercise, 
hypoxia, insulin, cytokines and growth factors. It is secreted by adipocytes and acts as an 
autoregulatory mechanism for angiogenesis in the adipose tissue (Cao 2010). Healthy 
expansion of the adipose tissue occurs when it is fully vascularised, however, adipocytes 
frequently fail to mount a proper response to local hypoxia and do not produce enough 
VEGFα (Sun, Wernstedt Asterholm et al. 2012, Halberg, Khan et al. 2009). Therefore, 
unhealthy expansion as observed in obesity is associated with non-vascularised adipose 
tissue leading to inflammation, ectopic fat deposition and insulin resistance (Cao 2010, 
Fatima, Campello et al. 2017). Overexpression of VEGFα in the adipose tissue increases 
number and size of blood vessels, protection against HFD induced hypoxia, improves 
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whole body insulin sensitivity and glucose tolerance (Sun, Wernstedt Asterholm et al. 
2012). However, blocking neovascularisation in the adipose tissue is suggested to prevent 
the development of obesity as growth of the adipose tissue is dependent on angiogenesis 
and anti-angiogenesis agents decrease body and adipose tissue weights in obese mice 
models (Rupnick, Panigrahy et al. 2002, Daquinag, Zhang et al. 2011). Nonetheless, lack 
of sufficient bloody supply to the tissue is thought to lead to earlier occurrence of hypoxia, 
fibroplasia and systemic insulin resistance as lipids are stored in less suitable locations 
other than the WAT (Wood, de Heredia et al. 2009).  Therefore, in line with this 
observation, ANXA1 may modify or fine tune adipose tissue expansion via VEGFα as, 
mRNA expression of VEGFα was significantly downregulated in response to acute AC2-
26 treatment, in the current study. 
4.6.12 Acetylcholinesterase 
Parasympathetic neurotransmitter; acetylcholine (ACh) is believed to have the ability to 
block inflammation by inhibiting synthesis and release of cytokines (Metz, Tracey 2005, 
Borovikova, Ivanova et al. 2000). ACh is hydrolysed by two homologous enzymes; 
acetylcholinesterase (AChE) and butyrylcholinestersase (BChE) and they both have 
different physiological functions depending on their localisation. AChE is 20-fold faster 
than BChE at hydrolysing ACh. Increased tissue and plasma levels of AChE and BChE 
are elevated in patients with Alzheimer’s disease, T2DM, hypertension, insulin resistance 
and hyperlipidaemia. Due to an increase in these enzymes, the levels of ACh are low, 
thereby disrupting the cholinergic anti-inflammatory pathway. AChE and BChE could 
serve as biomarkers of low-grade systemic inflammation as observed in obesity (Das 
2007). Previous studies have suggested impaired sympathetic/parasympathetic response 
and reduced cholinergic blockage may be responsible for the inflammation and adverse 
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metabolic sequelae observed in obesity (Shenhar-Tsarfaty, Sherf-Dagan et al. 2018).  
However, short-term cholinergic blockage with atropine; a competitive antagonist of the 
acetylcholine receptor enhanced insulin sensitivity in both human lean and abdominal 
obese subjects (Svensson, Jansson et al. 2011). 
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4.7 Summary 
In summary, the regulation of genes in response to acute AC2-26 indicate a protective 
role of ANXA1 in obesity and inflammation and provide a novel strategy to prevent the 
development of obesity associated inflammation and metabolic diseases. The regulatory 
response of majority of the genes investigated in response to acute AC2-26 demonstrated 
ANXA1 to mediate insulin sensitising effects and may partially regulate insulin actions. 
However, the experimental design of this study limited the determination of gene co-
expression (whether genes expressed dependently or independently of other genes 
analysed), small sample size (false positives or false negative statistical powers) and 
unable to determine if technical errors in chemical dose and duration of exposure arose 
between experimental repeats.   
